{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:09 23:24:50.411",
            "Expression": "mesenchymal allogeneic",
            "NStudiesAvail": 430269,
            "NStudiesFound": 477,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 477,
            "FieldList": [
                  "Acronym",
                  "AgreementOtherDetails",
                  "AgreementPISponsorEmployee",
                  "AgreementRestrictionType",
                  "AgreementRestrictiveAgreement",
                  "ArmGroupDescription",
                  "ArmGroupInterventionName",
                  "ArmGroupLabel",
                  "ArmGroupType",
                  "AvailIPDComment",
                  "AvailIPDId",
                  "AvailIPDType",
                  "AvailIPDURL",
                  "BaselineCategoryTitle",
                  "BaselineClassDenomCountGroupId",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "Acronym": [
                              "OLT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Traditional debridement and microfracture treatment adding a platelet-poor plasma (PPP) scaffold embedded in allogenic stromal mesenchymal cells derived from the umbilical cord in patients with osteochondral lesions of the talus.",
                              "Traditional debridement and microfracture treatment in patients with osteochondral lesions of the talus."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogenic stromal mesenchymal cells derived from the umbilical cord",
                              "Procedure: Debridement and microfracture",
                              "Procedure: Debridement and microfracture"
                        ],
                        "ArmGroupLabel": [
                              "Debridement and microfracture in LOC + Cells",
                              "Debridement and microfracture in LOC"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03905824"
                        ]
                  },
                  {
                        "Rank": 2,
                        "Acronym": [
                              "SAIL"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intramuscular Allogeneic Bone marrow-derived Mesenchymal Stromal Cell Injection",
                              "Intramuscular placebo injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic Mesenchymal Stromal Cell",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Mesenchymal Stromal Cell",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03042572"
                        ]
                  },
                  {
                        "Rank": 3,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Administration of allogeneic MSCs in the treatment of severe diffuse SSc or rapidly progressive and refractory to conventional treatments by prior cyclophosphamide"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS"
                        ],
                        "ArmGroupLabel": [
                              "INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02213705"
                        ]
                  },
                  {
                        "Rank": 4,
                        "Acronym": [
                              "GALENE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Twenty (20) subjects will be treated with 20 million (2 x 10^7) Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs) total divided into 10 injections of 2 million cells/cm of tract in 0.5 ml volume (for total volume of 5 ml per visit) at 4 week intervals for a maximum of 4 treatment sessions based on the discretion of the endoscopist at the time of injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Pilot"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02677350"
                        ]
                  },
                  {
                        "Rank": 5,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow",
                              "Placebo for Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03522545"
                        ]
                  },
                  {
                        "Rank": 6,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00953485"
                        ]
                  },
                  {
                        "Rank": 7,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All subjects will receive allogeneic adult mesenchymal bone marrow stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic adult mesenchymal bone marrow stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01297413"
                        ]
                  },
                  {
                        "Rank": 8,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Escalating doses of allogeneic MSC subconjunctival injection will be assigned 1,000,000 cells/50 \u00b5L at the low dose level.",
                              "Escalating doses of allogeneic MSC subconjunctival injection will be assigned 3,000,000 cells/150 \u00b5L at the medium dose level.",
                              "Escalating doses of allogeneic MSC subconjunctival injection will be assigned 6,000,000 cells total consisting of injection at 2 sites of 3,000,000 cells/150 \u00b5L each at the high dose level."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic MSC",
                              "Biological: Allogeneic MSC",
                              "Biological: Allogeneic MSC"
                        ],
                        "ArmGroupLabel": [
                              "Low dose of allogeneic MSC",
                              "Medium dose of allogeneic MSC",
                              "High dose of allogeneic MSC"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04626583"
                        ]
                  },
                  {
                        "Rank": 9,
                        "Acronym": [
                              "START"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "A dose-escalation with 3 cohorts with 3 subjects/cohort who receive doses of 1, 5 and 10 million cells/kg predicted body weight (PBW). Proceed from lower dose to next higher dose if no safety concerns for each cohort."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01775774"
                        ]
                  },
                  {
                        "Rank": 10,
                        "Acronym": [
                              "CSM/EICH2010"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Sequential Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell (MSC). Dosage 0,7 x 10e6 MSC/Kg/dose (cumulative minimum dose: 2,8 x 10e6 CSM/Kg."
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: Allogenic Mesenchymal Stem Cell"
                        ],
                        "ArmGroupLabel": [
                              "Allogenic Mesenchymal Stem Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01956903"
                        ]
                  },
                  {
                        "Rank": 11,
                        "Acronym": [
                              "ACESO-IHD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants in this group will be receive a single administration of intravenous allogeneic human Mesenchymal Stem Cells (hMSCs) (100 million).",
                              "Participants in this group will receive a single dose of placebo (Cell-free PlasmaLyte-A medium supplemented with 1% HSA) infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: 100 million Allogeneic Mesenchymal Human Stem Cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Group A: Allogeneic Mesenchymal Stem Cells (MSCs) Group",
                              "Group 2: Placebo Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04776239"
                        ]
                  },
                  {
                        "Rank": 12,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1550 nm Fraxel laser treatment (6-8 mJ, Level 2) to full face followed by IV infusion of Allogeneic Mesenchymal Bone Marrow Cells (0.5, 1.0, or 1.5 million cells/kg, up to 150 million cells)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Mesenchymal Bone Marrow Cells"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Mesenchymal Bone Marrow Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01771679"
                        ]
                  },
                  {
                        "Rank": 13,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "ALLOGENEIC MESENCHYMAL BONE MARROW CELLS",
                              "Lactated Ringer's Solution"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem cells",
                              "Biological: Stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cells",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01770613"
                        ]
                  },
                  {
                        "Rank": 14,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This will be a dose escalation study. The first 3 subjects will receive a single dose of 1 x 10^6 cells/kg or a maximum dose of 1 x 10^8 total cells IV.\n\nThe remaining subjects will receive a single dose of 2 x 10^6 cells/kg or a maximum dose of 2 x 10^8 total cells IV."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Human Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Human Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01983709"
                        ]
                  },
                  {
                        "Rank": 15,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The experimental arm is comprised of GVHD patients receiving allogenic bone marrow mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02824653"
                        ]
                  },
                  {
                        "Rank": 16,
                        "Acronym": [
                              "IPAAF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Direct injection of 75 million allogeneic bone marrow derived mesenchymal stem cells (MSC) into ileal pouch fistula at baseline and possibly again after 3 months if not completely healed."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: mesenchymal stem cells (MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells (MSCs)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04073472"
                        ]
                  },
                  {
                        "Rank": 17,
                        "Acronym": [
                              "MSC-SLE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Phase I-II, Allogeneic Umbilical Cord derived-MSCs injected by slow intravenous infusion according to the weight of the recipient and patient groups in the study, at doses of:\n\n1.10^6 CSM / kg\n2.10^6 CSM / kg\n4.10^6 CSM / kg 1 injection during 30min to 1h by Intravenous infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03562065"
                        ]
                  },
                  {
                        "Rank": 18,
                        "Acronym": [
                              "CEASE-CF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "One time IV Infusion of up to 5 x 10^6 allogeneic hMSCs/kg of body weight. A dose escalation using the \"3+3\" design will be employed. The three doses are 1 x 10^6, 3 x 10^6, and 5 x 10^6 hMSCs/kg. There is no placebo group. All study participants will receive stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Human Allogeneic Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02866721"
                        ]
                  },
                  {
                        "Rank": 19,
                        "Acronym": [
                              "Neptune"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "allogeneic mesenchymal stromal cell infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stromal cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02387151"
                        ]
                  },
                  {
                        "Rank": 20,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Placebo will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.",
                              "Mesenchymal Precursor Cells (MPCs), either 1.0 or 2.0 million cells/kg, will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic Mesenchymal Precursor Cells",
                              "Drug: Normal Saline"
                        ],
                        "ArmGroupLabel": [
                              "Normal Saline Placebo",
                              "Allogeneic Mesenchymal Precursor Cells"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01851070"
                        ]
                  },
                  {
                        "Rank": 21,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS"
                        ],
                        "ArmGroupLabel": [
                              "Experimental",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04366323"
                        ]
                  },
                  {
                        "Rank": 22,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Transplantation of allogenic adipose derived mesenchymal stem cells in patients with tibial fracture.",
                              "Placebo injection in the site of fracture in patients with tibia fracture."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cell injection",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell receipients",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02140528"
                        ]
                  },
                  {
                        "Rank": 23,
                        "Acronym": [
                              "ANU"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Forty (40) subjects will be treated with a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.",
                              "Forty (40) subjects will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.",
                              "Eight (8) subjects will be treated with a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allo-hMSCs",
                              "Drug: Placebo",
                              "Drug: Allo-hMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic hMSCs",
                              "Placebo",
                              "Pilot - Allogeneic hMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02675556"
                        ]
                  },
                  {
                        "Rank": 24,
                        "Acronym": [
                              "EXPAND"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05522569"
                        ]
                  },
                  {
                        "Rank": 25,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Experimental: Stem Cells ALLOGENEIC LOW OXYGEN MESENCHYMAL BONE MARROW CELLS Intervention: Biological: Stem cells",
                              "Lactated Ringer's Solution"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02672267"
                        ]
                  },
                  {
                        "Rank": 26,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receiving regular respiratory distress treatment",
                              "Patients receiving two serial doses of allogeneic and expanded adipose tissue-derived mesenchymal stromal cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "Treatment"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04348461"
                        ]
                  },
                  {
                        "Rank": 27,
                        "Acronym": [
                              "VALIANT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group 1 - Five (5) subjects will be treated with a single administration of 1 cc of 1% lidocaine with 1 cc of 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution delivered via intra-facet injection. These subjects will be part of the control (Standard care) group.",
                              "Group 2 - Five (5) subjects will be treated with a single administration of 20 million allogeneic mesenchymal stem cell delivered intra-facet via 6 injections of 1.5 mL per injection, total of 9 to 12ml. These subjects will be part of the experimental group.",
                              "Group A will consist of 15 subjects that will receive 20 million Allogeneic hMSCs delivered via lumbar level injection based on pain originator.",
                              "Group B will consist of 15 subjects who will receive 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution via lumbar level injection based on pain originator."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Placebo",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (hMSCs)",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (hMSCs)",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Group 1 - Placebo",
                              "Group 2 - Allogeneic Human Mesenchymal Stem Cells (hMSCs)",
                              "Group A - Allogeneic Human Mesenchymal Stem Cells (hMSCs)",
                              "Group B - Placebo"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03487731"
                        ]
                  },
                  {
                        "Rank": 28,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects with Interstitial Lung Disease (ILD) associated with Connective Tissue Disorder (CTD) will receive a new treatment called Allogeneic (coming from a healthy donor) Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Interstitial Lung Disease with Connective Tissue Disorder"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03929120"
                        ]
                  },
                  {
                        "Rank": 29,
                        "Acronym": [
                              "MSC&IMPLANTS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Evaluation of Osseointegration of Dental Implants to be done using Allogenic Mesenchymal Stem Cells.Primary and Secondary stability are measured using RFA."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogenic Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "osseointegration using Allogenic MSC's"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02731586"
                        ]
                  },
                  {
                        "Rank": 30,
                        "Acronym": [
                              "STEM-VAD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Three intravenous infusions of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more with each infusion 1 month apart.",
                              "Three intravenous infusions of 1.5 mL/kg Lactated Ringer's Solution with each infusion 1 month apart."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03925324"
                        ]
                  },
                  {
                        "Rank": 31,
                        "Acronym": [
                              "START"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.",
                              "A single dose of Plasma-Lyte A was administered intravenously over approximately 60-80 minutes."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells",
                              "Biological: Plasma-Lyte A"
                        ],
                        "ArmGroupLabel": [
                              "Human Mesenchymal Stromal Cells (hMSCs)",
                              "Plasma-Lyte A (placebo)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported",
                              "Sepsis with pneumonia",
                              "Sepsis without pneumonia",
                              "Pneumonia without sepsis",
                              "Aspiration only",
                              "Other",
                              "Volume control",
                              "Pressure-regulated volume control",
                              "Other"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002"
                        ],
                        "NCTId": [
                              "NCT02097641"
                        ]
                  },
                  {
                        "Rank": 32,
                        "Acronym": [
                              "MESRIX-SAFETY"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment with intra-glandular Injections of allogeneic adipose derived stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic adipose derived stem/stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic mesenchymal stem/stromal cell therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03874572"
                        ]
                  },
                  {
                        "Rank": 33,
                        "Acronym": [
                              "DREAM HF-1"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants randomly assigned to treatment will undergo a single index cardiac catheterization involving transendocardial delivery of rexlemestrocel-L into the myocardium at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results.",
                              "Participants randomly assigned to control treatment will undergo a single cardiac catheterization involving a scripted sham cardiac mapping and cell delivery procedure at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Mesenchymal Precursor Cells (MPCs)",
                              "Other: Sham Comparator"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Mesenchymal Precursor Cells",
                              "Control Treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02032004"
                        ]
                  },
                  {
                        "Rank": 34,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group will receive the implantation of autologous mesenchymal stem cell origin of adipose tissue with a dose of 2 x 50 million cells given with a distance of 1 month",
                              "This group will receive intrathecal implantation of allogeneic mesenchymal stem cells from the umbilical cord with a dose of 2 x 50 million cells given a distance of 1 month.",
                              "This group will receive intrathecal implantation of allogeneic mesenchymal stem cells from the umbilical cord as much as 2 x 50 million followed by 2 x 10cc mesenchymal stem cell secretions from adipose tissue intravenously given at a distance of 1 month."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous Adipose Mesenchymal Stem Cell Implantation",
                              "Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell Implantation",
                              "Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell and Adipose Secretome Implantation"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Adipose MSC Group",
                              "Allogeneic Umbilical Cord MSC Group",
                              "Allogeneic Umbilical Cord MSC and Adipose Secretome Group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04876326"
                        ]
                  },
                  {
                        "Rank": 35,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A fixed dose of Mesenchymal Stromal Cells (MSCs) will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 4 consecutive weeks, with the option of an additional 4 weeks of treatment, at the discretion of the principal investigator."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic bone marrow-derived mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells (MSCs)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02150551"
                        ]
                  },
                  {
                        "Rank": 36,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01378182"
                        ]
                  },
                  {
                        "Rank": 37,
                        "Acronym": [
                              "MESCEL-COVID19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Undifferentiated allogeneic mesenchymal cells derived from umbilical cord tissue",
                              "Standard of care"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal cells",
                              "Drug: Standard of care"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal cells",
                              "Standard of care"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04366271"
                        ]
                  },
                  {
                        "Rank": 38,
                        "Acronym": [
                              "PFCD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Direct injection of adult allogeneic bone marrow derived mesenchymal stem cells, at a dose of 75 million cells into perianal fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.",
                              "Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of adult allogeneic bone marrow derived mesenchymal stem cells, at a dose of 75 million cells into perianal fistula(s)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stem Cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04519671"
                        ]
                  },
                  {
                        "Rank": 39,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic bone marrow-derived MSCs will be delivered intravenously.",
                              "Allogeneic bone marrow-derived MSCs will be delivered intravenously.",
                              "Allogeneic bone marrow-derived MSCs will be delivered intravenously.",
                              "Allogeneic bone marrow-derived MSCs will be delivered intravenously."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)",
                              "Biological: Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)",
                              "Biological: Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)",
                              "Biological: Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)"
                        ],
                        "ArmGroupLabel": [
                              "Bone marrow-derived MSC transplantation (1 x 10 6 MSC/kg)",
                              "Bone marrow-derived MSC transplantation (3 x 10 6 MSC/kg)",
                              "Bone marrow-derived MSC transplantation (6 x 10 6 MSC/kg)",
                              "Bone marrow-derived MSC transplantation (10 x 10 6 MSC/kg)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02611167"
                        ]
                  },
                  {
                        "Rank": 40,
                        "Acronym": [
                              "UCMSCDKA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "single- or double-dose intravenous injection of umbilical cord mesenchymal stem cells for the treatment of severe type 1 diabetes patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: umbilical cord mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "umbilical cord mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02763423"
                        ]
                  },
                  {
                        "Rank": 41,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "allogeneic bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04791878"
                        ]
                  },
                  {
                        "Rank": 42,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells 1\u00d710^6 cells/kg, intravenously"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01763086"
                        ]
                  },
                  {
                        "Rank": 43,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00962923"
                        ]
                  },
                  {
                        "Rank": 44,
                        "Acronym": [
                              "ACESO"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants in this group will receive one peripheral intravenous infusion of 20 million allogeneic Mesenchymal Human Stem Cells (hMSCs)",
                              "Participants in this group will receive one peripheral intravenous infusion of 100 million allogeneic Mesenchymal Human Stem Cells (hMSCs)",
                              "Participants in this group will receive one peripheral intravenous infusion of 20 million allogeneic Mesenchymal Human Stem Cells (hMSCs)",
                              "Participants in this group will receive one peripheral intravenous infusion of 100 million allogeneic Mesenchymal Human Stem Cells (hMSCs)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: 20 million Allogeneic Mesenchymal Human Stem Cells",
                              "Drug: 100 million Allogeneic Mesenchymal Human Stem Cells",
                              "Drug: 20 million Allogeneic Mesenchymal Human Stem Cells",
                              "Drug: 100 million Allogeneic Mesenchymal Human Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Pilot Phase 20 million allogeneic hMSCs",
                              "Pilot Phase 100 million hMSCs",
                              "Randomized Phase 20 million allogeneic hMSCs",
                              "Randomized Phase 100 million allogeneic hMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02886884"
                        ]
                  },
                  {
                        "Rank": 45,
                        "Acronym": [
                              "ALLO-ASC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "1 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention.",
                              "10 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection",
                              "Biological: ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection"
                        ],
                        "ArmGroupLabel": [
                              "1 million cells/ml of ALLO-ASC",
                              "10 million cells/ml of ALLO-ASC"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01856140"
                        ]
                  },
                  {
                        "Rank": 46,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "5 subjects will receive AMSCs via direct injection into the kidney parenchyma only",
                              "5 subjects will receive AMSCs via intra-arterial infusion only",
                              "5 subjects will receive AMSCs via direct injection into the kidney parenchyma and intra-arterial infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic adipose derived mesenchymal stem cells",
                              "Drug: Allogeneic adipose derived mesenchymal stem cells",
                              "Drug: Allogeneic adipose derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Intra parenchymal injection",
                              "Intra-arterial infusion",
                              "Intra parenchymal injection & Intra-arterial infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04388761"
                        ]
                  },
                  {
                        "Rank": 47,
                        "Acronym": [
                              "SAMPSON-1"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of 1.25-1.5 x 10^6 cells/kg with a maximal dose of 100 x 10^6 cells on days 1 and 3 after study enrollment."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Mesenchymal Stromal Cell infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05286255"
                        ]
                  },
                  {
                        "Rank": 48,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "5 subjects randomized to receive 25 M allogeneic MPCs by transendocardial injection",
                              "5 subjects randomized to receive standard-of-care treatment with NOGA\u00ae mapping and staged injections.",
                              "5 subjects randomized to receive 75 M allogeneic MPCs by transendocardial injection",
                              "3 subjects randomized to receive standard-of-care treatment with NOGA\u00ae mapping and staged injections.",
                              "5 subjects randomized to receive 150 M allogeneic MPCs by transendocardial injection",
                              "2 subjects randomized to receive standard-of-care treatment with NOGA\u00ae mapping and staged injections."
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: Allogeneic Mesenchymal Precursor Cells (MPCs)",
                              "Procedure: Standard-of-care treatment with NOGA\u00ae mapping and staged injections.",
                              "Genetic: Allogeneic Mesenchymal Precursor Cells (MPCs)",
                              "Procedure: Standard-of-care treatment with NOGA\u00ae mapping and staged injections.",
                              "Genetic: Allogeneic Mesenchymal Precursor Cells (MPCs)",
                              "Procedure: Standard-of-care treatment with NOGA\u00ae mapping and staged injections."
                        ],
                        "ArmGroupLabel": [
                              "A1",
                              "A2",
                              "B1",
                              "B2",
                              "C1",
                              "C2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other",
                              "Experimental",
                              "Other",
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00555828"
                        ]
                  },
                  {
                        "Rank": 49,
                        "Acronym": [
                              "MSV_allo"
                        ],
                        "AgreementOtherDetails": [
                              "The only disclosure restriction on the PI is that the sponsor must review results communications prior to public release."
                        ],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [
                              "OTHER"
                        ],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.",
                              "Intraarticular injection of hyaluronic acid (60 mg)"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Allogenic mesenchymal stromal cells injection",
                              "Drug: Hyaluronic Acid"
                        ],
                        "ArmGroupLabel": [
                              "Allogenic mesenchymal stromal cells injection",
                              "Hyaluronic acid (Durolane)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01586312"
                        ]
                  },
                  {
                        "Rank": 50,
                        "Acronym": [
                              "CELEB"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "3 patients will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion",
                              "3 patients will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: hMSCs",
                              "Biological: hMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Group 1",
                              "Group 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02625246"
                        ]
                  },
                  {
                        "Rank": 51,
                        "Acronym": [
                              "RVF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Direct injection of adult allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into rectovaginal fistula at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.",
                              "Direct injection of normal saline with a possible repeat injection at 3 months if not completely healed from the first injection. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of adult allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into rectovaginal fistula."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stem Cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04519697"
                        ]
                  },
                  {
                        "Rank": 52,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.",
                              "Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.",
                              "Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human allogeneic mesenchymal bone marrow derived stem cells",
                              "Biological: Human allogeneic mesenchymal bone marrow derived stem cells",
                              "Biological: Human allogeneic mesenchymal bone marrow derived stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Group 1",
                              "Group 2",
                              "Group 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03602872"
                        ]
                  },
                  {
                        "Rank": 53,
                        "Acronym": [
                              "ALOASCU"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment consists in a cell suspension (5 million cells/mL) in aseptic buffered solution containing human expanded adipose-derived stem cells (eASCs) of allogeneic origin in disposable vials with no preservative agents. The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic adipose tissue-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "allogeneic ASCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01914887"
                        ]
                  },
                  {
                        "Rank": 54,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All patients to receive allogeneic UC-MSCs via intralesional injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord mesenchymal stem cells (UC-MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord mesenchymal stem cells (UC-MSCs)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05039411"
                        ]
                  },
                  {
                        "Rank": 55,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intraarticular dose of allogeneic MSCs suspended in 2-4ml Plasmalyte A followed by 2 ml of Hyaluronan",
                              "Single intraarticular dose of 2ml Plasmalyte"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Ex- vivo cultured adult allogeneic MSCs",
                              "Biological: Plasmalyte-A"
                        ],
                        "ArmGroupLabel": [
                              "Ex- vivo cultured adult allogeneic MSCs",
                              "Plasmalyte-A"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01453738"
                        ]
                  },
                  {
                        "Rank": 56,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with Covid-19 associated pneumonia receiving standard treatment and allogenic pooled olfactory mucosa-derived mesenchymal stem cells",
                              "Patients with Covid-19 associated pneumonia receiving standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells",
                              "Other: Standard treatment according to the Clinical protocols",
                              "Other: Standard treatment according to the Clinical protocols"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04382547"
                        ]
                  },
                  {
                        "Rank": 57,
                        "Acronym": [
                              "Alaunus"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will be treated with a single administration of allogeneic hMSCs: 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.",
                              "Participants will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: allogeneic human mesenchymal stem cells (allo-hMSCs)",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "allogeneic human mesenchymal stem cells (allo-hMSCs)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03265808"
                        ]
                  },
                  {
                        "Rank": 58,
                        "Acronym": [
                              "Liveradvance"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous allogenic bone marrow derived mesenchymal stem cells: 4 doses of 2 x 106/kg administered on days 1, 4, 11 and 18",
                              "Solution without cells on days 1, 4, 11 and 18"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogenic mesenchymal stem cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Allogenic Mesenchymal stem cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02857010"
                        ]
                  },
                  {
                        "Rank": 59,
                        "Acronym": [
                              "IPAAF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Direct injection of allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into the ileal pouch fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.",
                              "Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of allogeneic bone marrow derived mesenchymal stem cells at a dose of 75 million cells into ileal pouch fistula(s)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04519684"
                        ]
                  },
                  {
                        "Rank": 60,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic mesenchymal Stromal cells: 2 x 10^6/kg body weight MSC in a range of 1.5 x 10^6 MSC/ kg to 2.5 x 10^6 MSC/kg (at a maximum of 200 x10^6 MSC per study participant) with 5% DMSO iv",
                              "Placebo: consisting of a 5% DMSO-solution in isotonic solution",
                              "Allogeneic mesenchymal Stromal cells: 2 x 10^6/kg body weight MSC in a range of 1.5 x 10^6 MSC/ kg to 2.5 x 10^6 MSC/kg (at a maximum of 200 x10^6 MSC per study participant) with 5% DMSO iv",
                              "Placebo: consisting of a 5% DMSO-solution in isotonic solution"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: Allogeneic MSC",
                              "Drug: Placebo",
                              "Genetic: Allogeneic MSC",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "MSC week 4 and 3 before LVRS2",
                              "Placebo week 4 and 3 before LVRS2",
                              "MSC week 12 and 11 before LVRS2",
                              "Placebo week 12 and 11 before LVRS2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04918706"
                        ]
                  },
                  {
                        "Rank": 61,
                        "Acronym": [
                              "Disc_allo"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intradiscal injection of 25 millions MSC in 2 ml of saline",
                              "Infiltration of paravertebral musculature close to the affected disc(s) with 2 ml of 1% Mepivacaine"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogenic Mesenchymal Stromal Cells",
                              "Drug: Mepivacaine"
                        ],
                        "ArmGroupLabel": [
                              "Allogenic Mesenchymal Stromal Cells",
                              "Mepivacaine"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01860417"
                        ]
                  },
                  {
                        "Rank": 62,
                        "Acronym": [
                              "ELPIS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group A: Fifteen (20) patients will be treated with Allogenic human mesenchymal stem cells (Allo-hMSCs): A concentration of 5 million cells/ml delivered in a dose of 2.5 x 10^5 cells per kg of recipient (5 million/20kg) Allo-hMSCs. The entire dose of the cells will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.",
                              "Group B: Fifteen (10) patients will be treated with a placebo comparator. The placebo will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allo-hMSCs",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Group A - Allo-hMSCs",
                              "Group B"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02398604"
                        ]
                  },
                  {
                        "Rank": 63,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with end-stage heart failure due to ischemic cardiomyopathy will undergo combined cellular and mechanical support with implantation of off-the-shelf allogeneic mesenchymal stem cells and left ventricular assist device."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic stem cells implantation"
                        ],
                        "ArmGroupLabel": [
                              "Stem cells implantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01759212"
                        ]
                  },
                  {
                        "Rank": 64,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: Human Umbilical Cord Blood-derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "FURESTEM-CD Inj"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04520022"
                        ]
                  },
                  {
                        "Rank": 65,
                        "Acronym": [
                              "REDDSTAR"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "mesenchymal stromal cells in collagen scaffold"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stromal cells"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03509870"
                        ]
                  },
                  {
                        "Rank": 66,
                        "Acronym": [
                              "CISS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This is a Phase 1 dose escalation clinical trial that constitutes 3 dose cohorts with 3 participants per cohort who will receive intravenous doses of allogeneic bone marrow derived allogeneic mesenchymal stromal cells--0.3 million cells/kg, 1.0 million cells/kg, and 3.0 million cells/kg. We will proceed from the lower dose to the next higher dose if there are no safety concerns for each cohort."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "allogeneic mesenchymal stromal cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02421484"
                        ]
                  },
                  {
                        "Rank": 67,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "0.9% physiological saline",
                              "Low dose allogeneic mesenchymal stem cells derived from adipose tissue",
                              "High dose allogeneic mesenchymal stem cells derived from adipose tissue"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Placebos",
                              "Drug: Low dose allogeneic mesenchymal stromal cells",
                              "Drug: High dose allogeneic mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Control arm",
                              "Low dose treatment arm",
                              "High dose treatment arm"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04466007"
                        ]
                  },
                  {
                        "Rank": 68,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "One intrathecal injection of Hematopoietic stem cells and Mesenchymal stem cells derived from allogenic umbilical cord for each group of 36 cases of spastic CP and neurorehabilitation during the 12 months of follow up of clinical evaluation of developmental functions and spasticity",
                              "Comparison of effects of intrathecal injection of MNC and MSC on improvement of developmental functions and spasticity of CP patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MNC",
                              "Biological: MSC",
                              "Procedure: Control",
                              "Biological: MNC",
                              "Biological: MSC"
                        ],
                        "ArmGroupLabel": [
                              "MNC & MSC with Control",
                              "MNC & MSC"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03795974"
                        ]
                  },
                  {
                        "Rank": 69,
                        "Acronym": [
                              "ARTROCELL"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment with 40 millions of autologous autologous adult mesenchymal stem cells from expanded bone marrow administered intra-articularly.",
                              "Treatment with 40 millions of adult allogeneic expanded bone marrow mesenchymal stem cells administered intra-articularly.",
                              "Hyaluronic Acid 60mg/3ml administered intra-articularly."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Autologous MSCs",
                              "Drug: Allogenic MSCs",
                              "Drug: Hyaluronic Acid"
                        ],
                        "ArmGroupLabel": [
                              "Autologous Mesenchymal Stromal Cells (MSC)",
                              "Allogenic Mesenchymal Stromal Cells (MSC)",
                              "Active Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05086939"
                        ]
                  },
                  {
                        "Rank": 70,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stem cells, Intramuscular injection",
                              "Normal saline, Intramuscular injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells",
                              "Biological: Normal saline"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "Normal saline"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03239535"
                        ]
                  },
                  {
                        "Rank": 71,
                        "Acronym": [
                              "AMASS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "One transconjunctival injection of allogeneic ASCs into the LG in one eye.",
                              "One transconjunctival injection of Cryostor CS10 into the LG in one eye."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: ASCs",
                              "Drug: Cryostor CS10"
                        ],
                        "ArmGroupLabel": [
                              "Adipose tissue-derived mesenchymal stem cells (ASCs)",
                              "Placebo (vehicle, Cryostor CS10)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04615455"
                        ]
                  },
                  {
                        "Rank": 72,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects with chronic kidney disease will receive allogeneic adipose tissue-derived mesenchymal stem cells (MSC) in two intravenous infusions of 75x10^6 cells at day 0 and month 3.",
                              "Subjects with chronic kidney disease will receive a single intravenous infusion of allogeneic adipose tissue-derived mesenchymal stem cells (MSC) of 150x10^6 cells at day 0."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions",
                              "Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion"
                        ],
                        "ArmGroupLabel": [
                              "Dose Arm 1",
                              "Dose Arm 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04869761"
                        ]
                  },
                  {
                        "Rank": 73,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic Mesenchymal Stem Cell from umbilical cord"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stem Cell"
                        ],
                        "ArmGroupLabel": [
                              "UC-Mesenchymal Stem Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04501354"
                        ]
                  },
                  {
                        "Rank": 74,
                        "Acronym": [
                              "AdMSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Each subject receives three separate doses of 200 million allogeneic adipose-derived mesenchymal stem cells via intravenously infusion on days 0, 3, and 6 with a total of 600 million AdMSCs during 7 days in addition to their standard of care.",
                              "The control group will receive placebo infusion on day 0, 3 and 6 along with standard of care."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic adipose-derived stem cells",
                              "Biological: Allogeneic adipose-derived stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Study Group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05017298"
                        ]
                  },
                  {
                        "Rank": 75,
                        "Acronym": [
                              "MESADDE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Approximately 11 million ASCs in a 0.5 ml suspension"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Adipose tissue-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Adipose tissue-derived mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03878628"
                        ]
                  },
                  {
                        "Rank": 76,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Thirty of the enrolled patients were assigned to Group A to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Group 1",
                              "Other: Group 2",
                              "Other: Group 3"
                        ],
                        "ArmGroupLabel": [
                              "Group A"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01322906"
                        ]
                  },
                  {
                        "Rank": 77,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All patients will receive Adult Allogeneic Mesenchymal Cell from adipose tissue. It is not considered ethical the inclusion of a control group."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Adult Allogeneic Mesenchymal cells from adipose tissue."
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Mesenchymal Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02687646"
                        ]
                  },
                  {
                        "Rank": 78,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The dosage of the intravenous route is 100 million MSCs for each subject."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell"
                        ],
                        "ArmGroupLabel": [
                              "intravenous injection of UC-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04357600"
                        ]
                  },
                  {
                        "Rank": 79,
                        "Acronym": [
                              "CRATUS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group 1 participants will receive Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 20 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.",
                              "Group 2 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.",
                              "Group 3 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.",
                              "Group A - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion.",
                              "Group B - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion.",
                              "Group C - Placebo delivered via peripheral intravenous infusion. Participants in this group have the option to receive one additional infusion of 100million allo-hMSCs/kg with a 12 to 18 month interval.",
                              "Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million penicillin/streptomycin-free allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
                              "Biological: Placebo",
                              "Biological: Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)",
                              "Biological: Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Pilot phase - Group 1",
                              "Pilot Phase - Group 2",
                              "Pilot Phase - Group 3",
                              "Randomized Phase - Group A",
                              "Randomized phase - Group B",
                              "Randomized Phase - Group C",
                              "Addendum B - Antibiotic free cell Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02065245"
                        ]
                  },
                  {
                        "Rank": 80,
                        "Acronym": [
                              "CHAMP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Amputation performed at 7 days post allogeneic bone marrow derived mesenchymal stem cell injections.",
                              "Amputation performed with no MSC administration. Subjects will be followed for incidence of infection and wound healing status to week 24 as a comparator to the Active/Treatment group.",
                              "Tissue Collection Group:\n\nAmputation performed with no MSC administration. Subjects will not be followed after amputation is performed. Tissue collection will occur at time of amputation.",
                              "Patients undergoing lower extremity bypass grafting procedure. Skeletal muscle samples of the sartorius and anterior tibial muscle will be collected for comparison to treatment group. No study testing, nor follow up visits will occur.",
                              "Patients undergoing a standard of care surgical procedure under anesthesia. Core needle biopsies will be collected from the anterior tibial muscle at the time of surgical procedure. No study testing, nor follow up visits will occur."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Active/Treatment Group",
                              "Observation Group 1",
                              "Observation Group 2",
                              "Observation Group 3",
                              "Control Group 4"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention",
                              "No Intervention",
                              "No Intervention",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02685098"
                        ]
                  },
                  {
                        "Rank": 81,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intraarticular dose of allogeneic MSCs",
                              "Single intraarticular dose of 2ml Plasmalyte"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Ex- vivo cultured adult allogeneic MSCs",
                              "Biological: Plasmalyte-A"
                        ],
                        "ArmGroupLabel": [
                              "Ex- vivo cultured adult allogeneic MSCs",
                              "Plasmalyte-A"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01448434"
                        ]
                  },
                  {
                        "Rank": 82,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Received allogenic adipose tissue-derived adult mesenchymal stem cells (10million cells) in fibrin glue scaffold.",
                              "Received fibrin glue and normal saline.",
                              "Received only normal saline."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: allogenic adipose stem cell injection",
                              "Biological: fibrin glue/normal saline injection",
                              "Biological: normal saline injection"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell group",
                              "Active control (fibrin glue) group",
                              "Control (normal saline )group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02298023"
                        ]
                  },
                  {
                        "Rank": 83,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: human amniotic mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "human amniotic mesenchymal stem cell treatment group",
                              "blank control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04318600"
                        ]
                  },
                  {
                        "Rank": 84,
                        "Acronym": [
                              "AETHER"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 2 x10^6 (20 million) cells delivered via peripheral intravenous infusion",
                              "Patients will receive a matched placebo delivered via peripheral intravenous infusion",
                              "Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 100 x10^6 (20 million) cells delivered via peripheral intravenous infusion",
                              "Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 200 x10^6 (200 million) cells delivered via peripheral intravenous infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)",
                              "Biological: matched placebo",
                              "Biological: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)",
                              "Biological: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)"
                        ],
                        "ArmGroupLabel": [
                              "20 million hMSCs",
                              "Placebo",
                              "100 million hMSCs",
                              "200 million hMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02013700"
                        ]
                  },
                  {
                        "Rank": 85,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04432545"
                        ]
                  },
                  {
                        "Rank": 86,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02215811"
                        ]
                  },
                  {
                        "Rank": 87,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intravenous infusion and intrathecal injection (total of 100 million cells)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05152290"
                        ]
                  },
                  {
                        "Rank": 88,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion and intraarticular injection (total dose of 100 million cells)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05147675"
                        ]
                  },
                  {
                        "Rank": 89,
                        "Acronym": [
                              "Trident"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.",
                              "Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic hMSCs",
                              "Biological: Allogeneic hMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Group 1: 20 million Allogeneic hMSCs",
                              "Group 2: 100 million Allogeneic hMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02013674"
                        ]
                  },
                  {
                        "Rank": 90,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intravenous infusion and intralesional injection of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05158127"
                        ]
                  },
                  {
                        "Rank": 91,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intravenous and sub-tenon delivery (total dose of 100 million cells)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05147701"
                        ]
                  },
                  {
                        "Rank": 92,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05018858"
                        ]
                  },
                  {
                        "Rank": 93,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05158933"
                        ]
                  },
                  {
                        "Rank": 94,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05158101"
                        ]
                  },
                  {
                        "Rank": 95,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "One intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05003960"
                        ]
                  },
                  {
                        "Rank": 96,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05147766"
                        ]
                  },
                  {
                        "Rank": 97,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05158439"
                        ]
                  },
                  {
                        "Rank": 98,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05003908"
                        ]
                  },
                  {
                        "Rank": 99,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05147688"
                        ]
                  },
                  {
                        "Rank": 100,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05018819"
                        ]
                  },
                  {
                        "Rank": 101,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05152394"
                        ]
                  },
                  {
                        "Rank": 102,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05003388"
                        ]
                  },
                  {
                        "Rank": 103,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05003934"
                        ]
                  },
                  {
                        "Rank": 104,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05152381"
                        ]
                  },
                  {
                        "Rank": 105,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05018832"
                        ]
                  },
                  {
                        "Rank": 106,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05018767"
                        ]
                  },
                  {
                        "Rank": 107,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05018845"
                        ]
                  },
                  {
                        "Rank": 108,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05016804"
                        ]
                  },
                  {
                        "Rank": 109,
                        "Acronym": [
                              "CMM/EICH/2008"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.",
                              "Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.",
                              "Other: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue."
                        ],
                        "ArmGroupLabel": [
                              "Conventional treatment plus high dose: 3x10e6 cells / Kg.",
                              "Conventional treatment plus low dose: 1x10e6 cells / Kg"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01222039"
                        ]
                  },
                  {
                        "Rank": 110,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05003947"
                        ]
                  },
                  {
                        "Rank": 111,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05016817"
                        ]
                  },
                  {
                        "Rank": 112,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "three intrathecal injections of 50 million cells at two-month intervals."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05003921"
                        ]
                  },
                  {
                        "Rank": 113,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05158114"
                        ]
                  },
                  {
                        "Rank": 114,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal progenitor cells low-dose group",
                              "Mesenchymal progenitor cells mid-dose group",
                              "Mesenchymal progenitor cells high-dose group"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal progenitor cells",
                              "Biological: Mesenchymal progenitor cells",
                              "Biological: Mesenchymal progenitor cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal progenitor cells Dosage 1",
                              "Mesenchymal progenitor cells Dosage 2",
                              "Mesenchymal progenitor cells Dosage 3"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Other",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02641860"
                        ]
                  },
                  {
                        "Rank": 115,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal progenitor cells low-dose group",
                              "Mesenchymal progenitor cells high-dose group",
                              "No mesenchymal progenitor cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal progenitor cells",
                              "Biological: Mesenchymal progenitor cells",
                              "Biological: No mesenchymal progenitor cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal progenitor cells Dosage 1",
                              "Mesenchymal progenitor cells Dosage 2",
                              "No mesenchymal progenitor cells"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04208646"
                        ]
                  },
                  {
                        "Rank": 116,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive low-dose cell administration",
                              "Participants will receive medium-dose cell administration",
                              "Participants will receive high-dose cell administration"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSCTC-0010",
                              "Biological: MSCTC-0010",
                              "Biological: MSCTC-0010"
                        ],
                        "ArmGroupLabel": [
                              "Low Dose MSCTC-0010",
                              "Medium Dose MSCTC-0010",
                              "High Dose MSCTC-0010"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04385056"
                        ]
                  },
                  {
                        "Rank": 117,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells",
                              "Other: Liberation therapy"
                        ],
                        "ArmGroupLabel": [
                              "AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02587715"
                        ]
                  },
                  {
                        "Rank": 118,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells",
                              "Other: Liberation therapy"
                        ],
                        "ArmGroupLabel": [
                              "AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02418325"
                        ]
                  },
                  {
                        "Rank": 119,
                        "Acronym": [
                              "ARDS-MSC-205"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Infusion of allogeneic bone marrow derived mesenchymal stromal stem cells (MSC). First three patients receive a singe dose of 1x10^6 MSC/kg dose, next six patients receive a single dose of 2x10^6 MSC/kg."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stromal Stem Cells - KI-MSC-PL-205"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Stem Cell Treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04447833"
                        ]
                  },
                  {
                        "Rank": 120,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects receive a safety evaluation at 1 month, 3 months, 6 months, 9 months and 12 months after intravenous infusion of Cellgram-CKD 10mL at intervals of 2 weeks (14 days) 3 times.\n\nIn the case of Cellgram-CKD, a milky white cell suspension solution is filled in a colorless and transparent plastic syringe, and the syringe tip is fixed with an obturator."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cellgram-CKD"
                        ],
                        "ArmGroupLabel": [
                              "Cellgram-CKD"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05042206"
                        ]
                  },
                  {
                        "Rank": 121,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Intervention: One time intravenous infusion of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more.",
                              "Intervention: One time intravenous infusion of 1.5mL/kg Lactated Ringer's Solution (LRS) administered at a constant rate of approximately 2mL/min."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)",
                              "Drug: Lactated Ringer's Solution"
                        ],
                        "ArmGroupLabel": [
                              "Experimental: Human (aMBMC)",
                              "Placebo:Lactated Ringer's Solution (LRS)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported",
                              "Class II",
                              "Class III"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02467387"
                        ]
                  },
                  {
                        "Rank": 122,
                        "Acronym": [
                              "AMASCIS-01"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In patients randomly assigned to the placebo arm will receive a intravenous solution (containing the vehicle) with the same appearance as the drug under investigation. It will be administered as a single intravenous dose within the first two weeks after the onset of stroke symptoms.",
                              "The experimental drug is a solution of mesenchymal stem cells from adipose tissue. It will be administered as a single intravenous dose within the first two weeks after the onset of stroke symptoms.Dose: 1 million units/kg"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Placebo",
                              "Drug: Allogenic mesenchymal stem cells from adipose tissue"
                        ],
                        "ArmGroupLabel": [
                              "Placebo",
                              "Allogeneic stem cells from adipose tissue"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01678534"
                        ]
                  },
                  {
                        "Rank": 123,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with SLE, who receive pooled mesenchymal stem cells in addition to the standard treatment according to the Clinical protocols",
                              "Patients with SLE, who receive standard treatment according to the Clinical protocols"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Pooled mesenchymal stem cell",
                              "Other: Standard treatment according to the Clinical protocols",
                              "Other: Standard treatment according to the Clinical protocols"
                        ],
                        "ArmGroupLabel": [
                              "SLE patients MSC treatment",
                              "SLE patients standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04184258"
                        ]
                  },
                  {
                        "Rank": 124,
                        "Acronym": [
                              "ASTEC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "3 patients will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion",
                              "3 patients will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: hMSCs",
                              "Biological: hMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Group receiving 20 million hMSCs",
                              "Group receiving 100 million hMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03137199"
                        ]
                  },
                  {
                        "Rank": 125,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A group of 10 patients only will be subjected to electro-myogram test every 3 month and then follow up for their survival time without any cell therapy intervention.",
                              "A group of 10 patients will be take stem cells intra-thecally Dose: 1 million cells/kg for three times Intervals: Every 3 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Adipose derived mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "Adipose derived Mesenchymal Stem cell"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02855112"
                        ]
                  },
                  {
                        "Rank": 126,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02235844"
                        ]
                  },
                  {
                        "Rank": 127,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive 25 x 10^6 of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) with standard treatment.",
                              "Patients will undergo marrow cellution surgical procedure."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)",
                              "Procedure: Marrow cellution"
                        ],
                        "ArmGroupLabel": [
                              "Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)",
                              "Marrow cellution (standard treatment)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05016011"
                        ]
                  },
                  {
                        "Rank": 128,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogenic-adipose-derived mesenchymal stem cell (ALLO-ASC) with fibrin glue injection to the anal sphincter",
                              "0.9% normal saline with fibrin glue injection to the anal sphincter"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASC injection",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASC group",
                              "Normal saline group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02384499"
                        ]
                  },
                  {
                        "Rank": 129,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with cytopenia after allo-HSCT"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Sequential infusion of allogeneic mesenchymal stem cells expanded \"in vitro\""
                        ],
                        "ArmGroupLabel": [
                              "Patients with cytopenia after allo-HSCT"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02104440"
                        ]
                  },
                  {
                        "Rank": 130,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Routine treatment + Intravenous injection of human dental pulp stem cells",
                              "Routine treatment + Intravenous saline injection (Placebo)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)",
                              "Other: Intravenous saline injection (Placebo)"
                        ],
                        "ArmGroupLabel": [
                              "hDPSCs group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04336254"
                        ]
                  },
                  {
                        "Rank": 131,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Stem cells",
                              "Lactated Ringer's Solution"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Human Mesenchymal Stem Cells and Lactated Riunger's Solution",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Stem Cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02833792"
                        ]
                  },
                  {
                        "Rank": 132,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution. Infusions will be performed every 2 months for 1 year",
                              "400 mL of 0.9% NaCl solution. Infusions will be performed every 2 months for 1 year"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells",
                              "Other: Reference therapy: 400 mL of 0.9% NaCl solution"
                        ],
                        "ArmGroupLabel": [
                              "MSC group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01849159"
                        ]
                  },
                  {
                        "Rank": 133,
                        "Acronym": [
                              "MSV_LE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive a single Intravenous infusion of Mesenchymal Stem Cells (MSV) 1.5 million cells per kg wt suspended in isotonic medium (Physiological saline solution + 1% Human Albumin + 5 mM Glucose). All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial. GMP-compliant MSV will be prepared by IBGM-University of Valladolid",
                              "Participants will receive a placebo infusion that does not contain any mesenchymal stem cells. The placebo infusion will consist of physiological saline solution + 1% Human Albumin + 5 mM Glucose, which is the same vehicle used to deliver the MSCs in the experimental groups."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stromal cells (MSC)",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cells (MSC)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03673748"
                        ]
                  },
                  {
                        "Rank": 134,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00447460"
                        ]
                  },
                  {
                        "Rank": 135,
                        "Acronym": [
                              "UC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Targeted endoscopic delivery of remestemcel-L at a dose of 150 million cells into the submucosal layer of the colon wall at baseline.\n\nIf at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 million MSCs (same dose at initial).",
                              "Targeted endoscopic delivery of remestemcel-L at a dose of 300 million cells into the submucosal layer of the colon wall at baseline.\n\nIf at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 300 million MSCs (same dose at initial).",
                              "Direct injection of normal saline into the submucosal layer of the colon wall.\n\nIf not completely healed after 3 months, participants will then cross over to the treatment group to receive a direct injection of remestemcel-L at a dose of 150 or 300 million cells into the submucosal layer of the colon wall.\n\nIf at 6 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 or 300 million MSCs (same dose at initial)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Remestemcel-L",
                              "Drug: Remestemcel-L",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Remestemcel-L (150 million cells)",
                              "Remestemcel-L (300 million cells)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04543994"
                        ]
                  },
                  {
                        "Rank": 136,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All subjects will receive allogeneic adult adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic adult adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells(MSC) treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01649687"
                        ]
                  },
                  {
                        "Rank": 137,
                        "Acronym": [
                              "Cartistem"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "For control group patients currently standard treatment of arthroscopic curettage and microfracture is performed, and for study group patients allogenic umbilical cord blood-derived mesenchymal stem cell product(Cartistem\u00ae) is added on the lesion after above mentioned procedure.",
                              "standard treatment of arthroscopic curettage and microfracture for osteochondral lesion of talus"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cartistem",
                              "Biological: Cartistem"
                        ],
                        "ArmGroupLabel": [
                              "Cartistem",
                              "standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02338375"
                        ]
                  },
                  {
                        "Rank": 138,
                        "Acronym": [
                              "DCMII"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the placebo group will receive the placebo intervention.",
                              "Participants whose blood genotyping resulted with Genotype A (absence of any variant/ presence of benign variant) and randomized to the treatment group will receive the hMSC intervention.",
                              "Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the placebo group will receive the placebo intervention.",
                              "Participants whose blood genotyping resulted with Genotype B (variants of uncertain significance) and randomized to the treatment group will receive the hMSC intervention.",
                              "Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the placebo group will receive the placebo intervention.",
                              "Participants whose blood genotyping resulted with Genotype C (pathogenic or likely pathogenic variants) and randomized to the treatment group will receive the hMSC intervention."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Placebo",
                              "Biological: allogeneic human mesenchymal stem cells (hMSCs)",
                              "Other: Placebo",
                              "Biological: allogeneic human mesenchymal stem cells (hMSCs)",
                              "Other: Placebo",
                              "Biological: allogeneic human mesenchymal stem cells (hMSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Genotype A administered with placebo Group",
                              "Genotype A administered with hMSC Group",
                              "Genotype B administered with placebo Group",
                              "Genotype B administered with hMSC Group",
                              "Genotype C administered with placebo Group",
                              "Genotype C administered with hMSC Group"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04476901"
                        ]
                  },
                  {
                        "Rank": 139,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "2 treatment doses + 1 placebo 3 months apart",
                              "3 treatment doses 3 months apart",
                              "3 placebo doses 3 months apart"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: MSC+placebo",
                              "Drug: MSC",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "MSC+placebo",
                              "MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04506073"
                        ]
                  },
                  {
                        "Rank": 140,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "15 subjects randomized to receive 25 M allogeneic MPCs by transendocardial injection and mapping.",
                              "5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.",
                              "15 subjects randomized to receive 75 M allogeneic MPCs by transendocardial injection and mapping.",
                              "5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.",
                              "15 subjects randomized to receive 150 M allogeneic MPCs by transendocardial injection and mapping.",
                              "5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Precursor Cells (MPCs)",
                              "Procedure: standard-of-care treatment with mock mapping and injection procedures.",
                              "Biological: Mesenchymal Precursor Cells (MPCs)",
                              "Procedure: standard-of-care treatment with mock mapping and injection procedures.",
                              "Biological: Mesenchymal Precursor Cells (MPCs)",
                              "Procedure: standard-of-care treatment with mock mapping and injection procedures."
                        ],
                        "ArmGroupLabel": [
                              "A1",
                              "A2",
                              "B1",
                              "B2",
                              "C1",
                              "C2"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Sham Comparator",
                              "Active Comparator",
                              "Sham Comparator",
                              "Active Comparator",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00721045"
                        ]
                  },
                  {
                        "Rank": 141,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients received one dose of 1x 10^6 allogeneic adipose-derived mesenchymal stem cells/kg body weight intravenously within 48 hours of enrollment.",
                              "Patients received one dose of normal saline."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cells",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell arm",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01902082"
                        ]
                  },
                  {
                        "Rank": 142,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Targeted endoscopic delivery of remestemcel-L, at a dose of 150 million cells into the submucosal layer of the colon wall at baseline\n\nIf at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 million MSCs (same dose at initial)",
                              "Targeted endoscopic delivery of remestemcel-L, at a dose of 300 million cells into the submucosal layer of the colon wall at baseline.\n\nIf at 3 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 300 million MSCs (same dose at initial).",
                              "Direct injection of normal saline into the submucosal layer of the colon wall. If not completely healed after 3 months, participants will then cross over to the treatment group to receive a direct injection of remestemcel-L, at a dose of 150 or 300 million cells into the submucosal layer of the colon wall.\n\nIf at 6 months post injection of remestemcel-L there is clinical, endoscopic or radiographic improvement, patients will receive a second dose of remestemcel-L at a dose of 150 or 300 million MSCs (same dose at initial)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Remestemcel-L",
                              "Drug: Remestemcel-L",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "remestemcel-L (150 million cells)",
                              "remestemcel-L (300 million cells)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04548583"
                        ]
                  },
                  {
                        "Rank": 143,
                        "Acronym": [
                              "UMSC01"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UMSC01 cells mixed with normal saline will be administered to patients after the onset of diagnosis of multiple sclerosis.",
                              "For IV administration, normal saline will be administered to patients after the onset of diagnosis of multiple sclerosis. For IT administration, sham puncture procedure will partially penetrate without reaching subarachnoid space, and no spinal fluid will be drawn."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic umbilical cord mesenchymal stem cells",
                              "Biological: Control group"
                        ],
                        "ArmGroupLabel": [
                              "UMSC01",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05532943"
                        ]
                  },
                  {
                        "Rank": 144,
                        "Acronym": [
                              "UMSC01"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UMSC01 cells mixed with normal saline will be administered to patients after COVID-19 infection.",
                              "Normal saline will be administered to patients after COVID-19 infection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic umbilical cord mesenchymal stem cells",
                              "Biological: Controlled normal saline"
                        ],
                        "ArmGroupLabel": [
                              "UMSC01",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05501418"
                        ]
                  },
                  {
                        "Rank": 145,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in the control group will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, without injection of MSCs.",
                              "10x10^6 MSC",
                              "30x10^6 MSC",
                              "90x10^6 MSC"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.",
                              "Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.",
                              "Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.",
                              "Procedure: Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection."
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "Cohort 1",
                              "Cohort 2",
                              "Cohort 3"
                        ],
                        "ArmGroupType": [
                              "Sham Comparator",
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01144962"
                        ]
                  },
                  {
                        "Rank": 146,
                        "Acronym": [
                              "AMSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "implantation group will receive MSC and HA-CaSo4"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC"
                        ],
                        "ArmGroupLabel": [
                              "implantation group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02307435"
                        ]
                  },
                  {
                        "Rank": 147,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single infusion of 200 million cells per patient.",
                              "Single infusion with albumin and dmso in sodium chloride (identical concentrations as active treatment)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: ProTrans: Allogeneic transplantation with WJMSCs",
                              "Drug: Placebos"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic transplantation with WJMSCs",
                              "Sham transplantation (placebo)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03406585"
                        ]
                  },
                  {
                        "Rank": 148,
                        "Acronym": [
                              "SYMBOLpreclini"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03967275"
                        ]
                  },
                  {
                        "Rank": 149,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "3 patients receiving low dose",
                              "3 patients receiving medium dose",
                              "3 patients receiving high dose",
                              "6 patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: ProTrans",
                              "Drug: ProTrans",
                              "Drug: ProTrans"
                        ],
                        "ArmGroupLabel": [
                              "Low dose",
                              "Medium dose",
                              "High dose",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03973827"
                        ]
                  },
                  {
                        "Rank": 150,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "At this stage, 3 patients with knee OA will be treated by the cell products of this dose.",
                              "At this stage, 3 patients with knee OA will be treated by the cell products of this dose.",
                              "At this stage, 3 patients with knee OA will be treated by the cell products of this dose."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Chondrochymal\u00ae",
                              "Biological: Chondrochymal\u00ae",
                              "Biological: Chondrochymal\u00ae"
                        ],
                        "ArmGroupLabel": [
                              "Chondrochymal\u00ae 1 x 10^7 cells",
                              "Chondrochymal\u00ae 5 x 10^7 cells",
                              "Chondrochymal\u00ae 10 x 10^7 cells"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03589287"
                        ]
                  },
                  {
                        "Rank": 151,
                        "Acronym": [
                              "STAT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single dose of 10 million cells/kg predicted body weight (PBW) Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells will administered intravenously over approximately 60-80 minutes.",
                              "A single dose of cell reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40) will administered intravenously over approximately 60-80 minutes."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human Mesenchymal Stromal Cells",
                              "Biological: Cell Reconstitution Media"
                        ],
                        "ArmGroupLabel": [
                              "Human Mesenchymal Stromal Cells",
                              "Cell Reconstitution Media"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03818854"
                        ]
                  },
                  {
                        "Rank": 152,
                        "Acronym": [
                              "AMASCIS-02"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "15 patients will receive intravenous alogenic adipose tissue-derived stem cells in a single dose of one million cells per kg.",
                              "15 patients will receive a single intravenous placebo solution with the same appearance as the treatment group."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Alogenic adipose tissue-derived stem cells",
                              "Drug: Placebo solution"
                        ],
                        "ArmGroupLabel": [
                              "Treatment group",
                              "Placebo group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04280003"
                        ]
                  },
                  {
                        "Rank": 153,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04087889"
                        ]
                  },
                  {
                        "Rank": 154,
                        "Acronym": [
                              "PASSIoN"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All (near-)term newborns \u226536 weeks of gestation with or without clinical symptoms of PAIS but with a magnetic resonance imaging (MRI) confirmed PAIS (in the Middle Cerebral Artery region) will be eligible for this study. Following written parental consent, 10 patients will be included in our study."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03356821"
                        ]
                  },
                  {
                        "Rank": 155,
                        "Acronym": [
                              "ADMSP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "AD-MSCs\uff08adipose-derived multipotent mesenchymal stem cells \uff09 intravenous injection at a dose of 0.5 million cells/kg at week 0,week 4\uff0cweek 8 with a duration for treatment for 12 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: adipose-derived multipotent mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSCs group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03265613"
                        ]
                  },
                  {
                        "Rank": 156,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 200 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.",
                              "Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 100 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.",
                              "Subjects assigned to this arm will receive 5 intravenous infusions of HB-adMSCs at 50 million cells/dose. Infusions will occur at weeks 0, 2, 6, 10, and 14.",
                              "Subjects assigned to this arm will receive 5 intravenous infusions of placebo intervention (saline). Infusions will occur at weeks 0, 2, 6, 10, and 14."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs",
                              "Biological: HB-adMSCs",
                              "Biological: HB-adMSCs",
                              "Other: Placebos"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic HB-adMSCs 200MM",
                              "Allogeneic HB-adMSCs 100MM",
                              "Allogeneic HB-adMSCs 50MM",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04348435"
                        ]
                  },
                  {
                        "Rank": 157,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Week 1: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis)",
                              "Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin\u00ae, Novell Pharmaceutical Laboratories) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin\u00ae, Novell Pharmaceutical Laboratories)",
                              "Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis)",
                              "Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin\u00ae, Novell Pharmaceutical Laboratories) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One\u00ae Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin\u00ae, Novell Pharmaceutical Laboratories)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Hyaluronic Acid",
                              "Drug: Hyaluronic Acid",
                              "Biological: Umbilical Cord Mesenchymal Stem Cell",
                              "Biological: Recombinant Human Somatropin",
                              "Drug: Hyaluronic Acid",
                              "Biological: Umbilical Cord Mesenchymal Stem Cell",
                              "Drug: Hyaluronic Acid",
                              "Biological: Recombinant Human Somatropin"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "Intervention 1",
                              "Intervention 2",
                              "Intervention 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03800810"
                        ]
                  },
                  {
                        "Rank": 158,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic MSC (AlloMSC)"
                        ],
                        "ArmGroupLabel": [
                              "1"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00698191"
                        ]
                  },
                  {
                        "Rank": 159,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "High concentration of Allo-ASC 0.5cc (Total: 10 million cells) & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection",
                              "Low concentration of Allo-ASC 0.5cc (Total: 1 million cells) & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection",
                              "Normal saline 0.5cc & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: High concentration of Allo-ASC",
                              "Drug: Fibrin glue",
                              "Biological: Low concentration of Allo-ASC",
                              "Drug: Fibrin glue",
                              "Drug: Fibrin glue",
                              "Drug: Normal saline"
                        ],
                        "ArmGroupLabel": [
                              "High concentration of Allo-ASC group",
                              "Low concentration of Allo-ASC group",
                              "Placebo Comparator (Fibrin) group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03449082"
                        ]
                  },
                  {
                        "Rank": 160,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "CVA patients who have disability, will receive total protein of allogenic MSC-generated exosome transfected by miR-124, one month after attack, via Stereotaxis/Intraparanchymal"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: exosome"
                        ],
                        "ArmGroupLabel": [
                              "exosome or vesicle"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03384433"
                        ]
                  },
                  {
                        "Rank": 161,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This arm will receive standard protocol of care alone",
                              "This arm will receive high dose of Allogeneic Mesenchymal Stem Cells",
                              "This arm will receive intermediate dose of Allogeneic Mesenchymal Stem Cells",
                              "This arm will receive low dose of Allogeneic Mesenchymal Stem Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Mesenchymal Stem Cells",
                              "Biological: Allogeneic Mesenchymal Stem Cells",
                              "Biological: Allogeneic Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Control",
                              "Stem cells high dose",
                              "Stem cells intermediate dose",
                              "Stem cells low dose"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01591200"
                        ]
                  },
                  {
                        "Rank": 162,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The study is designed to examine the safety of administering EVs derived from allogeneic MSCs to 2nd degree burn wounds of less than 20% TBSA. The study will consist of a single dose level which will evaluate the safety of administering allogeneic Extracellular Vesicles-with a total of 10 patients. The chosen dosage will correlate to a dose of MSCs administered under another protocol (IND 14810). The dose level delivered will be EVs derived from approximately 1 X 104 MSCs for each cm2 treated area not to exceed 20% TBSA in total (cumulative, if more than one area is treated). The limitation in wound sizes to be treated will not change throughout the study. Up to 2 additional administrations of EVs will be given over a period of no more than 8 weeks. The first treatment will be administered within 48 hours of the burn injury. The subsequent treatments will be administered no less than 7 days and no more than 6 weeks apart."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: AGLE-102"
                        ],
                        "ArmGroupLabel": [
                              "AGLE-102"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05078385"
                        ]
                  },
                  {
                        "Rank": 163,
                        "Acronym": [
                              "MSCsTcGVHD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to standard first-line regimen including cyclophosphamide and prednisolone.",
                              "patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to standard first-line regimen including cyclophosphamide and prednisolone."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Biological: mesenchymal stem cell",
                              "Drug: Cyclosporine and Glucocorticoid"
                        ],
                        "ArmGroupLabel": [
                              "allogenic mesenchymal stem cells (MSCs)",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01526850"
                        ]
                  },
                  {
                        "Rank": 164,
                        "Acronym": [
                              "1ABC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Application of allogeneic ADSC stem cells in fibrin gel, to cover wound surface with thin cells layer.\n\nTherapy is based on standard procedure of diabetic foot ulcer treatment combined with application of allogeneic ADSC stem cells in fibrin solution onto the wound surface.",
                              "Application of fibrin gel to cover wound surface."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Application of allogeneic ADSC stem cells in fibrin gel",
                              "Procedure: Standard care in diabetic foot ulcer"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic ADSC cells in fibrin solution",
                              "Standard care in diabetic foot ulcer with aplication of fibrin gel to cover wound surface."
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03865394"
                        ]
                  },
                  {
                        "Rank": 165,
                        "Acronym": [
                              "MSCsTreatPBC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients who have primary biliary cirrhosis.",
                              "Patients who have primary biliary cirrhosis."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Biological: mesenchymal stem cell",
                              "Drug: ursodeoxycholic acid"
                        ],
                        "ArmGroupLabel": [
                              "allogenic mesenchymal stem cells (MSCs)",
                              "ursodeoxycholic acid (UDCA)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01440309"
                        ]
                  },
                  {
                        "Rank": 166,
                        "Acronym": [
                              "MSCGVHD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00749164"
                        ]
                  },
                  {
                        "Rank": 167,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Basic medication: Decitabine; Allogeneic umbilical cord mesenchymal stem cells.",
                              "Basic medication: Decitabine; placebo: saline."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic umbilical cord mesenchymal stem cells",
                              "Drug: Decitabine",
                              "Drug: Decitabine"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03184935"
                        ]
                  },
                  {
                        "Rank": 168,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02192749"
                        ]
                  },
                  {
                        "Rank": 169,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Stem cells implantation Patients with severe coronary artery disease with ischemic cardiomyopathy managed with intramyocardial administration of allogeneic mesenchymal stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01946048"
                        ]
                  },
                  {
                        "Rank": 170,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "2 intravenous infusions of suspension of 200 000 000 MSCs each at interval of 7 days. Infusions will be repeated every 3 months for 1 year.",
                              "2 intravenous infusions of 400 mL saline each at interval of 7 days. Infusions will be repeated every 3 months for 1 year."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Bone marrow mesenchymal stem cells",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "MSCs",
                              "placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02594839"
                        ]
                  },
                  {
                        "Rank": 171,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Core decompression surgery; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#).",
                              "Core decompression surgery."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)",
                              "Procedure: core decompression",
                              "Procedure: core decompression"
                        ],
                        "ArmGroupLabel": [
                              "Group 1",
                              "Group 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03180463"
                        ]
                  },
                  {
                        "Rank": 172,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive intravenous infusions of COVI-MSC (one vial, ~18.5 million cells) on Day 0, Day 2, and Day 4.",
                              "Subjects will receive intravenous infusions of COVI-MSC (two vials, ~37 million cells) on Day 0, Day 2, and Day 4."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: COVI-MSC",
                              "Biological: COVI-MSC"
                        ],
                        "ArmGroupLabel": [
                              "COVI-MSC 1 vial",
                              "COVI-MSC 2 vials"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04909892"
                        ]
                  },
                  {
                        "Rank": 173,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 100 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05152368"
                        ]
                  },
                  {
                        "Rank": 174,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "\"ex-vivo\" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue for spinal fusion",
                              "Instrumented spinal fusion together with patient's bone iliac crest."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: XCEL-MT-OSTEO-ALPHA",
                              "Procedure: Standard treatment"
                        ],
                        "ArmGroupLabel": [
                              "XCEL-MT-OSTEO-ALPHA",
                              "Standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01552707"
                        ]
                  },
                  {
                        "Rank": 175,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSC co-infusion with either HLA-mismatched PBSC or cord blood"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Mesenchymal stem cell infusion"
                        ],
                        "ArmGroupLabel": [
                              "1"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00504803"
                        ]
                  },
                  {
                        "Rank": 176,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Aspirin Tablet, 100mg/d; Allogeneic umbilical cord mesenchymal stem cells, 0.5-1*10^6/kg",
                              "Aspirin Tablet, 100mg/d; Placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)",
                              "Drug: Aspirin Tablet",
                              "Drug: Aspirin Tablet"
                        ],
                        "ArmGroupLabel": [
                              "Group 1",
                              "Group 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03186456"
                        ]
                  },
                  {
                        "Rank": 177,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "rabbit with posterior cruciate ligament rupture and treated with fibrin glue (sacffold)",
                              "rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with ligament derived conditioned medium",
                              "rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture condition",
                              "rabbit with posterior cruciate ligament rupture and treated with fibrin glue mix with adypose mesenchymal stem cells in hypoxic culture condition and ligament derived conditioned medium"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: adypose mesenchymal conditioned medium and ligament derived conditioned medium",
                              "Biological: adypose mesenchymal conditioned medium and ligament derived conditioned medium",
                              "Biological: adypose mesenchymal conditioned medium and ligament derived conditioned medium",
                              "Biological: adypose mesenchymal conditioned medium and ligament derived conditioned medium"
                        ],
                        "ArmGroupLabel": [
                              "control group",
                              "conditioned medium group",
                              "stem cells group",
                              "composite group"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator",
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04889963"
                        ]
                  },
                  {
                        "Rank": 178,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intravenous and intracavernosal or interstitial delivery (total dose of 100 million cells)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AlloRx"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Group (AlloRx)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05147779"
                        ]
                  },
                  {
                        "Rank": 179,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants receive Mesenchymal Stem Cells (MSCs) for adult respiratory distress syndrome (ARDS).\n\nParticipants receive a maximum dose of 3 x 10^6 cell/Kg by vein one time on Day 1."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells (MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02804945"
                        ]
                  },
                  {
                        "Rank": 180,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adipose mesenchymal cells with bone marrow mononuclear cells.\n\nTwo doses with a 6 month interval of allogenic Adipose mesenchymal cells +1 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously.",
                              "Adipose mesenchymal cells with bone marrow mononuclear cells.\n\nTwo doses with a 6 month interval of allogenic Adipose mesenchymal cells +10 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Adipose mesenchymal cells with bone marrow mononuclear cells",
                              "Biological: Adipose mesenchymal cells with bone marrow mononuclear cells"
                        ],
                        "ArmGroupLabel": [
                              "Dose 1 mil/kg",
                              "Dose 10 mil/kg"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02940418"
                        ]
                  },
                  {
                        "Rank": 181,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Eiligible patients receive cord blood transplantation with coinfusion of mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: cord blood transplantation"
                        ],
                        "ArmGroupLabel": [
                              "cord blood transplant"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01092026"
                        ]
                  },
                  {
                        "Rank": 182,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "conventional treatment; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) by i.v.",
                              "Conventional treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)",
                              "Drug: conventional treatment",
                              "Drug: conventional treatment"
                        ],
                        "ArmGroupLabel": [
                              "Treatment group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03180450"
                        ]
                  },
                  {
                        "Rank": 183,
                        "Acronym": [
                              "ACCeNT-CP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive a single intravenous infusion of a maximum of 10x107/kg allogeneic umbilical cord blood (CB) cells",
                              "Subjects will receive three intravenous infusions of 2x106/kg human umbilical cord tissue cells (hCT-MSC), manufactured from allogeneic umbilical cord donors",
                              "Subjects will not receive any study product infusion until after the 12 month assessment. At the 12 month visit, they will receive an infusion of allogeneic umbilical cord blood cells so that all study participants will receive some type of cellular therapy."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Infusion of allogeneic umbilical cord blood",
                              "Biological: Infusion of MSCs",
                              "Biological: Infusion of allogeneic umbilical cord blood"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Umbilical Cord Blood",
                              "Cord Tissue Mesenchymal Stromal Cells",
                              "Natural History"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03473301"
                        ]
                  },
                  {
                        "Rank": 184,
                        "Acronym": [
                              "ACE_CARD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Experimental: Cohort 1 Low dose, 20M cells, 3 patients",
                              "Experimental: Cohort 2 Med dose, 100M cells, 3 patients",
                              "Experimental: Cohort 3 High dose, 200M cells, 3 patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: intravenous delivery of allogeneic bone marrow-derived MSCs",
                              "Biological: intravenous delivery of allogeneic bone marrow-derived MSCs",
                              "Biological: intravenous delivery of allogeneic bone marrow-derived MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Low dose",
                              "Medium dose",
                              "High dose"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05491681"
                        ]
                  },
                  {
                        "Rank": 185,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Basic medication\uff1aAspirin Enteric-coated Tablets & Atorvastatin Calcium\uff1b Allogeneic umbilical cord mesenchymal stem cells",
                              "Basic medication\uff1aAspirin Enteric-coated Tablets & Atorvastatin Calcium; Placebo\uff1asaline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic umbilical cord mesenchymal stem cell",
                              "Drug: Aspirin Enteric-coated Tablets & Atorvastatin Calcium",
                              "Drug: Aspirin Enteric-coated Tablets & Atorvastatin Calcium"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03176498"
                        ]
                  },
                  {
                        "Rank": 186,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will undergo peripheral blood stem cell mobilisation and collection with subsequent high-dose chemotherapy. After finalization of high-dose chemotherapy subjects will receive bone marrow derived allogeneic multipotent mesenchymal stromal cells intravenous infusion two hours prior to autologous peripheral blood cells infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Peripheral blood stem cell mobilisation and collection",
                              "Drug: High-dose chemotherapy",
                              "Drug: Bone marrow derived allogeneic MMSCs infusion",
                              "Procedure: Autologous peripheral blood stem cells infusion"
                        ],
                        "ArmGroupLabel": [
                              "allogeneic MMSCs infusion"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02145923"
                        ]
                  },
                  {
                        "Rank": 187,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with severe coronary artery disease and chronic ischemic cardiomyopathy with a LVEF \u226440% who are scheduled for elective CABG according to accepted guidelines. Additional criteria include the following: age <75 years, history of myocardial infarction (not less than 14 days before the procedure), LVEF \u226440 % assessed with echocardiography, and a distinct area of dyskinetic or akinetic left ventricular myocardium corresponding with the infarct localization."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Intramyocardial implantation of of a novel mesenchymal precursor cell type (iMP)."
                        ],
                        "ArmGroupLabel": [
                              "Stem cells implantation"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01753440"
                        ]
                  },
                  {
                        "Rank": 188,
                        "Acronym": [
                              "SENECA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Target dose of 100 million allo-MSCs",
                              "Buminate solution"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allo-MSCs",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Allo-MSCs",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002"
                        ],
                        "NCTId": [
                              "NCT02509156"
                        ]
                  },
                  {
                        "Rank": 189,
                        "Acronym": [
                              "BPI+MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patient will receive nerve transfer procedure without augmentation",
                              "Following nerve transfer procedure, the end-to-end anastomosis will be wrapped with HAM-AdMSC composite as augmentation"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Nerve transfer procedure",
                              "Procedure: Nerve transfer with HAM-AdMSC composite wrapping"
                        ],
                        "ArmGroupLabel": [
                              "Control group (Nerve transfer procedure)",
                              "Experimental group (Nerve transfer with HAM-AdMSC composite wrapping)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04654286"
                        ]
                  },
                  {
                        "Rank": 190,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Arm 1: IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 8 weeks thereafter to week 46 (n=5), (total # doses = 10).",
                              "Arm 2: IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 4 weeks thereafter to week 46 (n=5), (total # doses = 15)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Bone Marrow MSC Derived Extracellular Vesicle Isolate",
                              "Drug: Bone Marrow MSC Derived Extracellular Vesicle Isolate"
                        ],
                        "ArmGroupLabel": [
                              "15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 8 weeks after that to week 46",
                              "15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 4 weeks after that to week 46"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05130983"
                        ]
                  },
                  {
                        "Rank": 191,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Study participants aged 18 or older who are having an allogeneic blood and marrow transplant (BMT), to treat leukemia, lymphoma or other cancer of the blood will receive an infusion of mesenchymal stromal cells (MSCs).",
                              "Study participants under 18 years of age who are having an allogeneic blood and marrow transplant (BMT), to treat leukemia, lymphoma or other cancer of the blood will receive an infusion of mesenchymal stromal cells (MSCs)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Interferon gamma (IFN\u03b3)-primed human bone marrow-derived mesenchymal stromal cells",
                              "Drug: Interferon gamma (IFN\u03b3)-primed human bone marrow-derived mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Adult Population",
                              "Pediatric Population"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04328714"
                        ]
                  },
                  {
                        "Rank": 192,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Stempeucel - CLI will be administered at the lowest dose",
                              "Stempeucel - CLI will be administered at intermediate dose",
                              "Standard protocol of care alone"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Mesenchymal Stem Cells",
                              "Biological: Allogeneic Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Low dose",
                              "Intermediate dose",
                              "Control arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01484574"
                        ]
                  },
                  {
                        "Rank": 193,
                        "Acronym": [
                              "COVID_MSV"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous injection of 1 million MSV cells/Kg in 100 ml of saline",
                              "Intravenous injection of 100 ml of saline containing no cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Experimental",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04361942"
                        ]
                  },
                  {
                        "Rank": 194,
                        "Acronym": [
                              "UwmWjmscAls"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intervention: Biological: Cell-based therapy of allogeneic Wharton's jelly-derived mesenchymal stem cells which are transplanted intrathecally (via a standard lumbar puncture) into the ALS subjects."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Biological: Cell-based therapy"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic WJ-MSCs injection"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02881476"
                        ]
                  },
                  {
                        "Rank": 195,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UMSC01 cells mixed with normal saline will be administered to patients after the onset of heart attack."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "UMSC01"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04056819"
                        ]
                  },
                  {
                        "Rank": 196,
                        "Acronym": [
                              "BR"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic culture-expanded adipose-derived mesenchymal stem cells (MSCs)",
                              "Excipient"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: COVI-MSC",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "COVI-MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04992247"
                        ]
                  },
                  {
                        "Rank": 197,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of \u2248 30 million cells) on Day 0, Day 2, and Day 4",
                              "Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: COVI-MSC",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "COVI-MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04905836"
                        ]
                  },
                  {
                        "Rank": 198,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of \u2248 30 million cells) on Day 0, Day 2, and Day 4",
                              "Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: COVI-MSC",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "COVI-MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04909879"
                        ]
                  },
                  {
                        "Rank": 199,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UCMSCs + CM is administered via intrathecal injection",
                              "UCMSCs is administered via intrathecal injection",
                              "Physiotherapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells",
                              "Biological: Conditioned Medium",
                              "Biological: Umbilical Cord Mesenchymal Stem Cells",
                              "Other: Standard Therapy"
                        ],
                        "ArmGroupLabel": [
                              "UCMSCs + CM",
                              "UCMSCs",
                              "Standard Therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04314687"
                        ]
                  },
                  {
                        "Rank": 200,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects with chronic kidney disease will receive allogeneic bone marrow-derived mesenchymal stem cells (MSC) in two intravenous infusions of 100x10^6 cells at time zero and three months",
                              "Subjects with chronic kidney disease will receive allogeneic bone marrow-derived mesenchymal stem cells (MSC) single intravenous infusion of 200x10^6 cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)",
                              "Drug: Allogeneic adipose-derived mesenchymal stem cells (MSC)"
                        ],
                        "ArmGroupLabel": [
                              "Dose Arm 1",
                              "Dose Arm 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05362786"
                        ]
                  },
                  {
                        "Rank": 201,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic culture-expanded adipose-derived mesenchymal stem cells (MSCs)",
                              "Excipient"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: COVI-MSC",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "COVI-MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04728698"
                        ]
                  },
                  {
                        "Rank": 202,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cellular therapy : injection of mesenchymal stem cells subjected to hepatogenic induction"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cellular therapy"
                        ],
                        "ArmGroupLabel": [
                              "Cellular therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02108132"
                        ]
                  },
                  {
                        "Rank": 203,
                        "Acronym": [
                              "ADSCs-BWs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients receive ALLO-ADSCs. Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging",
                              "All patients will be subjected to standard stepped treatment of burn wounds:\n\nInfusion therapy aimed to eliminate disorders of homeostasis during burn shock and burn toxemia;\nSystemic antibiotic therapy for preventing infectious complications;\nAdequate analgesia and sedation;\nDecompression necrotomy in the first 24 hours following the burn trauma;\nNecrectomy simultaneously with imposition of lyophilized xenografts performed in the first 1-5 days after applying burn;\nAutologous skin grafting 3-5 days after performed xenografts with the perforation coefficient 1:3"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASCs"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASCs",
                              "The standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03113747"
                        ]
                  },
                  {
                        "Rank": 204,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "\"ex-vivo\" expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue",
                              "Standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: XCEL-MT-OSTEO-ALPHA",
                              "Procedure: Surgery",
                              "Other: autologous iliac crest",
                              "Procedure: Surgery"
                        ],
                        "ArmGroupLabel": [
                              "XCEL-MT-OSTEO-ALPHA and surgery",
                              "Autologous iliac crest and surgery"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02230514"
                        ]
                  },
                  {
                        "Rank": 205,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants with moderate to severe acute respiratory distress syndrome (6 patients)",
                              "Participants with moderate to severe acute respiratory distress syndrome (10 patients)",
                              "Participants with moderate to severe acute respiratory distress syndrome (10 patients)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: HCR040 (Phase 1)",
                              "Drug: Placebo (Phase 2)",
                              "Drug: HCR040 (Phase 2)"
                        ],
                        "ArmGroupLabel": [
                              "HCR040 (Phase 1)",
                              "Control group (Phase 2)",
                              "HCR040 (Phase 2)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04289194"
                        ]
                  },
                  {
                        "Rank": 206,
                        "Acronym": [
                              "CLI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: allogeneic umbilical cord-derived mesenchymal stem cells",
                              "Biological: allogeneic umbilical cord-derived mesenchymal stem cells",
                              "Biological: Placebo (NaCl)"
                        ],
                        "ArmGroupLabel": [
                              "simple dose",
                              "double dose",
                              "placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03994666"
                        ]
                  },
                  {
                        "Rank": 207,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Expanded Allogeneic Adipose-derived multipotent mesenchymal stem cells(AD-MSCs) will be administered by intravenous drip at a dose of 2\u00d710 ^ 6 cells/kg at week 0, week 2, week 4, week 6, week 8 with a total of 5 times.\n\nPSORI-CM01 formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs.",
                              "Expanded Allogeneic Adipose-derived multipotent mesenchymal stem cells(AD-MSCs) will be administered by intravenous drip at a dose of 2\u00d710 ^ 6 cells/kg at week 0, week 2, week 4, week 6, week 8 with a total of 5 times.\n\nGu Ben Hua Yu formula will be orally administrated once a day for 12 weeks excpet the day for the infusion of AD-MSCs."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: PSORI-CM01 formula",
                              "Biological: adipose-derived multipotent mesenchymal stem cells",
                              "Drug: Gu Ben Hua Yu formula",
                              "Biological: adipose-derived multipotent mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "PSORI-CM01 group",
                              "Gu Ben Hua Yu group"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04785027"
                        ]
                  },
                  {
                        "Rank": 208,
                        "Acronym": [
                              "ASC COVID-19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "100 million allogeneic adipose-derived mesenchymal stromal cell",
                              "Saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Stem Cell Product",
                              "Drug: Stem Cell Product"
                        ],
                        "ArmGroupLabel": [
                              "ASC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04341610"
                        ]
                  },
                  {
                        "Rank": 209,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients are enrolled into one of three escalating dose panels based on the time of enrolment. The first three patients will receive 1 million cells/kg of body weight, the next three patients will receive 3 million cells/kg of body weight, and the final three patients will receive 10 million cells/kg of body weight. Progression through the escalating dose panels is subject to review by an independent Data Safety Monitoring Committee."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Umbilical Cord Tissue-Derived Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cell Therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04255147"
                        ]
                  },
                  {
                        "Rank": 210,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The dose-escalation methods with a modified continual reassessment at the five dose levels (1x10^6, 10x10^6, 20x10^6, 40x10^6, 80x10^6 cells/kg) will be performed to determine safety and feasibility of allogeneic BM-MSC infusion during pediatric cardiac surgery and the maximum tolerated dose in infants with CHD."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BM-MSC"
                        ],
                        "ArmGroupLabel": [
                              "Bone marrow-derived mesenchymal stromal cell (BM-MSC)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04236479"
                        ]
                  },
                  {
                        "Rank": 211,
                        "Acronym": [
                              "SIRONA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A total of 10 subjects will receive: A single peripheral intravenous (IV) infusion of 10 x10^6 (10 million) of LMSCs to be administered on day 1.",
                              "10 subjects will receive: A single peripheral intravenous (IV) infusion of Plasmalyte A containing human serum albumin (HSA) to be administered on day 1.",
                              "10 subjects will receive: A single peripheral intravenous (IV) infusion of 20x10^6 (20 million) LMSCs to be administered on day 1.",
                              "10 subjects will receive: A single peripheral intravenous (IV) infusion of 100x10^6 (100 million) LMSCs to be administered on day 1."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Peripheral Intravenous (IV) infusion of LMSCs",
                              "Biological: Peripheral Intravenous (IV) infusion of LMSCs",
                              "Biological: Peripheral Intravenous (IV) infusion of LMSCs",
                              "Biological: Peripheral Intravenous (IV) infusion of LMSCs"
                        ],
                        "ArmGroupLabel": [
                              "LMSCs 10 million IV",
                              "Placebo (Plasmalyte A,HSA) IV",
                              "LMSCs 20 million IV",
                              "LMSCs100 million IV"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02587572"
                        ]
                  },
                  {
                        "Rank": 212,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with newly diagnosed extensive cGVHD receive prednisone and cyclosporine or tacrolimus.\n\nPatients with refractory extensive cGVHD receive primary treatment (eg,prednisone and cyclosporine or tacrolimus, or plus mycophenolate mofetil, or methotrexate.)",
                              "Patients with newly diagnosed extensive cGVHD receive MSC plus prednisone and cyclosporine or tacrolimus.\n\nPatients with refractory extensive cGVHD receive MSC plus their primary immunosuppressive treatment (eg. prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate.)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Prednisone and cyclosporine or primary therapies",
                              "Biological: Mesenchymal stem cell (MSC)"
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "Mesenchymal stem cell (MSC)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00972660"
                        ]
                  },
                  {
                        "Rank": 213,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Infusion of 100 million adipose derived mesenchymal stromal cells from healthy donors",
                              "Infusion of 200 million adipose derived mesenchymal stromal cells from healthy donors",
                              "Infusion of saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: adipose derived mesenchymal stromal cells",
                              "Drug: adipose derived mesenchymal stromal cells",
                              "Drug: Saline"
                        ],
                        "ArmGroupLabel": [
                              "Infusion of 100 million ASC",
                              "Infusion of 200 million ASC",
                              "Infusion of placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04714801"
                        ]
                  },
                  {
                        "Rank": 214,
                        "Acronym": [
                              "UCMSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group receiving standard COVID-19 treatment and UCMSC infusion",
                              "Group receiving standard COVID-19 treatment and normal saline infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Normoxic Allogenic UCMSC",
                              "Other: Normal saline solution"
                        ],
                        "ArmGroupLabel": [
                              "Treatment",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05132972"
                        ]
                  },
                  {
                        "Rank": 215,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with Vietnames MOH procedure",
                              "drug therapy according to Vietnamese MOHS procedure"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells transplantation",
                              "Drug: drug therapy according to Vietnamese MOHS procedure",
                              "Drug: drug therapy according to Vietnamese MOHS procedure"
                        ],
                        "ArmGroupLabel": [
                              "Treatment (UC-MSC trasnplatation)",
                              "control arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04433104"
                        ]
                  },
                  {
                        "Rank": 216,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Low dose allogenic mesenchymal stem cells with IM injection",
                              "High dose allogenic mesenchymal stem cells with IM injection",
                              "normal saline with Intramuscular injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Allogenic MSC",
                              "Drug: Allogenic MSC",
                              "Drug: Normal saline"
                        ],
                        "ArmGroupLabel": [
                              "Low Dose Allogenic MSC",
                              "High Dose Allogenic MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02336646"
                        ]
                  },
                  {
                        "Rank": 217,
                        "Acronym": [
                              "COVID19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous 1*10E6 MSCs/kg body weight Mesenchymal Stromal Cells infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells infusion"
                        ],
                        "ArmGroupLabel": [
                              "Intervention"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04467047"
                        ]
                  },
                  {
                        "Rank": 218,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects diagnosed with End Stage Renal Disease (ESRD) and are currently on hemodialysis therapy with planned creation of a new upper extremity arteriovenous fistula will receive Adipose Derived Mesenchymal Stem Cells treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Adipose Derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Adipose Derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04392206"
                        ]
                  },
                  {
                        "Rank": 219,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Cotransplant with MSCs"
                        ],
                        "ArmGroupLabel": [
                              "HSC",
                              "MSC+HSC"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04247945"
                        ]
                  },
                  {
                        "Rank": 220,
                        "Acronym": [
                              "CISS2"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of 300 million Allogeneic, Bone Marrow-Derived Human Mesenchymal Stromal Cells",
                              "Intravenous infusion of Placebo, with excipients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells (MSCs)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03369275"
                        ]
                  },
                  {
                        "Rank": 221,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "PBSC will be intravenously infused at a dose of 2\u00d710^8/kg. MSCs will be intravenously infused at a dose of 1\u00d710^6 cells/kg once per week. The vital signs of all patients will be closely monitored during and for 24h after administration.If the NEU and PLT levels do not attain the completely response(CR)standards within 28d, a second course of the same treatment will be given."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: PBSC",
                              "Biological: MSCs"
                        ],
                        "ArmGroupLabel": [
                              "PBSC & MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02083718"
                        ]
                  },
                  {
                        "Rank": 222,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Under sterile conditions, the patient will be locally anesthetized in the affected tooth area; the root canal of the affected tooth will be exposed and prepared to perform the MSC / MSC-Endo / PRP implant. At the same time, the culture medium supernatant is removed from each tube and the MSC / MSC-Endo \"button (pellet)\" is resuspended in autologous platelet-rich plasma (PRP). Subsequently to the MSC / MSC-Endo / PRP suspension, 5% CaCl2 and thrombin will be added. Immediately, and before the clot forms, 20 microliters of the MSC / MSC-Endo / PRP suspension will be placed in the root canal, covered with a collagen membrane. Subsequently, the obturation procedure with bioceramics will be carried out at the level of the pulp chamber, ionomeric glass to protect the bioceramic and later composite resin to restore the tooth."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis"
                        ],
                        "ArmGroupLabel": [
                              "Allogenic transplant of BM-MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04545307"
                        ]
                  },
                  {
                        "Rank": 223,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "hMSC-Exos low-dose group",
                              "hMSC-Exos medium-dose group",
                              "hMSC-Exos high-dose group",
                              "basic treatment+hMSC-Exos (a quarter of MTD/day)",
                              "basic treatment+hMSC-Exos (MTD/day)",
                              "basic treatment+normal saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: low dose hMSC-Exos",
                              "Biological: medium dose hMSC-Exos",
                              "Biological: high dose hMSC-Exos",
                              "Biological: Dosage 1of hMSC-Exos",
                              "Biological: Dosage 2 of hMSC-Exos",
                              "Biological: No hMSC-derived exosomes"
                        ],
                        "ArmGroupLabel": [
                              "Phase 1: hMSC-Exos low dose",
                              "Phase 1: hMSC-Exos medium dose",
                              "Phase 1: hMSC-Exos high dose",
                              "Phase 2: hMSC-Exos dosage 1",
                              "Phase 2: hMSC-Exos dosage 2",
                              "Phase 2: control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04602104"
                        ]
                  },
                  {
                        "Rank": 224,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Ex vivo cultured adult allogenic MSCs",
                              "Other: Plasmalyte-A"
                        ],
                        "ArmGroupLabel": [
                              "Ex vivo cultured adult allogenic MSCs",
                              "Plasmalyte-A"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01091701"
                        ]
                  },
                  {
                        "Rank": 225,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "On the basis conventional symptomatic treatment and supportive therapy, P-MMSCs were given at 1 million cells/kg body weight/ time, once every 3 days for a total of 3 times: Day \"1\", Day \"4\", Day \"7\".",
                              "Conventional symptomatic treatments such as antibacterial (ceftriaxone, azithromycin), anticoagulants, hormones, oxygen therapy, mechanical ventilation and other supportive therapies"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells",
                              "Drug: Antibiotics",
                              "Drug: Hormones",
                              "Drug: Anticoagulant Therapy",
                              "Device: \u041exygen therapy",
                              "Drug: Antibiotics",
                              "Drug: Hormones",
                              "Drug: Anticoagulant Therapy",
                              "Device: \u041exygen therapy"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04461925"
                        ]
                  },
                  {
                        "Rank": 226,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03389919"
                        ]
                  },
                  {
                        "Rank": 227,
                        "Acronym": [
                              "AMSC_UC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "interventions: The MSCs of 5\u00d710*7 will be given in different sites within colonic submucosa at a total 100 ml with the use of the colonoscope. Once every week\uff0ca total of two times. Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used",
                              "interventions:Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Adipose-cord mesenchymal stromal cells (A-MSCs)",
                              "Other: Conventional drugs",
                              "Other: Conventional drugs"
                        ],
                        "ArmGroupLabel": [
                              "Intervention group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03609905"
                        ]
                  },
                  {
                        "Rank": 228,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01297972"
                        ]
                  },
                  {
                        "Rank": 229,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants who self-select into the Group 1 (Immediate Treatment) will be scheduled to undergo the HAM and HUMCWJ injections to the OA affected knee at the same visit.",
                              "Participants who self-select into Group 2 will choose to delay their HAM and HUMCWJ injection to the OA affected knee for at least 3 months or choose not to have the injections at all. Participants will be asked to keep track of pain management and therapy throughout the 3 months."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: HAM and HUMCWJ Injections"
                        ],
                        "ArmGroupLabel": [
                              "HAM and HUMCWJ Injections (Group 1)",
                              "Control (Group 2)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03337243"
                        ]
                  },
                  {
                        "Rank": 230,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cells are dissolved in saline and given intravenously over a period of 20-40 min. 100 million cells to subjects < 50 kg and 200 million cells to subjects 50-100 kg (>100 kg is an exclusion criterion).",
                              "Placebo (saline) is given intravenously over a period of 20-40 min."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: the ATMP Protrans",
                              "Biological: the ATMP Protrans"
                        ],
                        "ArmGroupLabel": [
                              "Wharton's jelly derived mesenchymal stromal cells (Protrans)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05061030"
                        ]
                  },
                  {
                        "Rank": 231,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive allogeneic hMSCs IV over 10-20 minutes once weekly for 4 weeks and standard of care drugs for heart failure.",
                              "Patients receive only standard of care drugs for heart failure."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Laboratory Biomarker Analysis",
                              "Other: Standard of Care",
                              "Drug: Mesenchymal Stem Cell Transplantation",
                              "Other: Laboratory Biomarker Analysis",
                              "Other: Standard of Care",
                              "Drug: Mesenchymal Stem Cell Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Arm I (hMSCs)",
                              "Arm II (standard of care drugs)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02408432"
                        ]
                  },
                  {
                        "Rank": 232,
                        "Acronym": [
                              "MISTIC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Doses will be given on days 1, 2, 3, and a fourth, optional dose may be given on day 7 at the discretion of the investigator and the treating physician."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "hCT-MSC infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04549285"
                        ]
                  },
                  {
                        "Rank": 233,
                        "Acronym": [
                              "ProTrans19+"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous administration, 1 dose, for 20 minutes",
                              "Intravenous administration, 1 dose, for 20 minutes"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Wharton's jelly-MSCs (WJ-MSC)",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic Wharton's jelly-MSCs (WJ-MSC)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04869397"
                        ]
                  },
                  {
                        "Rank": 234,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogenic Umbilical Cord derived stem cells injected intrathecally to enrolled MS patients",
                              "Allogenic Umbilical Cord derived stem cells injected intrathecally to enrolled MS patients along with a supervised physical therapy program",
                              "Supervised physical therapy program without stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord derived Mesenchymal Stem Cells",
                              "Biological: Umbilical cord derived Mesenchymal Stem Cells",
                              "Other: Supervised physical therapy",
                              "Other: Supervised physical therapy"
                        ],
                        "ArmGroupLabel": [
                              "Injection of Umbilical cord derived UC- MSCs",
                              "injection of UC- MSCs and SPT",
                              "Supervised Physical Therapy (SPT)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03326505"
                        ]
                  },
                  {
                        "Rank": 235,
                        "Acronym": [
                              "DMT1-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "type 1 diabetic patients receiving a single dose of allogeneic ex vivo expanded mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSCs"
                        ],
                        "ArmGroupLabel": [
                              "DMT1+MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02893306"
                        ]
                  },
                  {
                        "Rank": 236,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "TH-SC01 24 mL suspension of 120 million cells as a perilesional injection, once on Day 0."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: TH-SC01"
                        ],
                        "ArmGroupLabel": [
                              "TH-SC01"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04939337"
                        ]
                  },
                  {
                        "Rank": 237,
                        "Acronym": [
                              "VIVAAA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In a randomized fashion, the MSCs, in the appropriate dose, will be shipped to the performance site where the MSCs will be thawed, diluted and administered. The thawed MSCs with be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry. Patients will be premedicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home.",
                              "In a randomized fashion, the MSCs, in the appropriate dose, will be shipped to the performance site where the MSCs will be thawed, diluted and administered.The thawed MSCs with be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry. Patients will be premedicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home.",
                              "In a randomized fashion, the Plasmalyte A will be shipped to the performance site where it will be thawed and administered. The Plasmalyte A will be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry as will be performed on active groups in order to protect the blinding of this study. Patients will be pre-medicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. All patients will be admitted overnight for continued observation. The patient will be examined the following day and discharged home."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSCs",
                              "Drug: Placebo",
                              "Biological: MSCs",
                              "Drug: Placebo",
                              "Biological: MSCs",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Intravenous infusion of 1 million allogenic MSC's/Kg",
                              "Intravenous infusion of 3 million allogeneic MSCs/kg",
                              "Intravenous infusion of Plasmalyte A (placebo)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02846883"
                        ]
                  },
                  {
                        "Rank": 238,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogenic Bone Marrow mesenchymal stem cell in amniotic membrane transplant",
                              "Stem Cell with Amniotic Membrane Transplant"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Stem Cell with Amniotic Membrane Transplant",
                              "Procedure: Stem Cell with Amniotic Membrane Transplant"
                        ],
                        "ArmGroupLabel": [
                              "Bone Marrow mesenchymal stem cell",
                              "Allogenic limbal stem cell Transplant"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01562002"
                        ]
                  },
                  {
                        "Rank": 239,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Test group : CS20AT04 (allogenic bone marrow derived mesenchymal stem cells.)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: allogenic bone marrow derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "CS20AT04"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03174587"
                        ]
                  },
                  {
                        "Rank": 240,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The control group will undergo tendon repair procedure only (without augmentation)",
                              "The experimental group will undergo tendon repair procedure augmented with AAdMSC-HAM composite"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Tendon repair procedure",
                              "Procedure: Tendon repair augmented with AAdMSC-HAM composite"
                        ],
                        "ArmGroupLabel": [
                              "Control group (Tendon repair)",
                              "Experimental group (Tendon repair augmented with AAdMSC-HAM composite)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04670302"
                        ]
                  },
                  {
                        "Rank": 241,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 8 weeks thereafter to week 46 (n=5), (total # doses = 10).",
                              "IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 4 weeks thereafter to week 46 (n=5), (total # doses = 15)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: ExoFlo",
                              "Drug: ExoFlo"
                        ],
                        "ArmGroupLabel": [
                              "15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 8 weeks after that to week 46",
                              "15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 4 weeks after that to week 46"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05176366"
                        ]
                  },
                  {
                        "Rank": 242,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subject will receive the combined product of autologous cartilage cells and allogeneic AMSCs in a fibrin glue carrier."
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier"
                        ],
                        "ArmGroupLabel": [
                              "CartiLage Auto/Allo IMplantation for Focal Hip Cartilage Defects"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05553132"
                        ]
                  },
                  {
                        "Rank": 243,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Biological/Vaccine: Allogeneic HB-adMSCs\n\nAllogeneic HB-adMSCs will be administered intravenously to study participants who qualify.\n\nOther Names: Allogeneic Hope Biosciences adipose derived mesenchymal stem cells.",
                              "Placebo will be administered intravenously to study participants who qualify.\n\nOther Names: Sterile Saline Solution 0.9%"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Biological/Vaccine: Allogeneic HB-adMSCs",
                              "Other: Placebo",
                              "Biological: Biological/Vaccine: Allogeneic HB-adMSCs",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic HB-adMSCs.",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04995081"
                        ]
                  },
                  {
                        "Rank": 244,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Marrow stromal cell infusion"
                        ],
                        "ArmGroupLabel": [
                              "1"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00186914"
                        ]
                  },
                  {
                        "Rank": 245,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patients with FSGS who underwent intravenous injection of AD-MSC."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Intravenous injection"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02382874"
                        ]
                  },
                  {
                        "Rank": 246,
                        "Acronym": [
                              "CELOPHIN"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogenic Adiposse derived mesenchimal stem cells (MSC) Dose: 12,5 million cells",
                              "Allogenic Adiposse derived mesenchimal stem cells (MSC) Dose: 12,5 million cells at day 0 and 12,5 million cells at day 14"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Single Dose",
                              "Drug: Double Dose"
                        ],
                        "ArmGroupLabel": [
                              "Single dose Allogenic Adiposse derived mesenchimal stem cells",
                              "Double dose Allogenic Adiposse derived mesenchimal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05520086"
                        ]
                  },
                  {
                        "Rank": 247,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "hMSCs will be given via IV administration.",
                              "Lactated Ringer's Solution will be given via IV administration."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: hMSC",
                              "Biological: hMSC"
                        ],
                        "ArmGroupLabel": [
                              "hMSCs",
                              "Lactated Ringer's Solution"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04780685"
                        ]
                  },
                  {
                        "Rank": 248,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects assigned to this arm will receive 4 intravenous infusions of HB-adMSCs at 100 million cells/dose. HB-adMSC infusions will occur at day 0, 3, 7, and 10.",
                              "Subjects assigned to this arm will receive 4 intravenous infusions of placebo (saline solution). Infusions will occur at day 0, 3, 7, and 10."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSC",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "HB-adMSCs",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04362189"
                        ]
                  },
                  {
                        "Rank": 249,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adult ex-vivo expanded mesenchymal stromal cells from allogeneic bone marrow, cryopreserved, to combine with fibrin glue and cancellous human bone tissue + endomedullary nailing",
                              "Standard surgical treatment with isolated endomedullary nailing"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: XCEL-MT-OSTEO-BETA",
                              "Procedure: Surgical treatment",
                              "Procedure: Surgical treatment"
                        ],
                        "ArmGroupLabel": [
                              "XCEL-MT-OSTEO-BETA",
                              "Standard treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02630836"
                        ]
                  },
                  {
                        "Rank": 250,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "In the CABG with hUC-MSC treatment group, 1\u00d710^7 human umbilical cord Mesenchymal Stem Cells were injected to the edge of the myocardial infarction area at 20 points at the same time in CABG.",
                              "CABG was performed under general anesthesia."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "CABG with hUC-MSC treatment group",
                              "CABG group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04939077"
                        ]
                  },
                  {
                        "Rank": 251,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with Crohn's disease (refractory or intolerant to conventional therapies) treated with 2 successive injections of 1.5-2.0 x 10E6 allogenic MSC/kg BW at baseline and 4 weeks later."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells (MSC)"
                        ],
                        "ArmGroupLabel": [
                              "MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01540292"
                        ]
                  },
                  {
                        "Rank": 252,
                        "Acronym": [
                              "CELLULA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "250,000 cells/kg will be administered via intravenous infusion.",
                              "1,000,000 cells/kg will be administered via intravenous infusion.",
                              "4,000,000 cells/kg will be administered via intravenous infusion.",
                              "Placebo (Ringer's lactate solution) volume according to subject's weight."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Intravenous infusion of cells",
                              "Other: Intravenous infusion of cells",
                              "Other: Intravenous infusion of cells",
                              "Other: Intravenous infusion of cells"
                        ],
                        "ArmGroupLabel": [
                              "First arm",
                              "Second arm",
                              "Third arm",
                              "Fourth arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02328612"
                        ]
                  },
                  {
                        "Rank": 253,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "\"ex-vivo\" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue (under Xcelia-GMP conditions)for osteonecrosis of the femoral head",
                              "Isolated core decompression"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: XCEL-MT-OSTEO-ALPHA",
                              "Procedure: Standard treatment"
                        ],
                        "ArmGroupLabel": [
                              "XCEL-MT-OSTEO-ALPHA",
                              "Standard Treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01605383"
                        ]
                  },
                  {
                        "Rank": 254,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Application of IMP into peripheral vein (arm) by use of a perfusor."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: allo-APZ2-ACLF"
                        ],
                        "ArmGroupLabel": [
                              "allo-APZ2-ACLF"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03860155"
                        ]
                  },
                  {
                        "Rank": 255,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants in the hMSC treatment group will receive a total of 4 doses of the hMSC intervention. Each dose will be administered once about every 13 weeks within a year period."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Approximately 100 million cells allogeneic hMSC"
                        ],
                        "ArmGroupLabel": [
                              "hMSC Treatment group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04040348"
                        ]
                  },
                  {
                        "Rank": 256,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSC infusion for steroid-refractory grade II-IV acute GVHD. In this arm, 4 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.",
                              "MSC infusion for poor graft function. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.",
                              "MSC + DLI for poor donor T-cell chimerism after allogeneic HCT. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells",
                              "Biological: Mesenchymal stem cells",
                              "Biological: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "1",
                              "2",
                              "3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00603330"
                        ]
                  },
                  {
                        "Rank": 257,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Participants will receive an injection of 20 million, 100 million or 200 million autologous human mesenchymal stem cells.",
                              "Participants will receive an injection of 20 million, 100 million or 200 million allogeneic human mesenchymal stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Auto-hMSCs",
                              "Biological: Allo-hMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Auto-hMSCs",
                              "Allo-hMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01087996"
                        ]
                  },
                  {
                        "Rank": 258,
                        "Acronym": [
                              "PoseidonDCM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.",
                              "Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous hMSCs",
                              "Biological: Allogeneic hMSCs"
                        ],
                        "ArmGroupLabel": [
                              "Autologous hMSCs",
                              "Allogeneic hMSCs"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported",
                              "Class I - no limitation",
                              "Class II - Slight Limitation of Physical Activity",
                              "Class III - Marked Limitation of Physical Activity",
                              "Class IV -Inability to carry on physical activity"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG000",
                              "BG001",
                              "BG002"
                        ],
                        "NCTId": [
                              "NCT01392625"
                        ]
                  },
                  {
                        "Rank": 259,
                        "Acronym": [
                              "AMI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Dosage of intravenous route is 2 million MSCs/kg for each subject.",
                              "Dosage of intracoronary route is \u00b150 million MSCs for each subject.",
                              "Standard treatment of acute myocardia infarction"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells",
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Intravenous Group",
                              "Intracoronary Group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04340609"
                        ]
                  },
                  {
                        "Rank": 260,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: allo-APZ2-OTS",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Verum",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05464381"
                        ]
                  },
                  {
                        "Rank": 261,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSCs will be given at a median dose of 1\u00d710^6 cells/kg once weekly for 4 dose (as 1 cycle) or until CR. The response should be evaluated at 3 and 4 weeks. If symptoms of aGVHD progress at 3 weeks or the patients have NR at 4 weeks, these patients will switch to other therapy. If patients achieved PR at 4 weeks, another cycle will be given. Besides, CD25 monoclonal antibody (20mg/kg) will be administered at day 1,4,8,15, 21 and calcineurin inhibitors will also be used.",
                              "CD25 monoclonal antibody (20mg/kg, day 1,4,8,15,21) will be administered combined with calcineurin inhibitors. The response should be evaluated at 3 and 4 weeks. If symptoms of aGVHD progress at 3 weeks or the patients have NR at 4 weeks, these patients will switch to other therapy. If patients achieved PR at 4 weeks, another cycle will be given."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: CD25 monoclonal antibody",
                              "Drug: calcineurin inhibitors",
                              "Biological: MSCs",
                              "Drug: CD25 monoclonal antibody",
                              "Drug: calcineurin inhibitors"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "CD25 Mc Ab & calcineurin inhibitors"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02241018"
                        ]
                  },
                  {
                        "Rank": 262,
                        "Acronym": [
                              "HAPI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment 1: 1 subject will receive a single administration of allogeneic MSCs: 20 x 10^6 MSCs (20 million) cells delivered via peripheral intravenous infusion.",
                              "2 subjects will receive a single administration of allogeneic MSCs: 100 x 10^6 MSCs (100 million) cells delivered via peripheral intravenous infusion.",
                              "Cohort 1 (5 subjects): 20 million MSCs A single peripheral intravenous infusion of 20 x 10^6 MSCs (20 million cells) will be administered to each subject.",
                              "Cohort 2 (5 subjects): 100 million MSCs A single peripheral intravenous infusion of 100 x 10^6 MSCs (100 million cells) will be administered to each subject.",
                              "Cohort 3 (5 subjects): Placebo A single peripheral intravenous infusion of placebo (PlasmaLyte A containing 1% HSA) will be administered to each subject."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allo-hMSCs",
                              "Biological: Allo-hMSCs",
                              "Biological: Allo-hMSCs",
                              "Biological: Allo-hMSCs",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Safety Run-In: Treatment 1 Allo-hMSCs",
                              "Safety Run-In: Treatment 2 Allo-hMSCs",
                              "Randomized: Cohort 1 Allo-hMSCs",
                              "Randomized: Cohort 2 Allo-hMSCs",
                              "Randomized: Cohort 3 Allo-hMSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03058068"
                        ]
                  },
                  {
                        "Rank": 263,
                        "Acronym": [
                              "MEIC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This is an uncontrolled trial, phase IIa, proof of concept. Group control has not been included.\n\nAll patients will receive one single dose of 120 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Adipose derived allogenic mesenchymal stem cells (adAMSC)"
                        ],
                        "ArmGroupLabel": [
                              "Single Dose"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05521672"
                        ]
                  },
                  {
                        "Rank": 264,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02829216"
                        ]
                  },
                  {
                        "Rank": 265,
                        "Acronym": [
                              "NEPHSTROM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Bone marrow-derived Mesenchymal Stromal Cells",
                              "Cryostor CS10"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02585622"
                        ]
                  },
                  {
                        "Rank": 266,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenously-infused allogeneic, bone marrow-derived mesenchymal stromal cells (MSCs) in children with Osteogenesis Imperfecta Type III that will be infused at 0 months, 4 months, 8 months, 12 months, 16 months, and 20 months, after enrollment."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Bone marrow-derived mesenchymal stromal cells (MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Children with OI receiving Bone marrow-derived MSCs infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05559801"
                        ]
                  },
                  {
                        "Rank": 267,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "cAMR patients in this group receive additional intravenous allogeneic BM-MSCs (1*10^6/kg) every two weeks for four consecutive doses, besides current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib.",
                              "cAMR patients in this group receive current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: BM-MSCs",
                              "Other: Desensitization therapy (PP, IVIG, rituximab or Bortezomib)",
                              "Other: Desensitization therapy (PP, IVIG, rituximab or Bortezomib)"
                        ],
                        "ArmGroupLabel": [
                              "MSCs group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02563340"
                        ]
                  },
                  {
                        "Rank": 268,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with early poor graft function receive allogeneic BM-MSCs at the dose of 1*10^6/kg every week for four consecutive doses.",
                              "Patients with early poor graft function receive placebo of MSCs, i.e. saline every week for four consecutive doses."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: BM-MSCs",
                              "Other: Saline"
                        ],
                        "ArmGroupLabel": [
                              "MSCs group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02563366"
                        ]
                  },
                  {
                        "Rank": 269,
                        "Acronym": [
                              "GVHD-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01549665"
                        ]
                  },
                  {
                        "Rank": 270,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal stromal cell therapy in addition to corticosteroid therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cell therapy",
                              "Biological: Mesenchymal stromal cell therapy"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cell therapy",
                              "Corticosteroid therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01589549"
                        ]
                  },
                  {
                        "Rank": 271,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Low Dose Mesenchymal Stem Cells (MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Drug: Low Dose Mesenchymal Stem Cells ( MSCs)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03171194"
                        ]
                  },
                  {
                        "Rank": 272,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic (MSC's) Application to the Burn Wounds. The 1st group of 5 will be started on the lowest dose. If there are no adverse reactions, the 2nd group of 5 will receive a higher dose. This will be repeated for the 3rd and 4th groups with each receiving a higher dose.\n\nUp to 2 administrations of cells per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic (MSC's) Application to the Burn Wounds"
                        ],
                        "ArmGroupLabel": [
                              "Allogeneic (MSC's) Application to the Burn Wounds"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02104713"
                        ]
                  },
                  {
                        "Rank": 273,
                        "Acronym": [
                              "AMICI"
                        ],
                        "AgreementOtherDetails": [
                              "Publications (abstracts, posters or presentations) must be presented to Publication Steering Committee for review prior to submission or public display and are not allowed prior to the publication of the primary manuscript, or eighteen (18) months from the conclusion of the Study. PI shall provide Sponsor a copy of any proposed public disclosure at least 30 days prior to submission. Sponsor may ask PI to delay the disclosure for a maximum of 60 days to file proprietary protection."
                        ],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [
                              "OTHER"
                        ],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [
                              "Participants received matching-placebo solution 2 milliliters per minute (mL/min) infused Intracoronary for 60 min including line flush [0 Mesenchymal Precursor Cells (MPCs)/min] on Day 0.",
                              "Participants received MPC 12.5 solution 2 mL/min infused Intracoronary for 60 min including line flush (2.5x10^5 MPCs/min) on Day 0.",
                              "Participants received MPC 12.5 solution 2 mL/min infused Intracoronary for 60 min including line flush (5.0x10^5 MPCs/min) on Day 0."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Placebo",
                              "Biological: Mesenchymal Precursor Cells (MPC) 12.5 M",
                              "Biological: Mesenchymal Precursor Cells (MPC) 25 M"
                        ],
                        "ArmGroupLabel": [
                              "Placebo",
                              "Mesenchymal Precursor Cells (MPC) 12.5 M",
                              "Mesenchymal Precursor Cells (MPC) 25 M"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003",
                              "BG000",
                              "BG001",
                              "BG002",
                              "BG003"
                        ],
                        "NCTId": [
                              "NCT01781390"
                        ]
                  },
                  {
                        "Rank": 274,
                        "Acronym": [
                              "ASSIST-CLAD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "4 doses of Allogeneic bone-marrow derived MSCs (2x106 cells/kg) given intravenously twice weekly for 2 weeks",
                              "Placebo product manufactured to look like MSCs"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Bone-marrow derived MSCs",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Bone-marrow derived MSCs",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02709343"
                        ]
                  },
                  {
                        "Rank": 275,
                        "Acronym": [
                              "RACE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "During the first part of the study, 11 SDNS pediatric patients will receive 3 intravenous infusions of CB-MSCs at the dosage of 1.5 x 10^6/kg at a time interval of 1 to 2 weeks. The ongoing immunosuppressive treatment will be gradually tapered off after the first CB-MSC administration, as follows:\n\n25% reduction of the ongoing immunosuppressive treatment following the first administration;\n50% reduction of the ongoing immunosuppressive treatment following the second administration;\ninterruption of the ongoing immunosuppressive treatment following the third administration.\n\nIn the case that the hypothesis that P \u2265 0.600 is rejected and therefore the second part of the study will be required, 11 additional pediatric patients with SDNS will be treated with 3 intravenous infusions of CB-MSCs at the dosage of 2x10^6/kg at a time interval of 1 to 2 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Cord-blood mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04034316"
                        ]
                  },
                  {
                        "Rank": 276,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous infusion of 4 doses of allogenic adult mesenchymal stem cells from adipose tissue",
                              "Intravenous infusion of 4 doses of Placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Infusion of MSC",
                              "Drug: Infusion of placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02290041"
                        ]
                  },
                  {
                        "Rank": 277,
                        "Acronym": [
                              "PERISCOPE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.\n\nIn addition, the matrix-cell (PeriCord) construct will be placed on the ischemic area of the non-candidate revascularization area and will be fixed using surgical glue.\n\nPeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton\u00b4s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix .",
                              "The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed."
                        ],
                        "ArmGroupInterventionName": [
                              "Combination Product: PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton\u00b4s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix.",
                              "Procedure: Surgery by sternotomy"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03798353"
                        ]
                  },
                  {
                        "Rank": 278,
                        "Acronym": [
                              "MANUS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intramuscular injection of mesenchymal stromal cells (50 million allogeneic MSCs in 0.9% NaCl and 10% human serum albumin).",
                              "Intramuscular injection of placebo (NaCl 0.9% + 10% human serum albumin)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stromal cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "MSC injections",
                              "Placebo injections"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03211793"
                        ]
                  },
                  {
                        "Rank": 279,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "human umbilical cord derived MSC transplantation for SLE"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord derived MSC transplantation for SLE"
                        ],
                        "ArmGroupLabel": [
                              "human umbilical cord derived MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01741857"
                        ]
                  },
                  {
                        "Rank": 280,
                        "Acronym": [
                              "ADSTEM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "10 patients with RDEB will be selected to receive the intervention - mesenchymal stromal cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Intervention arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02323789"
                        ]
                  },
                  {
                        "Rank": 281,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Application of IMP on patients wound",
                              "Application of IMP on patients wound",
                              "Application of IMP on patients wound",
                              "Application of IMP on patients wound"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: allo-APZ2-CVU",
                              "Drug: Placebo",
                              "Biological: allo-APZ2-CVU",
                              "Biological: allo-APZ2-CVU"
                        ],
                        "ArmGroupLabel": [
                              "allo-APZ2-CVU (dose group 1: 1 x 10e6 cells/cm\u00b2)",
                              "Placebo",
                              "allo-APZ2-CVU (dose group 2: 3 x 10e6 cells/cm\u00b2)",
                              "allo-APZ2-CVU (dose group 3: 6 x 10e6 cells/cm\u00b2)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04971161"
                        ]
                  },
                  {
                        "Rank": 282,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution",
                              "Mesenchymal Stem Cells MSCs 5 x 10^6 cells/kg in Plasma-Lyte A solution",
                              "Placebo Infusion (Plasma-Lyte A solution only)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Low Dose Mesenchymal Stem Cells (MSCs)",
                              "Drug: High Dose Mesenchymal Stem Cells (MSCs)",
                              "Drug: Placebo Infusion"
                        ],
                        "ArmGroupLabel": [
                              "Low Dose Mesenchymal Stem Cells (MSCs)",
                              "High Dose Mesenchymal Stem Cells (MSCs)",
                              "Plasma Lyte A Solution"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02633163"
                        ]
                  },
                  {
                        "Rank": 283,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "PBSC will be intravenously infused at a dose of 2\u00d710^8/kg. MSCs will be intravenously infused at a dose of 1\u00d710^6 cells/kg once per week or until complete response(CR) . If the patients do not achieve CR or partial remission (PR) within 4 weeks, they will swithed to other therapy. If the patients achieve PR within 4 weeks, a second course of the same treatment will be given.",
                              "MSCs will be intravenously infused at a dose of 1\u00d710^6 cells/kg once per week or until CR. If the patients have no response (NR) within 4 weeks, they will switch to other therapy. If the patients achieve PR within 4 weeks, a second course of the same treatment will be given."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: PBSC",
                              "Biological: MSCs",
                              "Biological: MSCs"
                        ],
                        "ArmGroupLabel": [
                              "MSCs&PBSC",
                              "MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02240992"
                        ]
                  },
                  {
                        "Rank": 284,
                        "Acronym": [
                              "AloCELYVIR"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will received weekly infusion of AloCELYVIR during 8 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AloCELYVIR"
                        ],
                        "ArmGroupLabel": [
                              "AloCELYVIR"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04758533"
                        ]
                  },
                  {
                        "Rank": 285,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: Stem cell",
                              "Drug: Plasmalyte A"
                        ],
                        "ArmGroupLabel": [
                              "stem cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00883727"
                        ]
                  },
                  {
                        "Rank": 286,
                        "Acronym": [
                              "Cellkine"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single bilateral intra-articular injections of allogeneic BM-MSCs for lumbar facet joint arthropathy"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Single bilateral intra-articular injection of allogeneic BM-MSCs for lumbar facet joint arthropathy"
                        ],
                        "ArmGroupLabel": [
                              "BM-MSC injections for low back pain"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04410731"
                        ]
                  },
                  {
                        "Rank": 287,
                        "Acronym": [
                              "BOOST2B"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects eligible for the trial but not willing/able to participate in any of the experimental arms Matched historical controls. Subjects will be identified in historical registries and data will be retrieved from OI database",
                              "Administration of four doses of BOOST cells with the first dose between 1-4 years of age and the three additional doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BOOST cells"
                        ],
                        "ArmGroupLabel": [
                              "Prospective Control (Untreated) and historical controls",
                              "Treatment"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04623606"
                        ]
                  },
                  {
                        "Rank": 288,
                        "Acronym": [
                              "BOOSTB4"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "15 participants.\n\nAdministration of four postnatal doses of BOOST cells with the first dose as soon as possible after birth and the three additional doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight.",
                              "15 participants.\n\nAdministration of one prenatal dose of BOOST cells followed by three postnatal doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight.",
                              "1-30 participants.\n\nSubjects eligible for the trial but not willing/able to participate in any of the experimental arms.",
                              "30-150 participants.\n\nMatched historical controls. Subjects will be identified in historical registries and data will be retrieved from national OI registers and the OI Variant Database (Dalgleish 2018)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BOOST cells",
                              "Biological: BOOST cells"
                        ],
                        "ArmGroupLabel": [
                              "Postnatal",
                              "Prenatal",
                              "Prospective control (untreated)",
                              "Historic control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03706482"
                        ]
                  },
                  {
                        "Rank": 289,
                        "Acronym": [
                              "SAMCIS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset",
                              "Infusion of normal saline placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC Infusion",
                              "Biological: Placebo Comparator"
                        ],
                        "ArmGroupLabel": [
                              "MSC infusion",
                              "SHAM infusion"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01922908"
                        ]
                  },
                  {
                        "Rank": 290,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSCs-Exos. low-dose group",
                              "MSCs-Exos mid-dose group",
                              "MSCs-Exos high-dose group"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: low dosage MSCs-Exos administrated for nasal drip",
                              "Biological: mild dosage MSCs-Exos administrated for nasal drip",
                              "Biological: high dosage MSCs-Exos administrated for nasal drip"
                        ],
                        "ArmGroupLabel": [
                              "MSCs-Exos Dosage 1",
                              "MSCs-Exos Dosage 2",
                              "MSCs-Exos Dosage 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04388982"
                        ]
                  },
                  {
                        "Rank": 291,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "AstroStem-V which consists of three syringes and each syringe contains 1.0 x 10^8 cells / 3mL of saline with 30% human serum"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: AstroStem-V"
                        ],
                        "ArmGroupLabel": [
                              "AstroStem-V"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04527224"
                        ]
                  },
                  {
                        "Rank": 292,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00314483"
                        ]
                  },
                  {
                        "Rank": 293,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects enrolled into the CS20AT04 with corticosteroid taper regimen arm will receive two infusions of CS20AT04 (2.0\u00d710^6cell/kg), on 0 day and on 12 weeks post-enrollment."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: CS20AT04 (allogenic bone marrow derived mesenchymal stem cell)"
                        ],
                        "ArmGroupLabel": [
                              "Assigned interventions"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04835883"
                        ]
                  },
                  {
                        "Rank": 294,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "ALLO-ASC-SHEET Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells",
                              "Vehicle Control Hydrogel sheet without allogenic adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASC-SHEET",
                              "Biological: ALLO-ASC-SHEET"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASC-SHEET",
                              "Hydrogel SHEET(Vehicle control)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04497805"
                        ]
                  },
                  {
                        "Rank": 295,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal Precursor Cells (MPCs) - Dose 1 or Placebo",
                              "Mesenchymal Precursor Cells (MPCs) - Dose 2 or Placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Precursor Cells (MPCs)",
                              "Biological: Mesenchymal Precursor Cells (MPCs)"
                        ],
                        "ArmGroupLabel": [
                              "Cohort 1",
                              "Cohort 2"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01843387"
                        ]
                  },
                  {
                        "Rank": 296,
                        "Acronym": [
                              "ULSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous (IV) infusion of ULSC in 20 patients with COVID-19 ARDS:\n\nIn Phase 1, two separate cohorts per group will receive either a single dose (one infusion) or repeat dose regimen (two infusions separated by 48-hour interval). The first cohort enrolled will receive the single dose; the next cohort enrolled will be administered the repeat dose regimen.",
                              "Intravenous (IV) infusion of ULSC in 30 patients with COVID-19 ARDS:\n\nIn Phase 2a, 30 patients assigned ULSC will receive either a single dose (one infusion) or repeat dose regimen (two infusions separated by 48-hour interval). The ULSC dosing regimen will be chosen based on Phase 1 data of safety and tolerability.",
                              "Intravenous (IV) infusion of carrier control in 10 patients with COVID-19 ARDS:\n\nIn Phase 2a, 10 patients assigned Placebo will receive either single dose (one infusion) or repeat dose (two infusions separated by 48-hour interval) of carrier control; the dosing regimen will correspond to that of the experimental arm."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Lining Stem Cells (ULSC)",
                              "Biological: Umbilical Cord Lining Stem Cells (ULSC)",
                              "Other: Placebo (carrier control)"
                        ],
                        "ArmGroupLabel": [
                              "ULSC in Phase 1 Open Label",
                              "ULSC in Phase 2a Randomized",
                              "Placebo in Phase 2a Randomized"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04494386"
                        ]
                  },
                  {
                        "Rank": 297,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Escalating doses Dose escalation design with two dose levels. The low dose level involves a single intravenous infusion of \u03b3MSCs at 2x106 cells/kg. The high dose level involves a single intravenous infusion of \u03b3MSCs at 5x106 cells/kg."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Albuterol Sulfate",
                              "Drug: Interferon gamma-primed mesenchymal stromal cells (MSCs)",
                              "Drug: Prednisone"
                        ],
                        "ArmGroupLabel": [
                              "Infusion of \u03b3MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05035862"
                        ]
                  },
                  {
                        "Rank": 298,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Approximately 1x10E6 MSC/kg",
                              "Solution identical to experimental treatment, without the MSC"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cells",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal cells",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04615429"
                        ]
                  },
                  {
                        "Rank": 299,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Ambulatory patients receiving stem cell therapy",
                              "non-ambulatory patients receiving stem cell therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell",
                              "Drug: Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell"
                        ],
                        "ArmGroupLabel": [
                              "Ambulatory Patients",
                              "Non-Ambulatory Patients"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02484560"
                        ]
                  },
                  {
                        "Rank": 300,
                        "Acronym": [
                              "DW-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Low-dose group (5 x 10^7cells):\n\nDrug substance and the amount: 2.5 \u00d7 107 cells/1 mL/vial, 2 vials for low-dose group",
                              "High-dose group (1 x 10^8 cells):\n\nDrug substance and the amount: 2.5 \u00d7 107 cells/1 mL/vial, 4 vials for High-dose group",
                              "Control group (placebo):\n\nNo Drug substance: 4 vials for Place group"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: allogeneic mesenchymal stem cell",
                              "Drug: allogeneic mesenchymal stem cell",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Low-dose group",
                              "High-dose group",
                              "Control group (placebo)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04535856"
                        ]
                  },
                  {
                        "Rank": 301,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "AD-MSCs\uff08adipose-derived multipotent mesenchymal stem cells \uff09 intravenous injection at a dose of 2 million cells/kg at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks. The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Calcipotriol ointment",
                              "Biological: adipose-derived multipotent mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSCs plus Calcipotriol ointment group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03392311"
                        ]
                  },
                  {
                        "Rank": 302,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Procedure: Cellular transplantation"
                        ],
                        "ArmGroupLabel": [
                              "A"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00515307"
                        ]
                  },
                  {
                        "Rank": 303,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients received kidney transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.",
                              "Patients received hematopoietic stem cells transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.",
                              "Patients received mesenchymal stem cells transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed.",
                              "Patients received liver transplantation, with a baseline pre-transplant fecal sample and post-transplant samples collected. Standard transplantation procedures and precautions are being performed."
                        ],
                        "ArmGroupInterventionName": [
                              "Diagnostic Test: Intestinal microbiome new generation sequencing",
                              "Diagnostic Test: Intestinal microbiome new generation sequencing",
                              "Diagnostic Test: Intestinal microbiome new generation sequencing",
                              "Diagnostic Test: Intestinal microbiome new generation sequencing"
                        ],
                        "ArmGroupLabel": [
                              "Kidney transplant recipients",
                              "HSCT-recipients",
                              "MSCT-recipients",
                              "Liver transplant recipients"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04281797"
                        ]
                  },
                  {
                        "Rank": 304,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "15 patients will be given autologous bone marrow-derived mesenchymal stem cells (BM-MSC) and mesenchymal stem cell from allogeneic umbilical cord tissue (UC-MSC) combined with platelet-rich plasma (PRP) by intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC and PRP"
                        ],
                        "ArmGroupLabel": [
                              "MSC and PRP"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03484741"
                        ]
                  },
                  {
                        "Rank": 305,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Epidermolysis bullosa patients treated per study regimen with chemotherapy and stem cell transplant without mesenchymal stem cell infusions.",
                              "Epidermolysis bullosa patients treated per study regimen with chemotherapy and hematopoietic stem cell transplant with mesenchymal stem cell infusions using 300 cGY of TBI.",
                              "Epidermolysis bullosa patients treated regardless of original transplant arm with re-transplant using 300 cGy of TBI.",
                              "HLA-matched epidermolysis bullosa patients treated with hematopoietic cell transplant alone using 200 cGY BID of TBI (400 cGy total).",
                              "HLA-matched epidermolysis bullosa patients treated with hematopoietic cell transplant plus serial MSC infusions using 200 cGY BID of TBI (400 cGy total)",
                              "HLA-mismatched epidermolysis bullosa patients treated with hematopoietic cell transplant alone using 200 cGy BID of TBI (400 cGy total) + addition of low dose busulfan for recipients of HLA-mismatched bone marrow",
                              "HLA-mismatched epidermolysis bullosa patients treated with hematopoietic cell transplant plus serial MSC infusions using 200 cGy BID of TBI (400 cGy total) + addition of low dose busulfan for recipients of HLA-mismatched bone marrow"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Thymoglobulin",
                              "Drug: Cyclophosphamide",
                              "Drug: Fludarabine",
                              "Radiation: Total Body Irradiation",
                              "Procedure: Bone marrow infusion",
                              "Drug: Tacrolimus",
                              "Drug: Mycophenolate Mofetil",
                              "Drug: Thymoglobulin",
                              "Drug: Cyclophosphamide",
                              "Drug: Fludarabine",
                              "Radiation: Total Body Irradiation",
                              "Procedure: Bone marrow infusion",
                              "Drug: Tacrolimus",
                              "Drug: Mycophenolate Mofetil",
                              "Biological: Donor mesenchymal stem cell infusions",
                              "Drug: Thymoglobulin",
                              "Drug: Cyclophosphamide",
                              "Drug: Fludarabine",
                              "Radiation: Total Body Irradiation",
                              "Procedure: Bone marrow infusion",
                              "Drug: Tacrolimus",
                              "Drug: Mycophenolate Mofetil",
                              "Biological: Donor mesenchymal stem cell infusions",
                              "Drug: Thymoglobulin",
                              "Drug: Cyclophosphamide",
                              "Drug: Fludarabine",
                              "Radiation: Total Body Irradiation",
                              "Procedure: Bone marrow infusion",
                              "Drug: Mycophenolate Mofetil",
                              "Drug: Thymoglobulin",
                              "Drug: Cyclophosphamide",
                              "Drug: Fludarabine",
                              "Radiation: Total Body Irradiation",
                              "Procedure: Bone marrow infusion",
                              "Drug: Mycophenolate Mofetil",
                              "Biological: Donor mesenchymal stem cell infusions",
                              "Drug: Thymoglobulin",
                              "Drug: Cyclophosphamide",
                              "Drug: Fludarabine",
                              "Radiation: Total Body Irradiation",
                              "Procedure: Bone marrow infusion",
                              "Drug: Tacrolimus",
                              "Drug: Mycophenolate Mofetil",
                              "Drug: Busulfan",
                              "Drug: Thymoglobulin",
                              "Drug: Cyclophosphamide",
                              "Drug: Fludarabine",
                              "Radiation: Total Body Irradiation",
                              "Procedure: Bone marrow infusion",
                              "Drug: Tacrolimus",
                              "Drug: Mycophenolate Mofetil",
                              "Biological: Donor mesenchymal stem cell infusions",
                              "Drug: Busulfan"
                        ],
                        "ArmGroupLabel": [
                              "CLOSED TO ACCRUAL Arm A: HCT with 300 cGy of TBI",
                              "CLOSED TO ACCRUAL Arm B: HCT plus MSC, 300 cGy of TBI",
                              "Arm C: Re-Transplant with 300 cGy of TBI",
                              "Arm D: HCT with 200 cGy BID of TBI",
                              "Arm E: HCT plus MSC, 200 cGy BID of TBI",
                              "Arm F: HCT Alone, 200 cGy BID of TBI",
                              "Arm G: HCT plus MSC, 200 cGy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02582775"
                        ]
                  },
                  {
                        "Rank": 306,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "GXCPC1 contains 6.7\u00d710^6 or 4\u00d710^7 allogeneic adipose-derived stem cells (ADSCs) in 3 mL",
                              "Hya Joint Plus synovial fluid supplement 3mL"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: GXCPC1",
                              "Device: HA"
                        ],
                        "ArmGroupLabel": [
                              "GXCPC1",
                              "hyaluronic acid"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03943576"
                        ]
                  },
                  {
                        "Rank": 307,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Adult kidney transplant recipients with subclinical rejection (biopsy-proven antibody-mediated and/or cellular rejection, including borderline rejection) will be administered one low dose of allogeneic A-MSC.",
                              "Adult kidney transplant recipients with subclinical rejection (biopsy-proven antibody-mediated and/or cellular rejection, including borderline rejection) will be administered one high dose of allogeneic A-MSC."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)",
                              "Biological: High dose adipose tissue derived mesenchymal stromal cells (A-MSC)"
                        ],
                        "ArmGroupLabel": [
                              "Low Dose Group",
                              "High Dose Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05456243"
                        ]
                  },
                  {
                        "Rank": 308,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MPC dose 1 or Placebo",
                              "MPC dose 2 or Placebo",
                              "MPC dose 3 or Placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Precursor Cells (MPCs)",
                              "Drug: Mesenchymal Precursor Cells (MPCs)",
                              "Drug: Mesenchymal Precursor Cells (MPCs)"
                        ],
                        "ArmGroupLabel": [
                              "Cohort 1",
                              "Cohort 2",
                              "Cohort 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01576328"
                        ]
                  },
                  {
                        "Rank": 309,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: hUC-MSCs+Injectable collagen scaffold+CABG",
                              "Biological: hUC-MSCs+CABG",
                              "Procedure: CABG"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSCs+Injectable collagen scaffold+CABG",
                              "hUC-MSCs+CABG",
                              "CABG"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02635464"
                        ]
                  },
                  {
                        "Rank": 310,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "intravenous infusion, three doses of allo-APZ2-EB (2 x 10^6 cells/kg)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: allo-APZ2-EB"
                        ],
                        "ArmGroupLabel": [
                              "allo-APZ2-EB"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03529877"
                        ]
                  },
                  {
                        "Rank": 311,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single injection of mesenchymal stem cells at dose of 100M",
                              "Single injection of mesenchymal stem cells at dose of 300M",
                              "Single injection of normal saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: OSSM-001",
                              "Biological: OSSM-001",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "100M of OSSM-001",
                              "300M of OSSM-001",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05407766"
                        ]
                  },
                  {
                        "Rank": 312,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: REcycled CartiLage Auto/Allo IMplantation"
                        ],
                        "ArmGroupLabel": [
                              "RECLAIM"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03672825"
                        ]
                  },
                  {
                        "Rank": 313,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Conventional treatment and aerosol inhalation of MSCs-derived exosomes treatment participants will receive conventional treatment and 5 times aerosol inhalation of MSCs-derived exosomes (2.0*10E8 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSCs-derived exosomes"
                        ],
                        "ArmGroupLabel": [
                              "MSCs-derived Exosomes Treatment Group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04276987"
                        ]
                  },
                  {
                        "Rank": 314,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Autologue bone marrow mononuclear cell",
                              "Umbilical cord mesenchymal stem cell"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC",
                              "Biological: Intravenous Infusion of UC-MSC"
                        ],
                        "ArmGroupLabel": [
                              "BM-MNC experimental",
                              "UC-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04501341"
                        ]
                  },
                  {
                        "Rank": 315,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive Prochymal\u00ae consisting of 2 million hMSCs/kg actual body weight, intravenously (IV) on Days 1 and 4 along with daily standard of care which includes methylprednisolone 2 milligrams (mg)/kg IV or prednisone 2.5 mg/kg orally. Participants will also continue cyclosporine, tacrolimus, and/or mycophenolate mofetil (MMF) at full therapeutic doses.",
                              "Participants will receive Prochymal\u00ae consisting of 8 million hMSCs/kg actual body weight IV on Days 1 and 4 along with daily standard of care which includes methylprednisolone 2 mg/kg IV or prednisone 2.5 mg/kg orally. Participants will also continue cyclosporine, tacrolimus, and/or mycophenolate mofetil (MMF) at full therapeutic doses."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Prochymal\u00ae - 2 Million cells/kg",
                              "Drug: Methylprednisolone",
                              "Drug: Prednisone",
                              "Drug: Cyclosporine",
                              "Drug: Tacrolimus",
                              "Drug: Mycophenolate Mofetil",
                              "Drug: Prochymal\u00ae- 8 Million cells/kg",
                              "Drug: Methylprednisolone",
                              "Drug: Prednisone",
                              "Drug: Cyclosporine",
                              "Drug: Tacrolimus",
                              "Drug: Mycophenolate Mofetil"
                        ],
                        "ArmGroupLabel": [
                              "Prochymal\u00ae - 2 Million cells/kg",
                              "Prochymal\u00ae - 8 Million cells/kg"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00136903"
                        ]
                  },
                  {
                        "Rank": 316,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogenic Umbilical Cord derived stem cells injected intravenously to enrolled PD patients",
                              "Allogenic Umbilical Cord derived stem cells (MSCs) differentiated into neural stem cells (NSCs) injected intrathecaly and intravenously to enrolled PD patients."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Injection of Umbilical cord derived MSCs",
                              "Biological: Injection of Umbilical cord derived MSCs"
                        ],
                        "ArmGroupLabel": [
                              "Injection of Umbilical cord derived MSCs",
                              "Injection of MSCs differentiated into neural stem cells NSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03684122"
                        ]
                  },
                  {
                        "Rank": 317,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive hMSCs IV over 10-20 minutes on days 1, 14, 21, and 28 and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.",
                              "Patients receive hMSCs transendocardially for a total of 15 injections and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.",
                              "Patients receive standard of care treatment for heart failure."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Best Practice",
                              "Other: Laboratory Biomarker Analysis",
                              "Drug: Mesenchymal Stem Cell Transplantation",
                              "Other: Best Practice",
                              "Other: Laboratory Biomarker Analysis",
                              "Drug: Mesenchymal Stem Cell Transplantation",
                              "Other: Best Practice",
                              "Other: Laboratory Biomarker Analysis"
                        ],
                        "ArmGroupLabel": [
                              "Arm I (hMSCs IV)",
                              "Arm II (hMSCs transendocardially)",
                              "Arm III (standard of care)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02962661"
                        ]
                  },
                  {
                        "Rank": 318,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The patient will receive multiple injections in one session during the study. The injections will take place in the chronic wound bed and in the third distal part of the treated shin (in the form of a ring).\n\nMaximal amount of ABMD-MSC cells injected: 10-20*10^6 cells (up to volume of 20mL, depending on the wound size & patient weight)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ABMD-MSC"
                        ],
                        "ArmGroupLabel": [
                              "ABDM-MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01686139"
                        ]
                  },
                  {
                        "Rank": 319,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive conventional treatment and then be followed until the week 72 study visit.",
                              "Participants will receive conventional treatment plus a dose of BM-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit.",
                              "Participants will receive conventional treatment plus a dose of UC-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Conventional treatment",
                              "Genetic: Conventional plus BM-MSC treatment",
                              "Genetic: Conventional plus UC-MSC treatment"
                        ],
                        "ArmGroupLabel": [
                              "Conventional treatment",
                              "Conventional plus BM-MSC treatment",
                              "Conventional plus UC-MSC treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01844063"
                        ]
                  },
                  {
                        "Rank": 320,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "0.5 million (M) PLX-PAD cells per kg body weight",
                              "1.0 million (M) PLX-PAD cells per kg body weight",
                              "2.0 million (M) PLX-PAD cells per kg body weight"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: PLX-PAD",
                              "Drug: PLX-PAD",
                              "Drug: PLX-PAD"
                        ],
                        "ArmGroupLabel": [
                              "0.5 M PLX-PAD",
                              "1 M PLX-PAD",
                              "2 M PLX-PAD"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01795950"
                        ]
                  },
                  {
                        "Rank": 321,
                        "Acronym": [
                              "RESCeCUF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "31 patients were treated with one injection of Stromal Vascular Fraction from adipose tissue obtained by liposuction. Procedure: curettage, closure of the internal opening (IO) and SVF injection in IO (50%) and fistula tract (50%)",
                              "9 patients were treated with one injection of autologous mesenchymal stem cells from adipose tissue. Procedure: curettage, closure of the internal opening (IO) and autologous cell injection in IO (50%) and fistula tract (50%)",
                              "12 patients were treated with one injection of allogenic mesenchymal stem cells of healthy donors: Procedure: curettage, closure of the internal opening (IO) and allogenic cell injection in IO (50%) and fistula tract (50%)"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Mesenchymal Stem Cell injection",
                              "Procedure: Mesenchymal Stem Cell injection",
                              "Procedure: Mesenchymal Stem Cell injection"
                        ],
                        "ArmGroupLabel": [
                              "Stromal Vascular fraction",
                              "Autologous mesenchymal stem cells",
                              "Allogenic mesenchymal stem cells"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03726255"
                        ]
                  },
                  {
                        "Rank": 322,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: MSC"
                        ],
                        "ArmGroupLabel": [
                              "MSC Treatment",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04377334"
                        ]
                  },
                  {
                        "Rank": 323,
                        "Acronym": [
                              "HBPCOVID02"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "HB-ad MSC's allogeneic",
                              "Sterile Normal Saline"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: HB-adMSCs (allogeneic)",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Treatment",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05126563"
                        ]
                  },
                  {
                        "Rank": 324,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic mesenchymal stem cells",
                              "Standard therapy for patients with diabetic foot ulcer"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASC-DFU",
                              "Other: Standard therapy"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASC-DFU",
                              "Standard therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02619877"
                        ]
                  },
                  {
                        "Rank": 325,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic mesenchymal stem cells",
                              "Typical therapy conducted for burn injury patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASC-DFU",
                              "Device: Conventional Therapy"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASC-DFU",
                              "Conventional Therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02619851"
                        ]
                  },
                  {
                        "Rank": 326,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The treatment period consists of a single, 28-day cycle. Participants will be treated with ECP 2 to 3 times per week per the discretion of the treating physician. Participants will receive IV infusions of MSCs on days 1 (+ 2 days) and 8 (+/- 2 days). A third dose may be given on day 15 (+/- 2 days) if the principal investigator (PI) and treating physician determine the MSC infusions have benefited the participant.\n\nParticipants will be followed for up to 1 year for assessment of endpoints."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic mesenchymal stromal cells (MSCs)",
                              "Biological: Extracorporeal photopheresis (ECP)"
                        ],
                        "ArmGroupLabel": [
                              "MSCs + ECP"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05333029"
                        ]
                  },
                  {
                        "Rank": 327,
                        "Acronym": [
                              "SPINE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients with acute traumatic spinal cord injury grading AIS A (8 patients)",
                              "Patients with acute traumatic spinal cord injury grading AIS A or B (up to 20 patients)",
                              "Patients with acute traumatic spinal cord injury grading AIS A or B (up to 20 patients)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: FAB117-HC",
                              "Other: Control group",
                              "Drug: FAB117-HC"
                        ],
                        "ArmGroupLabel": [
                              "FAB117-HC (Ph 1)",
                              "Control group (Ph 2)",
                              "FAB117-HC (Ph 2)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02917291"
                        ]
                  },
                  {
                        "Rank": 328,
                        "Acronym": [
                              "STOD3"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects with a diagnosis of Type II or Type III osteogenesis imperfecta who have previously undergone a bone marrow transplant. Intervention: Mesenchymal Stromal Cells.",
                              "Subjects with Type II or III osteogenesis imperfecta who have not undergone a bone marrow transplant. Intervention: Mesenchymal Stromal Cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells",
                              "Biological: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Stratum A",
                              "Stratum B"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01061099"
                        ]
                  },
                  {
                        "Rank": 329,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogeneic bone marrow-derived mesenchymal stem cells (10^6/kg) from third party donors is intravenously given at day 0 (after renal artery reperfusion), day 7, day 14 and day 21.Induction therapy: ATG or Basiliximab; Maintenance therapy: low-dose Tacrolimus + mycophenolic acid + prednisone.\n\nThe third-party MSCs have no similar HLA alleles of kidney donors, and have no HLA alleles specific to preformed anti-HLA antibodies in recipients prior to KTx.",
                              "Placebo (saline) is intravenously given at day 0 (after renal artery reperfusion), day 7, day 14 and day 21. Induction therapy: ATG or Basiliximab; Maintenance therapy: low-dose Tacrolimus + mycophenolic acid + prednisone."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: bone marrow-derived mesenchymal stem cells",
                              "Drug: Induction therapy (ATG or Basiliximab)",
                              "Drug: Maintenance therapy (Low-dose CNI + MPA + steroids)",
                              "Other: Saline",
                              "Drug: Induction therapy (ATG or Basiliximab)",
                              "Drug: Maintenance therapy (Low-dose CNI + MPA + steroids)"
                        ],
                        "ArmGroupLabel": [
                              "MSCs group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02561767"
                        ]
                  },
                  {
                        "Rank": 330,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "low-dose group",
                              "high-dose group",
                              "No MPCs-derived exosomes"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Dosage 1 of MPCs-derived exosomes",
                              "Biological: Dosage 2 of MPCs-derived exosomes",
                              "Biological: No MPCs-derived exosomes"
                        ],
                        "ArmGroupLabel": [
                              "MPCs-derived exosomes Dosage 1",
                              "MPCs-derived exosomes Dosage 2",
                              "No exosomes"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04544215"
                        ]
                  },
                  {
                        "Rank": 331,
                        "Acronym": [
                              "NEUROSTEM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Allogenic mesenchymal stem cells from bone marrow"
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: intravitreal injection of MSV"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem from valladolid (MSV)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03173638"
                        ]
                  },
                  {
                        "Rank": 332,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Safety of adipose tissue-derived stem/stromal cells (ASCs) for 24 months in patients with recente onset type 1 diabetes.",
                              "To investigate the efficacy of daily 2000 UI Cholecalciferol/day for 24 months in patients with recente onset type 1 diabetes."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation",
                              "Biological: Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation"
                        ],
                        "ArmGroupLabel": [
                              "Adipose tissue-derived stem/stromal cells",
                              "Daily 2000 UI of daily oral cholecalciferol"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03920397"
                        ]
                  },
                  {
                        "Rank": 333,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: Cyclophosphamide",
                              "Drug: Fludarabine",
                              "Drug: Anti-thymocyte globulin",
                              "Drug: Cyclosporine A",
                              "Drug: Mycophenolate mofetil",
                              "Procedure: Mesenchymal stem cell transplantation",
                              "Radiation: Total body irradiation",
                              "Procedure: Bone marrow or umbilical cord blood (UCG) stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Transplant in Epidermolysis Bullosa"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01033552"
                        ]
                  },
                  {
                        "Rank": 334,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "infusion of Mesenchymal stem cells at dose 1 mln cells per kg",
                              "Without MSC infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "With MSC",
                              "Without MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01941394"
                        ]
                  },
                  {
                        "Rank": 335,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UMSC01 cells mixed with normal saline will be administered to patients after the onset of stroke."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UMSC01"
                        ],
                        "ArmGroupLabel": [
                              "UMSC01"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04434768"
                        ]
                  },
                  {
                        "Rank": 336,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSCs will be used to treat refractory CMV infection or CMV-associated diseases. MSCs will be intravenously infused at a dose of 1\u00d710^6 cells/kg. If anticipates do not attain the complete remission standards within 14d, a second course of the same treatment will be given."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSCs"
                        ],
                        "ArmGroupLabel": [
                              "MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02083731"
                        ]
                  },
                  {
                        "Rank": 337,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Efficacy of MSC infusion on one-year overall survival of patients transplanted with HLA-mismatched PBSC.\n\nPatients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2 Gy total body irradiation.\n\nMSC cells (1,5-3,0 x 10E6 MSC/Kg BW) will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor.",
                              "Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2Gy total body irradiation.\n\nIsotonic solution will be injected will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells",
                              "Other: Isotonic solution"
                        ],
                        "ArmGroupLabel": [
                              "Mensenchymal Stem Cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01045382"
                        ]
                  },
                  {
                        "Rank": 338,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will be given conventional therapy plus human cord mesenchymal stem cells transplantation with a 6 months follow-up.",
                              "Participants will be given conventional therapy plus combination of hCBMNCs together with hUCMSCs transplantation with a 6 months follow-up.",
                              "Participants will be given conventional therapy only with a 6 months follow-up."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells",
                              "Biological: human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells",
                              "Drug: Conventional therapy"
                        ],
                        "ArmGroupLabel": [
                              "Group1 :Conventional plus hUCMSCs treatment",
                              "Group 2: Conventional plus hCBMNCs and hUCMSCs therapy",
                              "Group 3:Conventional therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01443689"
                        ]
                  },
                  {
                        "Rank": 339,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cohort 1 will receive two single intravenous dose of UC MSCs of 1.5 million cells per kilogram body weight on their Study Month 0, and Study Month 3.\n\n- Each treatment period was separated by a 4 - week washout to allow the effective systemic elimination of the UC MSCs before subsequent treatment initiation",
                              "Cohort 2 will receive two single intravenous dose of UC MSCs of 1.5 million cells per kilogram body weight on their Study Month 7, and Study Month 10"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency",
                              "Biological: Umbilical Cord-Derived Mesenchymal Stem Cell for Male Patients with Sexual Deficiency"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical Cord-Derived Mesenchymal Stem Cell, then Placebo (group A)",
                              "Placebo, then Umbilical Cord-Derived Mesenchymal Stem Cell (group B)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05345418"
                        ]
                  },
                  {
                        "Rank": 340,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will receive intramuscular and local injection of stempeucel(R) in addition to standard protocol of care"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stempeucel(R)"
                        ],
                        "ArmGroupLabel": [
                              "Stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03056742"
                        ]
                  },
                  {
                        "Rank": 341,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "- Administration Method: 1 mL is withdrawn from 1 vial of clusters of adipose-derived mesenchymal stem cells, composed of adipose-derived mesenchymal stem cells and diluted with 20 mL of saline, which is divided into 1 cc pre-filled syringes and administered in 20 divided doses to 15-20 parts of the muscle in divided doses along the working areacourse of the tibial artery and peroneal artery below the knee joint (above the lower ischemic area) of the subject (above the lower ischemic area) of the subjects under general anesthesia or spinal anesthesia so that the entire diluted solution is administered.",
                              "- Administration Method: 1 mL is withdrawn from 1 vial of clusters of adipose-derived mesenchymal stem cells, composed of adipose-derived mesenchymal stem cells and diluted with 20 mL of saline, then administered to 15-20 parts of the muscle along the working areacourse of the tibial artery and peroneal artery below the knee joint (above the lower ischemic area) of the subject (above the lower ischemic area) of the subjects under general anesthesia or spinal anesthesia."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^7 cells/1 mL/vial)",
                              "Biological: Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^8 cells/1 mL/vial)"
                        ],
                        "ArmGroupLabel": [
                              "Test Group 1 (Low Dose)",
                              "Test Group 2 (High Dose)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04661644"
                        ]
                  },
                  {
                        "Rank": 342,
                        "Acronym": [
                              "T2DM"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "30 patients with Type 2 Diabetes Mellitus will be enrolled and received mononuclear cells and mesenchymal stem cells by intravenous infusion.",
                              "30 patients with Type 2 Diabetes Mellitus will be enrolled and treated by standard medicines."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: BM-MNC and UC-MSC",
                              "Other: Control"
                        ],
                        "ArmGroupLabel": [
                              "BM-MNC and UC-MSC",
                              "Stand medicines"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03943940"
                        ]
                  },
                  {
                        "Rank": 343,
                        "Acronym": [
                              "MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymal Stem cell + Nacl 0.9%"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal Stem Cell + NaCl 0,9% 2ml"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04499105"
                        ]
                  },
                  {
                        "Rank": 344,
                        "Acronym": [
                              "MSC-CY"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cyclophosphamide 50 mg/kg/day at +3, +4 day once daily after BMT Mesenchymal stromal cells 1*10^6/kg at day of recovery"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Cyclophosphamide",
                              "Biological: Mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "MSC+CY"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02270307"
                        ]
                  },
                  {
                        "Rank": 345,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intramuscular injection",
                              "Intramuscular injection"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: mesenchymal stem cells",
                              "Drug: Plasmalyte A"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00883870"
                        ]
                  },
                  {
                        "Rank": 346,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intra-articular injection of XSTEM-OA"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: XSTEM-OA"
                        ],
                        "ArmGroupLabel": [
                              "XSTEM-OA"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05344157"
                        ]
                  },
                  {
                        "Rank": 347,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "SBI-101 device containing 250 million MSCs",
                              "SBI-101 device containing 750 million MSCs",
                              "Case control subjects will receive only standard-of-care treatment and will be followed for the same safety assessments as active study participants."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: SBI-101",
                              "Biological: SBI-101"
                        ],
                        "ArmGroupLabel": [
                              "Low dose cohort",
                              "High dose cohort",
                              "Case controls"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04445220"
                        ]
                  },
                  {
                        "Rank": 348,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Trophic factors from umbilical cord mesenchymal stem cells administered intra-nasally"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Trophic factors from umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Intra-nasal infusion of MTF"
                        ],
                        "ArmGroupType": [
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02192736"
                        ]
                  },
                  {
                        "Rank": 349,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Repeated intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells (hUC-MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC Transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000"
                        ],
                        "NCTId": [
                              "NCT02481440"
                        ]
                  },
                  {
                        "Rank": 350,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02034188"
                        ]
                  },
                  {
                        "Rank": 351,
                        "Acronym": [
                              "EVADE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cohort study with a representative sample of patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: blood sample",
                              "Biological: bone marrow sample"
                        ],
                        "ArmGroupLabel": [
                              "immune escape mecanims"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03964922"
                        ]
                  },
                  {
                        "Rank": 352,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Trophic factors from umbilical cord mesenchymal stem cells administered intra-articularly.",
                              "Trophic factors from umbilical cord mesenchymal stem cells administered subcutaneously once per week for 12 weeks."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Trophic factors from umbilical cord mesenchymal stem cells",
                              "Biological: Trophic factors from umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Intra-articular knee injection of MTF",
                              "Subcutaneous injection of MTF"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02003131"
                        ]
                  },
                  {
                        "Rank": 353,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical cord mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01985464"
                        ]
                  },
                  {
                        "Rank": 354,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive standardized treatment, consisting of Oseltamivir and Azithromycin",
                              "Patients receive intravenous infusion of 1x10^6 unit of umbilical-cord derived mesenchymal stem cells (UC-MSCs)/kgBW in 100 cc of 0.9% NaCl for 1 hour, in addition to standardized treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Oseltamivir",
                              "Drug: Azithromycin",
                              "Drug: Oseltamivir",
                              "Drug: Azithromycin",
                              "Biological: Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Control Group",
                              "Experiment Group"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04457609"
                        ]
                  },
                  {
                        "Rank": 355,
                        "Acronym": [
                              "IDUNN"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive MC0518 1-2 million cells/ kilogram infusions (based on body weight at the Screening Visit) once a week for 4 weeks (Visit Day 1, 8, 15, and 22). Participants with partial response (PR) on Day 28 will have 2 additional MC0518 infusions administered on Day 29 and 36.",
                              "Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP), anti-thymocyte globulin (ATG), everolimus, and ruxolitinib (RUX)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MC0518",
                              "Biological: BAT"
                        ],
                        "ArmGroupLabel": [
                              "MC0518",
                              "Best Available Therapy (BAT)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04629833"
                        ]
                  },
                  {
                        "Rank": 356,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects will receive intravenous infusions of COVI-MSC (two vials or a total of \u2248 30 million cells) on Day 0, Day 2, and Day 4",
                              "Subjects will receive intravenous infusions of placebo (two vials) on Day 0, Day 2, and Day 4"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: COVI-MSC",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "COVI-MSC",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04903327"
                        ]
                  },
                  {
                        "Rank": 357,
                        "Acronym": [
                              "MSC Secretome"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Escalating doses of allogenic MSC eye drops will be assigned at the lowest dose level.",
                              "Escalating doses of allogenic MSC eye drops will be assigned at the medium dose level.",
                              "Escalating doses of allogenic MSC eye drops will be assigned at the high dose level."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC Secretome Eye Drops",
                              "Biological: MSC Secretome Eye Drops",
                              "Biological: MSC Secretome Eye Drops"
                        ],
                        "ArmGroupLabel": [
                              "Low dose of allogenic MSC drops",
                              "Medium dose of allogenic MSC drops",
                              "High dose of allogenic MSC drops"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05204329"
                        ]
                  },
                  {
                        "Rank": 358,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human umbilical cord tissue-derived mesenchymal stem cells administered into the knee joint once",
                              "Human umbilical cord tissue-derived mesenchymal stem cells administered once per day for 3 consecutive days"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord tissue-derived mesenchymal stem cells",
                              "Biological: Human umbilical cord tissue-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Intra-articular knee injection of UC-MSC",
                              "IV injection of UC-MSC"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02237846"
                        ]
                  },
                  {
                        "Rank": 359,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment with direct intra-myocardial Injection of 100 million allogeneic adipose derived stem cells (CSCC_ASC) into the heart"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic adipose derived stem cells (CSCC_ASC)"
                        ],
                        "ArmGroupLabel": [
                              "Stem cell therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02387723"
                        ]
                  },
                  {
                        "Rank": 360,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "SBI-101 device containing 250 million MSCs",
                              "SBI-101 device containing 750 million MSCs",
                              "Sham device containing no MSCs"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: SBI-101",
                              "Biological: SBI-101",
                              "Device: Sham"
                        ],
                        "ArmGroupLabel": [
                              "Low dose cohort",
                              "High dose cohort",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Sham Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03015623"
                        ]
                  },
                  {
                        "Rank": 361,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication",
                              "standard frailty treatment and supplementary medication"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord Mesenchymal Stem Cells transplantation",
                              "Drug: standard frailty treatment and supplementary medication",
                              "Drug: standard frailty treatment and supplementary medication"
                        ],
                        "ArmGroupLabel": [
                              "Treatment (UC-MSC trasnplatation)",
                              "control arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04919135"
                        ]
                  },
                  {
                        "Rank": 362,
                        "Acronym": [
                              "OA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "After arthroscopy intervention, patient will be given 10 million UC-MSCs and 2 cc Secretome twice with 2 weeks interval via intra-articular injection.",
                              "After arthroscopy intervention, patient will be given 2 cc Secretome, 10 million UC-MSCs, and 2 cc Secretome with 2 weeks interval via intra-articular injection.",
                              "Without arthroscopy intervention, patient will be given 10 million UC-MSCs and 2 cc Secretome twice with 2 weeks interval via intra-articular injection.",
                              "Without arthroscopy intervention, patient will be given 2 cc Secretome, 10 million UC-MSCs, and 2 cc Secretome with 2 weeks interval via intra-articular injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome",
                              "Biological: Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome",
                              "Biological: Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome",
                              "Biological: Non Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome"
                        ],
                        "ArmGroupLabel": [
                              "Arthroscopy + Booster",
                              "Arthroscopy + Pre-Conditioning",
                              "Non Arthroscopy + Booster",
                              "Non Arthroscopy + Pre-Conditioning"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04314661"
                        ]
                  },
                  {
                        "Rank": 363,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Other: Bone Marrow Cell Transplantation",
                              "Drug: Cyclophosphamide",
                              "Drug: Cyclosporin",
                              "Procedure: Mesenchymal Stem Cell Transplantation",
                              "Drug: Busulfan",
                              "Other: Bone Marrow Cell Transplantation",
                              "Radiation: Irradiation, Total Body",
                              "Drug: Cyclophosphamide",
                              "Procedure: Mesenchymal Stem Cell Transplantation",
                              "Drug: Busulfan"
                        ],
                        "ArmGroupLabel": [
                              "1",
                              "2"
                        ],
                        "ArmGroupType": [
                              "Other",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00705120"
                        ]
                  },
                  {
                        "Rank": 364,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Those randomized to the treatment arm will receive MPCs injected directly into the LV endocardium following clinical surgical maneuvers to recruit the LV (mitral valve repair, aortic valve repair, and/or resection of endocardial fibroelastosis) or BDG.\n\nMPCs will be delivered directly into the LV endocardium via a 23-25 gauge needle following completion of all surgical procedures. A total dose of 20 million cells will be delivered, divided evenly into ~11 injections of 50 \u00b5L each. The total volume is not to exceed 2.0 mL.",
                              "Those subjects randomized to the control arm will receive standard LV recruitment or BDG with no injection."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MPC; rexlemestrocel-L"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm",
                              "Control Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03079401"
                        ]
                  },
                  {
                        "Rank": 365,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single topical dose of XSTEM-VLU",
                              "Single topical dose of CryoStor CS10"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: XSTEM-VLU",
                              "Other: Vehicle"
                        ],
                        "ArmGroupLabel": [
                              "XSTEM-VLU",
                              "Vehicle"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05549609"
                        ]
                  },
                  {
                        "Rank": 366,
                        "Acronym": [
                              "MESRIX-III"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "60 patients will be randomized to receive adipose-derived allogeneic stem cells",
                              "60 patients will receive placebo consisting of CryoStor10 (BiolifeSolutions), the freeze media for ASCs containing 10% Dimethyl sulfoxide (DMSO)."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stem cells",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Stem cell group",
                              "Placebo group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04776538"
                        ]
                  },
                  {
                        "Rank": 367,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells",
                              "Hydrogel sheet without Allogenic mesenchymal stem cell"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASC-DFU",
                              "Procedure: Vehicle sheet"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASC-DFU",
                              "Vehicle Sheet"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03370874"
                        ]
                  },
                  {
                        "Rank": 368,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "IM injection Single treatment; multiple injections",
                              "IM injection Double treatment; multiple injections"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: PLX-PAD",
                              "Biological: PLX-PAD"
                        ],
                        "ArmGroupLabel": [
                              "PLX-PAD low dose",
                              "PLX-PAD high dose"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00951210"
                        ]
                  },
                  {
                        "Rank": 369,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Experimental: ALLO-ASC-DFU Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells",
                              "Placebo Comparator: Vehicle Control Hydrogel sheet without allogenic adipose-derived mesenchymal stem cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASC-DFU",
                              "Procedure: Hydrogel SHEET(Vehicle control)"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASC-DFU",
                              "Hydrogel SHEET(Vehicle control)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03754465"
                        ]
                  },
                  {
                        "Rank": 370,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single dose of 500\u3395/\u33a0 of cartilage defect"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cartistem",
                              "Procedure: Microfracture treatment"
                        ],
                        "ArmGroupLabel": [
                              "Cartistem",
                              "Microfracture treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01041001"
                        ]
                  },
                  {
                        "Rank": 371,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single peripheral IV infusion of 25 million Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Single peripheral IV infusion of 50 million Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Single peripheral IV infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Single peripheral IV infusion of 200 million Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Single peripheral IV infusion of placebo."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Study Group A",
                              "Study Group B",
                              "Study Group C",
                              "Study Group D",
                              "Study Group E"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03169231"
                        ]
                  },
                  {
                        "Rank": 372,
                        "Acronym": [
                              "Keloid"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A patient will be given UC-MSCs 2 million cells / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.",
                              "A patient will be given CM 1 cc / cm3. After 3 weeks, the patient will be given CM 1 cc / cm3. The maximum size of Keloid is 15 cm per patient.",
                              "A patient will be given Triamcinolone acetonide 40 mg / cc / cm3. After 3 weeks the patient will be given Triamcinolone acetonide 40 mg/cc / cm3. The maximum size of Keloid is 15 cm per patient."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical Cord-Mesenchymal Stem Cells and Conditioned Medium",
                              "Biological: Conditioned Medium",
                              "Biological: Conditioned Medium",
                              "Biological: Triamcinolone Acetonide"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs + CM",
                              "CM + CM",
                              "Triamcinolon acetonide"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04326959"
                        ]
                  },
                  {
                        "Rank": 373,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant recipient's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.",
                              "This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant donor's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.",
                              "This group would get no stem cell infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells",
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Autologus Mesenchymal Stem Cells",
                              "Allogeniec Mesenchymal Stem Cells",
                              "Control without Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02409940"
                        ]
                  },
                  {
                        "Rank": 374,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical Cord Mesenchymal Stem Cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03505034"
                        ]
                  },
                  {
                        "Rank": 375,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "2.5 x 10^6 MSC per kg will be infused intravenously on Day 1",
                              "Plasmalyte with 0.5% Human Serum Albumin will be infused intravenously on Day 1"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells (MSCs)",
                              "Other: Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)"
                        ],
                        "ArmGroupLabel": [
                              "Group A Treatment",
                              "Group B Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04061746"
                        ]
                  },
                  {
                        "Rank": 376,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Biological: Mesenchymal stromal cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stromal cell treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02055625"
                        ]
                  },
                  {
                        "Rank": 377,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial of ALLO-ASC-DFU-101"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASC-DFU"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASC-DFU treatment"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03183726"
                        ]
                  },
                  {
                        "Rank": 378,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "bone marrow-derived mesenchymal stem cells",
                              "Placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: bone marrow-derived mesenchymal stem cells",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01849887"
                        ]
                  },
                  {
                        "Rank": 379,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects with ALLO-ASC-CD injection in phase 1 clinical trial of ALLOASC-CD-101"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASC-CD"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASC-CD injection"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03183661"
                        ]
                  },
                  {
                        "Rank": 380,
                        "Acronym": [
                              "hUC-MSC-SLE"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Human Umbilical Cord derived MSCs",
                              "Drug: Cyclophosphamide"
                        ],
                        "ArmGroupLabel": [
                              "Human Umbilical Cord derived MSCs",
                              "Cyclophosphamide"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01539902"
                        ]
                  },
                  {
                        "Rank": 381,
                        "Acronym": [
                              "GVHD Cyto-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cyto-MSC (5 million UCMSCs per kg bodyweight) and standard treatment",
                              "Placebo (normal saline) and standard treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical cord derived mesenchymal stem cell",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Group A",
                              "Group B"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03847844"
                        ]
                  },
                  {
                        "Rank": 382,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months",
                              "Placebo: Sham operation, 10ml saline, once a month for 4 months"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Umbilical Cord Mesenchymal Stem Cells",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical Cord Mesenchymal Stem Cells",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03521336"
                        ]
                  },
                  {
                        "Rank": 383,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months",
                              "Sham operation and 10ml saline as placebos, once a month for 4 months"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Umbilical Cord Mesenchymal Stem Cells",
                              "Drug: Placebos"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical Cord Mesenchymal Stem Cells",
                              "Control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03521323"
                        ]
                  },
                  {
                        "Rank": 384,
                        "Acronym": [
                              "SEED-MSC"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "All patients were required to have successful revascularization of an infarct-related artery on coronary angiography at the time of randomization. All patients received aspirin (300 mg loading dose, then 100 mg daily) and clopidogrel (600 mg loading dose, then 75 mg daily) with optimal medical therapy according to the American College of Cardiology (ACC)/ American Heart Association (AHA) guidelines for treatment of ST-segment elevation myocardial infarction (STEMI)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Mesenchymal stem cell",
                              "Drug: Control group"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cell treatment group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01392105"
                        ]
                  },
                  {
                        "Rank": 385,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: PLX-PAD IM injection",
                              "Biological: PLX-PAD IM injection",
                              "Biological: PLX-PAD IM injection"
                        ],
                        "ArmGroupLabel": [
                              "PLX-PAD low dose",
                              "PLX-PAD intermediate dose",
                              "PLX-PAD high dose"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00919958"
                        ]
                  },
                  {
                        "Rank": 386,
                        "Acronym": [
                              "CLT-OA1"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical cord derived-mesenchymal stromal cells at a dose of 2x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee",
                              "Umbilical cord derived-mesenchymal stromal cells at a dose of 20x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee",
                              "Umbilical cord derived-mesenchymal stromal cells at a dose of 80x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical cord derived-mesenchymal stromal cells",
                              "Biological: umbilical cord derived-mesenchymal stromal cells",
                              "Biological: umbilical cord derived-mesenchymal stromal cells"
                        ],
                        "ArmGroupLabel": [
                              "CLT low-dose",
                              "CLT medium-dose",
                              "CLT high-dose"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03810521"
                        ]
                  },
                  {
                        "Rank": 387,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cohort 1: Low-dose BC-U001 Cohort 2: Medium-dose BC-U001 Cohort 3: High-dose BC-U001"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: hUC-MSC infusion (BC-U001)"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC infusion (BC-U001)"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04971980"
                        ]
                  },
                  {
                        "Rank": 388,
                        "Acronym": [
                              "MSCforGVHD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00827398"
                        ]
                  },
                  {
                        "Rank": 389,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "first cohort: 1 million stem cells/kg administered at days 1, 8 and 15\nsecond cohort: 2 million stem cells / kg administered at days 1, 8 and 15\nthird cohort: 4 million stem cells / kg administered at days 1, 8 and 15",
                              "Lactate Ringer\u00b4s solution"
                        ],
                        "ArmGroupInterventionName": [
                              "Genetic: Stem cells",
                              "Genetic: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Treatment",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01663116"
                        ]
                  },
                  {
                        "Rank": 390,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single intravenous infusion (1-2 millions of MSCs per kilogram body weight) of ex-vivo expanded third-party MSC (from healthy donors) will be performed in patients assigned to the MSC procedure in addition to the liver transplantation."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stromal Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stromal Cells (MSC)",
                              "No treatment."
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02260375"
                        ]
                  },
                  {
                        "Rank": 391,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "0.5 \u00d7 10 ^ 6 / kg (body weight) of it-hMSC per person",
                              "1 \u00d7 10 ^ 6 / kg (body weight) of it-hMSC per person",
                              "2 \u00d7 10 ^ 6 / kg (body weight) of it-hMSC per person",
                              "Highest dose of it-hMSC",
                              "Sub high dose of it-hMSC",
                              "placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: it-hMSC",
                              "Biological: it-hMSC",
                              "Biological: it-hMSC",
                              "Biological: it-hMSC",
                              "Biological: it-hMSC",
                              "Biological: it-hMSC"
                        ],
                        "ArmGroupLabel": [
                              "Low dose group",
                              "Middle dose group",
                              "High dose group",
                              "Highest dose cell group",
                              "Sub high dose cell group",
                              "placebo group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04953663"
                        ]
                  },
                  {
                        "Rank": 392,
                        "Acronym": [
                              "ADMIRE-CD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Cx601 is a cell suspension in aseptic buffered solution containing human expanded adipose-derived stem cells (eASCs) of allogeneic origin in disposable vials with no preservative agents. The cells will be given at a dose of 120 million cells (5 million cells / mL) for intralesional injection.",
                              "Placebo (saline solution) will be given also for intralesional injection at the same quantity (volume, 24 mL) and following the same schedule."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Cx601",
                              "Other: Saline solution"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm",
                              "Placebo-control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01541579"
                        ]
                  },
                  {
                        "Rank": 393,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Direct injection of vertebral bone marrow derived mesenchymal stem cells at a dose of 100 million cells into the ileal pouch fistula(s) at baseline with a possible repeat injection at 3 months if not completely healed from the first injection.",
                              "Direct injection of normal saline. If not completely healed after 6 months, participants will then cross over to the treatment group to receive a direct injection of vertebral allogeneic bone marrow derived mesenchymal stem cells at a dose of 100 million cells into ileal pouch fistula(s)."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Ossium vBM-MSC",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Vertebral Bone Marrow Derived Mesenchymal Stem Cells (vBM-MSC)",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05075811"
                        ]
                  },
                  {
                        "Rank": 394,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The people in this group will receive intravenous MSCs 2 x 10^6/kg as a single dose and standardized treatment of acute ischemic stroke.",
                              "The people in this group will receive placebo and standardized treatment of acute ischemic stroke."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human umbilical cord mesenchymal stem cells",
                              "Other: standardized treatment",
                              "Biological: Placebo",
                              "Other: standardized treatment"
                        ],
                        "ArmGroupLabel": [
                              "MSCs group",
                              "control group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04093336"
                        ]
                  },
                  {
                        "Rank": 395,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive no interventions after rectal cancer treatment.",
                              "Patients receive NeuroRegen scaffold transplantation after rectal cancer treatment.",
                              "Patients receive autologous bone marrow mononuclear cells with NeuroRegen scaffold transplantation after rectal cancer treatment.",
                              "Patients receive allogeneic human umbilical cord mesenchymal stem cells with NeuroRegen scaffold transplantation after rectal cancer treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: Laparoscopic surgery",
                              "Device: NeuroRegen scaffold transplantation",
                              "Biological: NeuroRegen scaffold/BMMCs transplantation",
                              "Biological: NeuroRegen scaffold/HUC-MSCs transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Laparoscopic surgery",
                              "NeuroRegen scaffold transplantation",
                              "NeuroRegen scaffold/BMMCs transplantation",
                              "NeuroRegen scaffold/HUC-MSCs transplantation"
                        ],
                        "ArmGroupType": [
                              "Sham Comparator",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02648386"
                        ]
                  },
                  {
                        "Rank": 396,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients in group A will receive two autologous AD-MSC administrations on day 0 and day 90 \u00b1 7",
                              "Patients in group B will receive two autologous AD-MSC administrations on day 180 \u00b1 14 and day 270 \u00b1 14"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency",
                              "Biological: Autologous adipose-derived mesenchymal stem cell administration for female with sexual functional deficiency"
                        ],
                        "ArmGroupLabel": [
                              "AD-MSCs infusions, then Placebo",
                              "Placebo, then AD-MSCs infusions"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05329662"
                        ]
                  },
                  {
                        "Rank": 397,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single intravenous infusion of 0.5\u00d710^6, 1\u00d710^6, 2\u00d710^6 it-hMSC/kg",
                              "Single intravenous infusion of 1 ml/kg placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: it-hMSC",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Experimental: it-hMSC",
                              "Placebo-controlled: Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04590118"
                        ]
                  },
                  {
                        "Rank": 398,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05113342"
                        ]
                  },
                  {
                        "Rank": 399,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Injection of High Dose MPCs with Hyaluronic Acid",
                              "Injection of Low Dose MPCs with Hyaluronic Acid",
                              "Injection of saline solution.",
                              "Injection of hyaluronic acid solution"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Single Dose MPCs Injection",
                              "Biological: Single Dose MPCs Injection",
                              "Procedure: Single injection of saline solution",
                              "Procedure: Single injection of hyaluronic acid"
                        ],
                        "ArmGroupLabel": [
                              "High Dose MPCs",
                              "Low Dose MPCs",
                              "Saline injection",
                              "Hyaluronic acid injection"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Sham Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01290367"
                        ]
                  },
                  {
                        "Rank": 400,
                        "Acronym": [
                              "ENTRUST"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients will have a patch of expanded somatic mesenchymal stromal cells (MSCs) seeded onto a decellularised human tracheal-scaffold surgically implanted to repair bronchial fistula."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: BPF-001"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04435249"
                        ]
                  },
                  {
                        "Rank": 401,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Third party donor Mesenchymal Stem Cells (MSC) will be administered via intrathecal administration at the assigned dose on days 0, 7 and 14. Dose escalation will be guided by a fast track design. One patient is entered per dose level until a DLT is experienced. At that point, two additional patients will be enrolled at the same dose level. Dose levels will be 2.5 x 10e6 MSC/kg per dose, 5 x 10e6 MSC/kg per dose or 7.5 x 10e6 MSC/kg per dose."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal Stem Cell"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02410239"
                        ]
                  },
                  {
                        "Rank": 402,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Selected SLE patients were randomly divided into treated group and control group. In the treated group, 100-300 million allogeneic human umbilical cord derived mesenchymal stem cells were infused intravenously for one SLE patient. The possible adverse events, including immediately after mesenchymal stem cells infusions, as well as the long-term safety profiles were observed."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "mesenchymal stem cells"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03219801"
                        ]
                  },
                  {
                        "Rank": 403,
                        "Acronym": [
                              "HERA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Single dose of 20 million Longeveron Mesenchymal Stem Cells (LMSCs) will be delivered followed by vaccination with Fluzone High-Dose at 1 week post-infusion.",
                              "Single dose of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) followed by vaccination with Fluzone High-Dose at either 1 week (Cohort B) or 4 weeks (Cohort C) post infusion.",
                              "2 cohorts to receive a single infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort A: 30 subjects) or placebo (Cohort B:30 subjects) followed by vaccination with Fluzone High-Dose."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Biological: Fluzone High Dose Vaccine",
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Biological: Fluzone High Dose Vaccine",
                              "Biological: Longeveron Mesenchymal Stem Cells (LMSCs)",
                              "Biological: Fluzone High Dose Vaccine"
                        ],
                        "ArmGroupLabel": [
                              "Pilot Phase- Cohort A",
                              "Pilot Phase Cohort B & C",
                              "Double-Blind,Randomized,Placebo Phase"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02982915"
                        ]
                  },
                  {
                        "Rank": 404,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Ex vivo cultured human mesenchymal stem cells from Wharton jelly, in a blinded syringe (initial treatment) / Placebo (month 6)",
                              "Placebo in a blinded syringe (initial treatment) / XCEL-UMC-BETA (month 6)"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: XCEL-UMC-BETA",
                              "Drug: Placebo",
                              "Drug: XCEL-UMC-BETA",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "XCEL-UMC-BETA/placebo",
                              "Placebo/XCEL-UMC-BETA"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03003364"
                        ]
                  },
                  {
                        "Rank": 405,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00557635"
                        ]
                  },
                  {
                        "Rank": 406,
                        "Acronym": [
                              "AMETHYST"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive a single dose of GEM00220 at 15 million cells",
                              "Participants will receive a single dose of GEM00220 at 60 million cells",
                              "Participants will receive a single dose of GEM00220 at 150 million cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: GEM00220",
                              "Biological: GEM00220",
                              "Biological: GEM00220"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm - Low Dose",
                              "Treatment arm - Mid dose",
                              "Treatment arm - High dose"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04961658"
                        ]
                  },
                  {
                        "Rank": 407,
                        "Acronym": [
                              "TAF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Trinity Evolution"
                        ],
                        "ArmGroupLabel": [
                              "Trinity Evolution"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00988338"
                        ]
                  },
                  {
                        "Rank": 408,
                        "Acronym": [
                              "ACT-AKI"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment with AC607",
                              "Treatment with Placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: AC607",
                              "Biological: Vehicle Only"
                        ],
                        "ArmGroupLabel": [
                              "AC607",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01602328"
                        ]
                  },
                  {
                        "Rank": 409,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects with ALLO-ASC-DFU treatment in phase 2 clinical trial of ALLO-ASC-DFU-201",
                              "Subjects with Standard therapy in phase 2 clinical trial of ALLO-ASC-DFU-201"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASC-DFU",
                              "Other: Standard therapy"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASC-DFU",
                              "Standard therapy"
                        ],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03183804"
                        ]
                  },
                  {
                        "Rank": 410,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "10 subjects to receive lowest dose of NeoFuse (MPCs)",
                              "4 subjects standard posterolateral spinal fusion with instrumentation",
                              "10 subjects to receive middle dose of NeoFuse",
                              "3 subjects standard posterolateral spinal fusion with instrumentation",
                              "10 subjects to receive highest dose of NeoFuse",
                              "3 subjects with standard posterolateral spinal fusion with instrumentation"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: NeoFuse",
                              "Procedure: posterolateral spinal fusion with instrumentation",
                              "Biological: NeoFuse",
                              "Procedure: posterolateral spinal fusion with instrumentation",
                              "Biological: NeoFuse",
                              "Procedure: posterolateral spinal fusion with instrumentation"
                        ],
                        "ArmGroupLabel": [
                              "1",
                              "2",
                              "3",
                              "4",
                              "5",
                              "6"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator",
                              "Experimental",
                              "Active Comparator",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT00549913"
                        ]
                  },
                  {
                        "Rank": 411,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "First three subjects enrolled will receive a single infusion of mesenchymal stromal cells based on their individual weight",
                              "Subsequent subjects enrolled will receive two infusions (a week apart) of mesenchymal stromal cells based on their individual weight",
                              "Subsequent subjects enrolled will receive four infusions (a week apart) of mesenchymal stromal cells based on their individual weight"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Autologous mesenchymal stromal cells (MSCs)",
                              "Biological: Autologous mesenchymal stromal cells (MSCs)",
                              "Biological: Autologous mesenchymal stromal cells (MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Dose Level 1: Infusion of MSCs",
                              "Dose Level 2: Infusion of MSCs",
                              "Dose Level 3: Infusion of MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02359929"
                        ]
                  },
                  {
                        "Rank": 412,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Application of IMP on patients wound"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: allo-APZ2-DFU"
                        ],
                        "ArmGroupLabel": [
                              "Experimental: allo-APZ2-DFU"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03267784"
                        ]
                  },
                  {
                        "Rank": 413,
                        "Acronym": [],
                        "AgreementOtherDetails": [
                              "Publications (abstracts, posters or presentations) must be presented to the Publication Steering Committee for review prior to submission or public display and are not allowed prior to the publication of the primary manuscript, or eighteen (18) months from the conclusion of the Study. PI shall provide Sponsor a copy of any proposed public disclosure at least 30 days prior to submission. Sponsor may ask PI to delay the disclosure for a maximum of 60 days to file proprietary protection."
                        ],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [
                              "OTHER"
                        ],
                        "AgreementRestrictiveAgreement": [
                              "Yes"
                        ],
                        "ArmGroupDescription": [
                              "Participants were treated with intravenous (IV) remestemcel-L at a dose of 2\u00d710^6 mesenchymal stromal cells (MSCs)/kilogram (kg) actual body weight at Screening, twice per week, for each of 4 consecutive weeks (initial therapy) given at least 3 days apart and no more than 5 days apart for any infusion. Eligible participants received an additional once per week infusion, for each of 4 consecutive weeks (continued therapy) of remestemcel-L and twice per week infusions, for each of 4 consecutive weeks (aGVHD flare therapy) of remestemcel-L at the same initial therapy dose of 2\u00d710^6 MSCs/kg actual body weight at Screening."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: remestemcel-L"
                        ],
                        "ArmGroupLabel": [
                              "Remestemcel-L 2\u00d710^6 MSCs/kg"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02336230"
                        ]
                  },
                  {
                        "Rank": 414,
                        "Acronym": [
                              "Bonecure"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "HC-SVT-1001. Intraosseous use. 3x10(6) cells/cm3. (Initial protocol) HC-SVT-1002. Intraosseous use. 3x10(6) cells/cm3. (Protocol amendment)"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment)"
                        ],
                        "ArmGroupLabel": [
                              "Experimental"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02483364"
                        ]
                  },
                  {
                        "Rank": 415,
                        "Acronym": [
                              "PRIME"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [],
                        "ArmGroupLabel": [],
                        "ArmGroupType": [],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05210309"
                        ]
                  },
                  {
                        "Rank": 416,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Wharton's Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans\u00ae).Study patients 1-3 will receive a single dose of 25 million cells, patients 4-6 will receive 100 million cells and patients 7-9 will receive 200 million cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ProTrans\u00ae"
                        ],
                        "ArmGroupLabel": [
                              "Treatment"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04896853"
                        ]
                  },
                  {
                        "Rank": 417,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: MSCs"
                        ],
                        "ArmGroupLabel": [
                              "MSCs treated"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03631589"
                        ]
                  },
                  {
                        "Rank": 418,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The group of patients receive allogeneic MSCs therapies."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal Stem Cells(MSCs)"
                        ],
                        "ArmGroupLabel": [
                              "The MSCs group"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02706132"
                        ]
                  },
                  {
                        "Rank": 419,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymal stem cells",
                              "Other: Saline"
                        ],
                        "ArmGroupLabel": [
                              "Mesenchymal stem cells cohort",
                              "Saline cohort"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04194671"
                        ]
                  },
                  {
                        "Rank": 420,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intraarticular injection of 2\u00d710~7 Umbilical-cord mesenchimal stem cells with plateler Rich Plasma(5ml)",
                              "Intraarticular injection of hyaluronic acid"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Umbilical-cord mesenchymal stromal cells (UC-MSCs)",
                              "Other: Hyaluronic acid"
                        ],
                        "ArmGroupLabel": [
                              "Intervention group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03166865"
                        ]
                  },
                  {
                        "Rank": 421,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Dose A: PNEUMOSTEM\u00ae 10 million cells per kg Dose B: PNEUMOSTEM\u00ae 20 million cells per kg"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "PNEUMOSTEM\u00ae"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02381366"
                        ]
                  },
                  {
                        "Rank": 422,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Dose level 1. 3 subjects will receive OSSM-001 at 2M cells/kg and followed for 28 days post dose to observe for DLT.",
                              "Dose level 2. If no DLTs are observed in the previous dose level, 3 subjects will receive OSSM-001 at 6M cells/kg and followed for 28 days post dose to observe for DLT.",
                              "Dose level 3. If no DLTs are observed in the previous dose level, 3 subjects will receive OSSM-001 at 12M cells/kg and followed for 28 days post dose to observe for DLT.",
                              "Dose level 4. If no DLTs are observed in the previous dose level, 3 subjects will receive OSSM-001 at 24M cells/kg and followed for 28 days post dose to observe for DLT."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: OSSM-001",
                              "Biological: OSSM-001",
                              "Biological: OSSM-001",
                              "Biological: OSSM-001"
                        ],
                        "ArmGroupLabel": [
                              "2M cells/kg",
                              "6M cells/kg",
                              "12M cells/kg",
                              "24M cells/kg"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05443464"
                        ]
                  },
                  {
                        "Rank": 423,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "2 million human MSC (hMSC)/kg infusion versus placebo infusion",
                              "4 million hMSC/kg infusion versus placebo infusion",
                              "6 million hMSC/kg infusion versus placebo infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: 2 million hMSC/kg",
                              "Biological: placebo",
                              "Biological: 4 million hMSC/kg",
                              "Biological: placebo",
                              "Biological: 6 million hMSC/kg",
                              "Biological: placebo"
                        ],
                        "ArmGroupLabel": [
                              "Cohort 1",
                              "Cohort 2",
                              "Cohort 3"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03186417"
                        ]
                  },
                  {
                        "Rank": 424,
                        "Acronym": [
                              "SCA"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Ten patients in the group only receive nerve functional evaluation and electrophysiology examination before and 1,3,6,12 months after recruit. They will not accept cell therapy.",
                              "10 patients in the group accept stem cell transplantation."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: stem cell transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Control group",
                              "Stem cell transplantation"
                        ],
                        "ArmGroupType": [
                              "No Intervention",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01489267"
                        ]
                  },
                  {
                        "Rank": 425,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three doses of Neural progenitor cell (4*10^6) intrathecally at 48-72h, 5d and 10d after birth.+routine therapy",
                              "Three doses of concentrated paracrine factors of human mesenchymal stem cell \uff080.5ml\uff09 intrathecally at 12h,24h,48h after birth.+routine therapy",
                              "Three doses of concentrated paracrine factors 0.5ml intrathecally at 12h,24h,48h after birth.And three doses of neural progenitor cell (4*10^6) intrathecally at 48-72h, 5d and 10d after birth.+routine therapy",
                              "neonates only receive routine therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: neural progenitor cell",
                              "Biological: Paracrine factors",
                              "Biological: progenitor cell and paracrine factors"
                        ],
                        "ArmGroupLabel": [
                              "Neural progenitor cell",
                              "Paracrine factors",
                              "Progenitor cell and paracrine factors",
                              "Routine therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02854579"
                        ]
                  },
                  {
                        "Rank": 426,
                        "Acronym": [
                              "RIMECARD"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical cord derived mesenchymal are injected intravenously to Patients.",
                              "Intravenous placebo solution are administrated to Patients."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ucMSC",
                              "Other: Controls"
                        ],
                        "ArmGroupLabel": [
                              "ucMSC",
                              "Controls"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01739777"
                        ]
                  },
                  {
                        "Rank": 427,
                        "Acronym": [
                              "scorem-cells"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Revascularization surgery, placement of an extracellular matrix patch without WJ-MSCs and injection of culture medium without WJ-MSCs will be performed.",
                              "Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSCs around the infarcted zone will be performed."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Wharton's jelly-derived mesenchymal cells",
                              "Biological: Wharton's jelly-derived mesenchymal cells"
                        ],
                        "ArmGroupLabel": [
                              "Comparison/control group",
                              "Experimental group"
                        ],
                        "ArmGroupType": [
                              "Placebo Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04011059"
                        ]
                  },
                  {
                        "Rank": 428,
                        "Acronym": [
                              "ExoOA-1"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intra-articular knee injection of exosomes (3-5 x 10e11 particles) derived from allogeneic mesenchymal stromal cells. Single dose."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Exosomes (sEVs)"
                        ],
                        "ArmGroupLabel": [
                              "Experimental group - sEVs"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05060107"
                        ]
                  },
                  {
                        "Rank": 429,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "Yes"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Target dose of 2 times 106 MSC/kg for up to 12 doses"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSC"
                        ],
                        "ArmGroupLabel": [
                              "1"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02379442"
                        ]
                  },
                  {
                        "Rank": 430,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Human Umbilical Cord Derived MSC:\n\nPatients who receive standard of care plus treatment with ex vivo cultured adult human Umbilical Cord Derived Mesenchymal Stem Cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human Umbilical Cord Derived MSC"
                        ],
                        "ArmGroupLabel": [
                              "Human Umbilical Cord Derived MSC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01754454"
                        ]
                  },
                  {
                        "Rank": 431,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: HUC-MSCs Transplantation",
                              "Biological: HUC-MSCs with Injectable Collagen Scaffold Transplantation"
                        ],
                        "ArmGroupLabel": [
                              "HUC-MSCs Transplantation",
                              "HUC-MSCs with Injectable Collagen Scaffold Transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02644447"
                        ]
                  },
                  {
                        "Rank": 432,
                        "Acronym": [
                              "RP"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "a total 2 ml volume of Conditioned Medium derived Umbilical Cord Mesenchymal Stem Cell will be injected by peribulbar",
                              "1.8 ml cell preparations are suspended in physiological NaCl until it reaches a total of 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) suspension will be injected by peribulbar",
                              "1.8 ml cell preparations are suspended in Conditioned Medium (CM) until it reaches total of 2 ml volume of cell suspension. Umbilical Cord Mesenchymal Stem Cell (UC-MSC) + Conditioned Medium (CM) suspension will be injected by peribulbar"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Conditioned Medium (CM)",
                              "Biological: Umbilical Cord Mesenchymal Stem Cell (UC-MSC)",
                              "Biological: Umbilical Cord Mesenchymal Stem Cell (UC-MSC)",
                              "Biological: Conditioned Medium (CM)"
                        ],
                        "ArmGroupLabel": [
                              "Conditioned Medium (CM)",
                              "UC-MSC + NaCl",
                              "UC-MSC+CM"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Active Comparator",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04315025"
                        ]
                  },
                  {
                        "Rank": 433,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will be infusion via the intravenous at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication",
                              "1.5 x 10^6 umbilical Cord Mesenchymal Stem Cells per body kg will be infusion via the intrathecal at baseline, and the second transplantation will be performed 3 months after the first transplantation and combination with standard frailty treatment and supplementary medication",
                              "standard stroke treatment and rehabilitation therapy"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSC infusion via intravenous route",
                              "Other: standard stroke treatment and rehabilitation therapy",
                              "Biological: UC-MSC infusion via intrathecal route",
                              "Other: standard stroke treatment and rehabilitation therapy",
                              "Other: standard stroke treatment and rehabilitation therapy"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSC infusion via intravenous route",
                              "UC-MSC infusion via intrathecal route",
                              "control arm"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Other"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05292625"
                        ]
                  },
                  {
                        "Rank": 434,
                        "Acronym": [
                              "COVID-19"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Five patients, of any sex and age, with bilateral COVID-19 pneumonia, severe SIRA with PaO2 / FiO2 less than 150, lymphopenia less than 800 total lymphocytes, CT with bilateral pneumonia, SOFA less than 11 and that has not improved in relation to the following parameters: a) persistent PaO2 / FiO2 less than 150; b) persistent fever, c) increase in D-dimer of at least 50% of the baseline and / or ferritin greater than 1000, after 48 h of hospital stay receiving the standard management measures used at that time in the Care Center, will be included in the study. This treatment will be administered after discussing it with the relatives that it is a procedure considered as rescue and will be carried out with informed consent.",
                              "The results obtained in the treated group will be compared against the historical controls treated in INCMNSZ, evaluating the same variables."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Infusion IV of Mesenchymal Stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Treated group",
                              "Control Group"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04416139"
                        ]
                  },
                  {
                        "Rank": 435,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: Administration of ERC"
                        ],
                        "ArmGroupLabel": [
                              "Intramuscular injection of ERC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01558908"
                        ]
                  },
                  {
                        "Rank": 436,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive EN001 intravenously (IV) once on Day 1. Before 30 minutes EN001 dosing, there will be premedication (solu-cortef 1-2 mg/kg + Lorazepam 0.1 mg/kg (max 2 mg) + Ondansetron (5 mg/m^2) + Chlorpheniramine (1 mg for 2~6 years old; 2 mg for 6~12 years old; 4 mg for over 12 years old)+ Acetaminophen) administered to assure safety of participants from issues such as immune rejection, due to the process of thawing in a frozen state of EN001.",
                              "Participants will receive EN001 intravenously (IV) once on Day 1. Before 30 minutes EN001 dosing, there will be premedication (solu-cortef 1-2 mg/kg + Lorazepam 0.1 mg/kg (max 2 mg) + Ondansetron (5 mg/m^2) + Chlorpheniramine (1 mg for 2~6 years old; 2 mg for 6~12 years old; 4 mg for over 12 years old)+ Acetaminophen) administered to assure safety of participants from issues such as immune rejection, due to the process of thawing in a frozen state of EN001."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: EN001",
                              "Drug: EN001"
                        ],
                        "ArmGroupLabel": [
                              "Dose group A (Low dose)",
                              "Dose group B (High dose)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05338099"
                        ]
                  },
                  {
                        "Rank": 437,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive EN001 intravenously (IV) once on Day 0.",
                              "Participants will receive EN001 intravenously (IV) once on Day 0."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: EN001",
                              "Drug: EN001"
                        ],
                        "ArmGroupLabel": [
                              "Dose group A (Low dose)",
                              "Dose group B (High dose)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05333406"
                        ]
                  },
                  {
                        "Rank": 438,
                        "Acronym": [
                              "ELPIS"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "10 consecutive HLHS patients will be enrolled and treated with Longeveron Mesenchymal Stem Cells (LMSCs). A single administration of LMSCs will be performed via intramyocardial injections during the Stage II (BDCPA) surgery. Dosing is based on body weight. Each LMSC-treated patient will be given 2.5 x 105 LMSCs per kg of body weight. The entire dose of the cells will be roughly 600 microliters.",
                              "Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial.",
                              "Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Longeveron Mesenchymal Stem Cells",
                              "Biological: Longeveron Mesenchymal Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Cohort A - Phase 1 (Open Label)",
                              "Cohort B - Phase 2 Treatment Group",
                              "Cohort C - Phase 2 Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "No Intervention"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03525418"
                        ]
                  },
                  {
                        "Rank": 439,
                        "Acronym": [
                              "IMPACT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Single-stage cartilage repair surgery using autologous chondrons (10-20%) and allogeneic MSCs (80-90%) in a fibrin glue carrier with a dosage of two million cells/ cm2 applied once during a surgical procedure."
                        ],
                        "ArmGroupInterventionName": [
                              "Other: Cartilage repair surgery"
                        ],
                        "ArmGroupLabel": [
                              "Cartilage repair surgery"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02037204"
                        ]
                  },
                  {
                        "Rank": 440,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "BX-U001 (hUC-MSC suspension) will be tested at dose of 0.75 or 1.5\u00d710^6 cells/kg of body weight via a single IV infusion using a blood transfusion kit.",
                              "The control arm will be given placebo which contains the same cell suspension solution but without cells. Placebo will be given the same way as BX-U001 via a single IV infusion using a blood transfusion kit."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: hUC-MSC suspension",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSC treatment",
                              "Placebo control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03828344"
                        ]
                  },
                  {
                        "Rank": 441,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Dose level 1 is 40 x 10^6",
                              "Dose level 2 is 160 x 10^6",
                              "RAPA-501 cells at either dose level 1 or dose level 2 (whichever has been deemed safe during phase 1)",
                              "Placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: RAPA-501-Allo off-the-shelf Therapy of COVID-19",
                              "Biological: RAPA-501-Allo off-the-shelf Therapy of COVID-19",
                              "Biological: RAPA-501-Allo off-the-shelf Therapy of COVID-19",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Single agent RAPA-501 cells (dose level 1)",
                              "Single agent RAPA-501 cells (dose level 2)",
                              "RAPA-501 cells",
                              "Placebo-control Cohort"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04482699"
                        ]
                  },
                  {
                        "Rank": 442,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical cords from healthy donor are processed with 24 hours after vaginal delivery.\n\nThe cords are delivered in a sterilized jar the laboratory to process. After washing in PBS to remove any contaminating blood, the cord is cut into small pieces. The pieces are minced and digested by enzyme. The UC-MSCs is cultured and expanded using commercially available serum-free and xeno-free medium at 37\u00b0C in a humidified atmosphere with 5% CO2. The UC-MSCs is suspended in 15 ml of saline buffer"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human umbilical cord-derived mesenchymal stem cell infusion"
                        ],
                        "ArmGroupLabel": [
                              "human umbilical cord-derived mesenchymal stem cell transplantation for patients with liver cirrhosis"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05331872"
                        ]
                  },
                  {
                        "Rank": 443,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: MesenCure",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "treatment",
                              "control"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05497401"
                        ]
                  },
                  {
                        "Rank": 444,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "50 participants will receive the investigational drug (Chondrogen and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day.",
                              "50 participants will receive the placebo (Saline and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Chondrogen",
                              "Biological: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Active Participant of Phase 2B Clinical Study Chondrogen",
                              "Placebo Participant of Phase 2B Clinical Study Chondrogen"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04520945"
                        ]
                  },
                  {
                        "Rank": 445,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Osteoarthritic Knee of the patients who will be treated wth high tibial osteotomy and implantation of allogenic human umbilical cord blood-derived stem cells."
                        ],
                        "ArmGroupInterventionName": [
                              "Procedure: umbilical cord blood stem cell implantation for osteoarthritis treatment"
                        ],
                        "ArmGroupLabel": [
                              "Osteoarthritic knee patients"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04234412"
                        ]
                  },
                  {
                        "Rank": 446,
                        "Acronym": [
                              "ALF"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Biological: Stemchymal\u00ae ALF/ ACLF patients will receive low (0.5 x 10^6 cells/kg) or high (2 x 10^6 cells/kg) dose of Stemchymal\u00ae through intravenous infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Stemchymal\u00ae"
                        ],
                        "ArmGroupLabel": [
                              "Stemchymal\u00ae"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03629015"
                        ]
                  },
                  {
                        "Rank": 447,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Umbilical-cord mesenchymal stromal cells (UC-MSCs)\n\nAllogeneic UC-MSCs 20 x 10e6 diluted on 3 mL of saline solution + 5% of Plasma AB\n\nArm 2a: single infusion group. UC-MSCs at 0 month\n\nArm 2b: double infusion group. UC-MSCs at 0 and 6 months",
                              "Drug: Hyaluronic Acid 3 mL of HA intra-articular injection at baseline and 6 months"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: umbilical-cord mesenchymal stromal cells",
                              "Drug: Hyaluronic Acid"
                        ],
                        "ArmGroupLabel": [
                              "Umbilical-cord mesenchymal stromal cells",
                              "Hyaluronic Acid (HA)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02580695"
                        ]
                  },
                  {
                        "Rank": 448,
                        "Acronym": [
                              "STALLONe"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "A single infusion of 2x10e6 cells per meter squared was performed 30 to 120 days following allogeneic stem cell transplant."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: GD2 CAR modified Tri-virus specific cytotoxic t-cells"
                        ],
                        "ArmGroupLabel": [
                              "GD2 CAR modified Tri-virus CTL infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "<=18 years",
                              "Between 18 and 65 years",
                              ">=65 years",
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000",
                              "BG000"
                        ],
                        "NCTId": [
                              "NCT01460901"
                        ]
                  },
                  {
                        "Rank": 449,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "91 patients will be involved in this group",
                              "91 patients will be involved in this group"
                        ],
                        "ArmGroupInterventionName": [
                              "Other: hUC-MSCs",
                              "Other: glucocorticoids"
                        ],
                        "ArmGroupLabel": [
                              "hUC-MSCs combined with glucocorticoids group.",
                              "glucocorticoids group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05531266"
                        ]
                  },
                  {
                        "Rank": 450,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patients receive oncolytic adenovirus Ad5-DNX-2401 IA over 20-30 minutes on day 0.",
                              "Patients receive oncolytic adenovirus Ad5-DNX-2401 as in part I. After 2 weeks, patients undergo surgery, then receive oncolytic adenovirus Ad5-DNX-2401 IA over 20-30 minutes."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Oncolytic Adenovirus Ad5-DNX-2401",
                              "Biological: Oncolytic Adenovirus Ad5-DNX-2401",
                              "Procedure: Therapeutic Conventional Surgery"
                        ],
                        "ArmGroupLabel": [
                              "Part I (oncolytic adenovirus Ad5-DNX-2401)",
                              "Part II (oncolytic adenovirus Ad5-DNX-2401, surgery)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03896568"
                        ]
                  },
                  {
                        "Rank": 451,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Application of IMP on patients wound"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: allo-APZ2-CVU"
                        ],
                        "ArmGroupLabel": [
                              "allo-APZ2-CVU"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03257098"
                        ]
                  },
                  {
                        "Rank": 452,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "transplantation of mesenchymal stem cell will be given to the infants with BPD.",
                              "transplantation of mesenchymal stem cell will be not given to the infants with BPD."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: transplantation of mesenchymal stem cell",
                              "Drug: no transplantation of mesenchymal stem cell"
                        ],
                        "ArmGroupLabel": [
                              "transplantation of mesenchymal stem cell",
                              "no transplantation of mesenchymal stem cell"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03378063"
                        ]
                  },
                  {
                        "Rank": 453,
                        "Acronym": [
                              "IMPACT"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "One dose of 6x10e6 cells/kg administered intravenously.",
                              "Placebo infusion"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Cord Tissue Mesenchymal Stromal Cells",
                              "Other: Placebo Infusion"
                        ],
                        "ArmGroupLabel": [
                              "MSC",
                              "Placebo Infusion"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04089579"
                        ]
                  },
                  {
                        "Rank": 454,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 with the goals of ablating host repressive T cells.",
                              "Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own adipose derived mesenchymal stem cells (AD-MSCs) at a dose of 3000000/kg/d on day 1 to 3.",
                              "Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own AD-MSC transdifferentiated HSCs (AD-HSCs) at a dose of 3000000/kg/d from day 1 to 4."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Rabbit antithymoglobulin (ATG)",
                              "Drug: Rabbit antithymoglobulin (ATG)",
                              "Procedure: Adipose derived mesenchymal stem cells ( AD-MSCs)",
                              "Drug: Rabbit antithymoglobulin (ATG)",
                              "Procedure: AD-MSC transdifferentiated HSCs (AD-HSCs)"
                        ],
                        "ArmGroupLabel": [
                              "Rabbit antithymoglobulin \uff08ATG\uff09",
                              "Rabbit ATG & AD-MSCs",
                              "Rabbit ATG & AD-HSCs"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02407470"
                        ]
                  },
                  {
                        "Rank": 455,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (2.0*10^8 nano vesicles/3 ml)",
                              "Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (4.0*10^8 nano vesicles/3 ml)",
                              "Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (8.0*10^8 nano vesicles/3 ml)",
                              "Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (12.0*10^8 nano vesicles/3 ml)",
                              "Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (16.0*10^8 nano vesicles/3 ml)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: 1X level of MSCs-Exo",
                              "Biological: 2X level of MSCs-Exo",
                              "Biological: 4X level of MSCs-Exo",
                              "Biological: 6X level of MSCs-Exo",
                              "Biological: 8X level of MSCs-Exo"
                        ],
                        "ArmGroupLabel": [
                              "1X level",
                              "2X level",
                              "4X level",
                              "6X level",
                              "8X level"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04313647"
                        ]
                  },
                  {
                        "Rank": 456,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "MSCs will be given the patients in MSCs group. Besides, azithromycin (AZM) and glucocorticoid will also be administered.",
                              "AZM and glucocorticoid will be given for the patients in Non-MSCs group."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: MSCs",
                              "Drug: AZM",
                              "Drug: Glucocorticoid",
                              "Drug: AZM",
                              "Drug: Glucocorticoid"
                        ],
                        "ArmGroupLabel": [
                              "MSCs",
                              "Non-MSCs"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02543073"
                        ]
                  },
                  {
                        "Rank": 457,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "UC-MSC, iv, 1\u00d710^6 cells/kg, once a week, for 4 weeks. Anti-CD25 mAb, iv, 20mg\uff0ctwice in first week and once a week thereafter, 4 weeks. Other treatment would replace it according to clinical experience if aGVHD continue to progress within 3 weeks of treatment or patients are lack of response after 4 weeks of treatment. The treatment would be repeated in another 4 weeks if patients receive partial response after the first 4 weeks of treatment.",
                              "Anti-CD25 mAb, iv, 20mg\uff0ctwice in first week and once a week thereafter, for 4 weeks. Other treatment would replace it according to clinical experience if aGVHD continue to progress within 3 weeks of treatment or patients are lack of response after 4 weeks of treatment. The treatment would be repeated in another 4 weeks if patients receive partial response after first 4 weeks of treatment."
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: UC-MSC",
                              "Drug: Anti-CD25 mAb",
                              "Drug: Anti-CD25 mAb"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSC and anti-CD25 mAb",
                              "Anti-CD25 mAb"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04738981"
                        ]
                  },
                  {
                        "Rank": 458,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Group 1: 5.0 x 10^7 cells Group 2: 7.5 x 10^7 cells Group 3: 10.0 x 10^7 cells"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASC"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASC"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02580617"
                        ]
                  },
                  {
                        "Rank": 459,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The first 10 consecutive patients will all receive investigational product.",
                              "An interim analysis, for safety will be conducted and reviewed by the Data Safety and Monitoring Board (DSMB) after the first 10 patients have completed treatment and reached the 28 day endpoint. If there are no safety concerns, the trial will proceed with enrollment on the phase 2 portion of the study where the subsequent 40 patients will be randomized in a 1:1 fashion between treatment with MSCs and placebo. The investigational product will be further randomized to the MSCs manufactured by Duke or University of Miami. These products are considered to be comparable.",
                              "An interim analysis, for safety will be conducted and reviewed by the Data Safety and Monitoring Board (DSMB) after the first 10 patients have completed treatment and reached the 28 day endpoint. If there are no safety concerns, the trial will proceed with enrollment on the phase 2 portion of the study where the subsequent 40 patients will be randomized in a 1:1 fashion between treatment with MSCs and placebo"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.",
                              "Biological: Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University.",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Open Label infusion of hCT-MSC",
                              "Randomized infusion of hCT-MSC",
                              "Randomized infusion of Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04399889"
                        ]
                  },
                  {
                        "Rank": 460,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 1 million cells/kg (up to a maximum of 100 million cells) by IV infusion on two occasions (Day 0 and Day 7)",
                              "Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 2 million cells/kg (up to a maximum of 200 million cells) by IV infusion on two occasions (Day 0 and Day 7)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Mesenchymoangioblast-derived mesenchymal stem cells",
                              "Biological: Mesenchymoangioblast-derived mesenchymal stem cells"
                        ],
                        "ArmGroupLabel": [
                              "Cohort A",
                              "Cohort B"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02923375"
                        ]
                  },
                  {
                        "Rank": 461,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Treatment arm"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: AGLE 102"
                        ],
                        "ArmGroupLabel": [
                              "AGLE 102"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04173650"
                        ]
                  },
                  {
                        "Rank": 462,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Other: Allogeneic mesenchymal stem cells",
                              "Device: Polyurethene Film"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASC-DFU",
                              "Conventional Therapy"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02579369"
                        ]
                  },
                  {
                        "Rank": 463,
                        "Acronym": [
                              "hCT-MSCs"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Subjects 1-3 will receive a single infusion of hCT-MSCs.",
                              "Subjects 4-6 will receive two infusions of hCT-MSCs.",
                              "Subjects 6-12 will receive three infusions of hCT-MSCs."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: hCT-MSC infusion",
                              "Biological: hCT-MSC infusion",
                              "Biological: hCT-MSC infusion"
                        ],
                        "ArmGroupLabel": [
                              "Single hCT-MSC infusion",
                              "Two hCT-MSC infusions",
                              "Three hCT-MSC infusions"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03099239"
                        ]
                  },
                  {
                        "Rank": 464,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [
                              "No"
                        ],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [
                              "No"
                        ],
                        "ArmGroupDescription": [
                              "Drug name and ingredients: CARTISTEM [allogeneic-unrelated, umbilical cord blood-derived mesenchymal stem cells, ex vivo cultured, combined with sodium hyaluronate] Dosage: Administer 0.5 mL of the combination product per cm^2 of the cartilage defect"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: CARTISTEM\u00ae"
                        ],
                        "ArmGroupLabel": [
                              "CARTISTEM\u00ae"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [
                              "Female",
                              "Male",
                              "Hispanic or Latino",
                              "Not Hispanic or Latino",
                              "Unknown or Not Reported",
                              "American Indian or Alaska Native",
                              "Asian",
                              "Native Hawaiian or Other Pacific Islander",
                              "Black or African American",
                              "White",
                              "More than one race",
                              "Unknown or Not Reported"
                        ],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01733186"
                        ]
                  },
                  {
                        "Rank": 465,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Biological: ALLO-ASC-DFU"
                        ],
                        "ArmGroupLabel": [
                              "ALLO-ASC-DFU"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT02394873"
                        ]
                  },
                  {
                        "Rank": 466,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "20-30 intramuscular injections, single dose of allo-APZ2-PAOD, 150 - 225 x 10^6 cells per patient (depending on length of lower leg)",
                              "20-30 intramuscular injections, vehicle solution (depending on length of lower leg)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: allo-APZ2-PAOD",
                              "Drug: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "allo-APZ2-PAOD",
                              "Placebo"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03339973"
                        ]
                  },
                  {
                        "Rank": 467,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Investigational Product - 4.0\u00d710^6 cells/2 mL of SMUP-IA-01 (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)",
                              "Investigational Product - 1.0\u00d710^7 cells/2 mL of SMUP-IA-01 (2 ml of 1% sodium hyaluronate injection is administered before administration of SMUP-IA-01)",
                              "Investigational Product - 2 ml of 1% sodium hyaluronate (2 ml of sodium chloride injection is administered before administration of 1% sodium hyaluronate)"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: SMUP-IA-01(low dose)",
                              "Biological: SMUP-IA-01(mid dose)",
                              "Drug: Active Control Group Sodium chloride"
                        ],
                        "ArmGroupLabel": [
                              "Study Group 1: SMUP-IA-01 (low dose)",
                              "Study Group 2:SMUP-IA-01 (mid dose)",
                              "Active Control Group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05182034"
                        ]
                  },
                  {
                        "Rank": 468,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Intravenous Allogeneic Menstrual Blood Stem Cells Secretome injection+Routine treatment",
                              "Intravenous saline injection (Placebo)+Routine treatment"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Allogeneic human menstrual blood stem cells secretome",
                              "Other: Intravenous saline injection"
                        ],
                        "ArmGroupLabel": [
                              "Menstrual blood stem cell secretome group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT05019287"
                        ]
                  },
                  {
                        "Rank": 469,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Thirty of the enrolled patients were assigned to Group A to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.",
                              "Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as bone marrow stem cells transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Conserved therapy",
                              "Procedure: Allogenic bone marrow stem cells transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Group A(conserved therapy )",
                              "Group B (BMSC Transplantion)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01221454"
                        ]
                  },
                  {
                        "Rank": 470,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Thirty of the enrolled patients were assigned to Group A were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.",
                              "Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as bone marrow stem cells transplantation"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Conserved therapy",
                              "Procedure: Allogenic bone marrow stem cells transplantation"
                        ],
                        "ArmGroupLabel": [
                              "Group A(conserved therapy )",
                              "Group B (BMSC Transplantion)"
                        ],
                        "ArmGroupType": [
                              "Active Comparator",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT01223664"
                        ]
                  },
                  {
                        "Rank": 471,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Participants will receive conventional and treatment with MSCs, MSCs were suspended in 100 mL of normal saline, and the total number of transplanted cells was calculated by 1*10E6 cells per kilogram of weight. This product is generally a course of treatment, a total of 1 time, depending on the condition of the need to be given again at an interval of 1 week.",
                              "Participants will receive conventional treatment and Placebo intravenously."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UC-MSCs",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "UC-MSCs treatment group",
                              "Control group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04339660"
                        ]
                  },
                  {
                        "Rank": 472,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "The investigational product is intravenously administered according to the planned dose.",
                              "The investigational product is intravenously administered according to the planned dose.",
                              "The investigational product is intravenously administered according to the planned dose."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: PN-101",
                              "Biological: PN-101",
                              "Biological: PN-101"
                        ],
                        "ArmGroupLabel": [
                              "Low dose group",
                              "Intermediate dose group",
                              "High dose group"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04976140"
                        ]
                  },
                  {
                        "Rank": 473,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Experimental Group 1: Three intra-articular injection of allogeneic P-MMSCs up to 2\u2022107cells (target dose up to 6\u2022107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients",
                              "Experimental Group 2: Three intra-articular injection of autologous BM-MMSCs up to 2\u2022107cells (target dose up to 6\u2022107 cells) with 20 mg Hyaluronic Acid at 4-weeks intervals - 15 patients",
                              "Three intra-articular injection of 20 mg Hyaluronic Acid - 15 patients"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: Placenta-derived MMSCs",
                              "Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe",
                              "Biological: Bone marrow-derived MMSCs",
                              "Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe",
                              "Drug: Hyalgan 20 mg in 2 ML Prefilled Syringe"
                        ],
                        "ArmGroupLabel": [
                              "Hyaluronic Acid (HA) + P-MMSCs",
                              "Hyaluronic Acid (HA) + BM-MMSCs",
                              "Hyaluronic Acid (HA)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Active Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04453111"
                        ]
                  },
                  {
                        "Rank": 474,
                        "Acronym": [
                              "REGEN"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "100 million human MSCs in 200mls of normal saline, intravenously, once-off, over 1-2hours"
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: human Mesenchymal Stem Cell (MSC) infusion therapy"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Population"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04174898"
                        ]
                  },
                  {
                        "Rank": 475,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "A single IV infusion of ULSC's in patients with DM or PM"
                        ],
                        "ArmGroupInterventionName": [
                              "Drug: Umbilical Cord Lining Stem Cells"
                        ],
                        "ArmGroupLabel": [
                              "Treatment Arm"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT04723303"
                        ]
                  },
                  {
                        "Rank": 476,
                        "Acronym": [
                              "CERES"
                        ],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [
                              "Three (3) subjects will be treated with a single administration of 2 x 10^7 (20 million) UCMSCs delivered via peripheral intravenous infusion.",
                              "Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.",
                              "Three (3) subjects will be treated with a single IV administration of 2 x 10^7 (20 million) BMMSCs delivered via peripheral intravenous infusion.",
                              "Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) BMMSCs delivered via peripheral intravenous infusion.",
                              "Participants randomized to receive a single administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.",
                              "Participants randomized to receive a single administration of 1 x 10^8 (100 million) BMMSC delivered via peripheral intravenous infusion.",
                              "Participants randomized to receive a single administration of placebo via peripheral intravenous infusion."
                        ],
                        "ArmGroupInterventionName": [
                              "Biological: UCMSCs",
                              "Biological: UCMSCs",
                              "Biological: BMMSCs",
                              "Biological: BMMSCs",
                              "Biological: UCMSCs",
                              "Biological: BMMSCs",
                              "Other: Placebo"
                        ],
                        "ArmGroupLabel": [
                              "Pilot Phase: Group 1 (UCMSCs - 20 million)",
                              "Pilot Phase: Group 3 (UCMSCs - 100 million)",
                              "Pilot Phase: Group 2 (BMMSCs - 20 million)",
                              "Pilot Phase: Group 4 (BMMSCs -100 million)",
                              "Group A (UCMSCs - 100 million)",
                              "Group B (BMMSCs - 100 million)",
                              "Group C (Placebo)"
                        ],
                        "ArmGroupType": [
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Experimental",
                              "Placebo Comparator"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03059355"
                        ]
                  },
                  {
                        "Rank": 477,
                        "Acronym": [],
                        "AgreementOtherDetails": [],
                        "AgreementPISponsorEmployee": [],
                        "AgreementRestrictionType": [],
                        "AgreementRestrictiveAgreement": [],
                        "ArmGroupDescription": [],
                        "ArmGroupInterventionName": [
                              "Drug: Jointstem"
                        ],
                        "ArmGroupLabel": [
                              "Long Term Follow-up after Jointstem Transplantation"
                        ],
                        "ArmGroupType": [
                              "Experimental"
                        ],
                        "AvailIPDComment": [],
                        "AvailIPDId": [],
                        "AvailIPDType": [],
                        "AvailIPDURL": [],
                        "BaselineCategoryTitle": [],
                        "BaselineClassDenomCountGroupId": [],
                        "NCTId": [
                              "NCT03509025"
                        ]
                  }
            ]
      }
}